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AN ANCIENT CHINESE MEDICINE AND MULTI-STEP EVOLUTION 
INFORMS MALARIA DRUG DISCOVERY 
 
 
Abstract 
 
Malaria is a treatable communicable disease yet remains a common cause of death 
and disease especially among pregnant women and children.  Most of malaria’s 
worldwide burden disproportionately lies in Southeast Asia and Sub-Saharan Africa.  
Western medicine’s 100+ year history of combating Plasmodium falciparum has taught us 
that the global population of malaria parasites has a unique and dangerous ability to 
rapidly evolve and spread drug resistance.  Recently it was documented that resistance to 
the first-line antimalarial artemisinin may be developing in Southeast Asia. 
The goal of this work is to develop new targets for antimalarial drug development 
and use these new tools to better understand the evolutionary process of adaptation to 
antimalarial drugs.  We focused on derivatives of the natural product antimalarial 
febrifugine.  We first identified that febrifugine derivative halofuginone targets the P. 
falciparum cytoplasmic prolyl tRNA synthetase (cPRS).  We then found another febrifugine 
derivative, halofuginol, which shared halofuginone’s mechanism of action but lacked its 
toxicity in an in vivo murine model of malaria. 
By studying the multiple mechanisms that P. falciparum utilizes to evolve resistance 
to halofuginone, we present a three-step sequential model of the evolution of drug 
resistance in malaria.  In the case of halofuginone, we found non-genetic regulation of the 
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clag family of genes achieved specific increase of proline pools in addition to genetic 
modification of the cPRS were fundamental in the evolution of resistance. 
By focusing on cPRS drug resistance mutations with a reverse genetic approach, we 
further found evidence that drug resistance mutations can be the second of a two-step 
evolutionary process.  We found that both cPRS mutations L482F (HFGRI) and L482H 
(HFGRII) required a cellular environment with the overexpression of clag gene family 
members to confer resistance to halofuginone. 
Taken together, these data identify the cPRS as a new and promising target for 
malaria drug development, halofuginol as a promising chemical scaffold for the 
development of future cPRS-based antimalarials, and a new model of the evolution of 
drug resistance involving sequential non-genetic and genetic adaptations. 
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1.1 MALARIA    
Malaria is an infectious disease caused by mosquito-transmission of eukaryotic protozoan parasites of the 
genus Plasmodium with quite possibly the largest global health impact of any disease.   Young children, ages 
6-36 months, and pregnant women are the most at risk for severe disease.  That being said, symptoms of 
malaria vary greatly depending on the age-group and previous exposure to the disease 1,2. 
Clinical definitions of malaria divide cases into two broad categories: uncomplicated and complicated 
malaria.  A case of uncomplicated malaria is defined as a malaria-infected person with fewer than 5000 
parasites/microL of blood, usually experiencing a constellation of symptoms including fever, chills, malaise, 
fatigue, and diaphoresis.  Complicated malaria is defined by hyperparasitemia (≥100,000 parasites/microL) 3. 
Much of the clinical symptomotology of complicated malaria is due to cytoadherance of infected and non-
infected red blood cells in small blood vessels.  These capillary-blocking rosettes cause small infarctions, 
capillary leakage, and end organ dysfunction that can include the spleen, kidneys, lungs, brain, and liver 2.  
Though five Plasmodium species can infect humans, most cases of severe malaria are caused by P. 
falciparum infections 1. 
Figure 1.1.1: Clinical burden of Plasmodium falciparum in 2007 
 
This map shows the mean predicted clinical burden of Plasmodium falciparum malaria in terms of the 
number of clinical cases in people of all ages per year per 5x5km. 4,5. 
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Putting on the hat of social epidemiology, malaria is also a disease of climate and a disease of poverty.  The 
worldwide burden of malarial disease is estimated at 1,238,000 deaths in 2010.  The clear majority 
(1,133,000 ) of those deaths occurred in Sub-Saharan Africa in 2010,6 where the greatest burden of clinical 
disease also predominates (Figure 1.1.1).  Despite the shocking number of world-wide mortalities, this 
represents steady progress.  From 2004 to 2010, malaria mortality has decreased most likely due to scaling-
up of malaria control measures especially in Sub-Saharan Africa 6. 
The epidemiological distribution of malaria described above is shaped by climate and its effect on 
Plasmodium-transmitting vectors.  Much of the burden of malaria is restricted to tropical and sub-tropical 
climates.  The Anopheline mosquitoes present in tropical climates, especially in Sub-Saharan Africa, are far 
more competent vectors for malaria than those found elsewhere.  Thus malaria control and eradication faces 
far greater challenges in the tropics than those that were faced by formerly endemic nations in more 
temperate climes (eg. The United States of America) 7. 
From a critical anthropological lens, malaria is also a disease of poverty.  On the basis of country-level data, 
Gwatkin and Guillot estimated that 57.9% of all deaths from malaria in the world in 1990 occurred among 
the poorest 20% of the world’s population. 8.  The relationship between malaria and poverty is a tautological 
circle: in some respects it is both caused by poverty and the cause of poverty itself.  Malaria, among other 
infectious diseases, has been suggested as part of the reason for impoverished living conditions in less 
developed countries.  More specifically, Sachs et al. estimate that malaria has inflicted an annual cost of $12 
billion through death and disability in the continent of Africa 9.  Part of that cost is also due to the cost of 
malaria treatment itself, which falls disproportionately on low-income households in sub-Saharan Africa.  A 
1994 survey in Malawi demonstrated that malaria-related costs accounted for 32% of annual household 
income of families in the low income bracket, compared to 4% for wealthier Malawian households 10. 
On the other side, poverty itself perpetuates malarial disease and maintains the conditions that perpetuate 
endemic malarial disease.  Poverty prevents access to prevention and treatment.  Poverty forces people to 
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live in swampy mosquito-infested environments.  There is also some evidence that malarial disease is more 
common and severe in undernourished children for yet unappreciated physiological reasons 11,12. 
 
1.2 PARASITE BIOLOGY    
Human malaria infections are caused by four species – P. falciparum, P. vivax, P. malariae, P. ovale, and P. 
knowlesi.  Plasmodia are classified in the unicellular protist phylum Apicomplexa, named for the apical 
complex of organelles (rhoptries, micronemes, and dense granules) present in the sporozoite – the infectious 
stage of each member of Apicomplexa; the apical organelles are also present in the merozoite and ookinete 
forms of Plasmodia.  Most members also contain a chloroplast-like organelle, the apicoplast, required for 
isoprenoid biosynthesis Plasmodia 13.  Apicomplexa also includes related species: Babesia, Cryptosporidiosis, 
and Toxoplasma.   
The genus Plasmodium includes hundreds of species. Each species is largely defined by its secondary host; 
in the case of P. falciparum, P. vivax, P. malariae, P. ovale, and P. knowlesi, humans are the secondary host 
and Anopheline mosquitos, the primary.  P. relictum and P. elongatum are two avian malarias that often rise 
to world-wide attention when they infect the penguins living in captivity 14. 
Any parasitic organism with two hosts must have a complex life cycle and developmental program to allow 
it to survive in multiple environments and travel from one host to another.  The parasite P. falciparum 
accomplishes this with a haploid genome of approximately 23 million base-pairs of DNA (Mb) and just over 
5,000 genes 15.  To put this in context, the average size of a bacteria genome such as E. coli is 4-5 million 
bases while the human genome is 3.2 billion bases 16-18. 
A human malaria infection begins with the bite of a female Anopheline mosquito carrying sporozoites 
waiting in its salivary glands (Figure 1.2.1).  Plasmodium sporozoites travel from superficial capillaries to 
infect liver hepatocytes within 2 hours 2 (Figure 1.2.1 #1).  Within hepatocytes, the haploid hepatic parasites 
undergo the first cycle of asexual replication – exoerythrocytic schizogony. 
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Figure 1.2.1: The life cycle human-infecting Plasmodia. 
Life-cycle stages of human malaria are enumerated 1-8 beginning with the bite of a malaria-infected 
mosquito 1. 
In this replicative stage one merozoite gives rise to thousands of merozoites 19 (Figure 1.2.1 #2).  These 
merozoites enter the blood stream and begin the hematogenous stage of infection responsible for malaria’s 
clinical symptoms and morbidity (Figure 1.2.1 #4).  However in P. vivax and P. ovale infections, a subset of 
merozoites become inactive and form the latent hypnozoite form of malaria responsible for recrudescent 
infections (Figure 1.2.1 #3). 
The erythrocytic stage of malaria infection usually manifests itself 12 to 14 days after the initial mosquito 
bite.  Once in the blood stream, daughter merozoites attach and infect red blood cells to commence the 
second phase of asexual replication.  Within the erythrocyte, malaria parasites surround themselves with the 
parasitophorous vacuole – a membrane that the parasite invaginates from the erythrocyte cell membrane.  
The parasite remodels the host erythrocyte in many ways including reprogramming nutrient import via the 
new permeability pathway/PSAC transport 20.  The parasite undergoes replication, passing through the 
hallmarked asexual life-cycle stages: ring, trophozoite, and schizont.  Asymmetric cell division produces 16-
32 maturing merozoites within the infected erythrocyte. Upon full maturation of the daughter merozoites, 
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the late stage schizonts initiate a calcium-dependent lysis program 21 and release the daughter merozoites 
that will perpetuate the un-ending erythrocytic cycle (Figure 1.2.1 #5).  The bursting of infected red blood 
cells triggers the release of a storm of host cytokines resulting in the classic symptoms of uncomplicated 
malaria – fever, tachycardia, tachypnea, chills, malaise, fatigue, diaphoresis, and headache 2. 
During a clinical case of malaria, only ring-stage parasites are present in the peripheral blood.  Late-stages – 
trophozoites and schizonts – are either sequestered in small capillaries and post-capillary venules of specific 
organs or filtered out of circulation by macrophage-mediated splenic clearance.  Much of the burden of 
parasite sequestration occurs in the brain and lungs leading to the end-organ dysfunction associated with 
severe malaria 22.  
A small subset of ring-stage erythrocytic cycle parasites leave the asexual stage and become committed to 
form male and female gametocytes – the sexual forms of Plasmodium 23 (Figure 1.2.1 #6).  Mature 
gametocytes sequester to small vessels awaiting ingestion by a feeding female mosquito (Figure 1.2.1 #7).  
Plasmodium parasites only undergo meiosis, i.e. sexual reproduction, within the mid-gut of the mosquito 
vector (Figure 1.2.1 #8).  After recombination of genetic material from male and female gametocytes, 
sporogenesis in the mosquito midgut reproduces the transmissible sporozoites that migrate to the salivary 
glands to restart the cycle. 
1.3 HISTORY OF CONTROL AND ERADICATION       
Eradication of any infectious disease relies on four major conditions: biologic feasibility, adequate public 
health infrastructure, sufficient funding, and sustained political/societal will 24.  This thesis will focus mostly 
on the biological feasibility, which must be achievable before the three other conditions can come onboard 
for the eradication of any human disease.  Within the field of public health, small pox eradication is held up 
as an example of a well-organized and successful eradication campaign.  It is also illustrative of the three 
disease characteristics that facilitate eradication 25, many of which remain challenges for any malaria 
eradication effort.  First, the main intervention of the small pox eradication campaign was a highly effective 
vaccine that eliminated the possibility of future infection.  Second, disease state – whether a person is 
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infected or not infected with the smallpox virus – is apparent by visual diagnosis; there is no latent or sub-
clinical yet contagious carrier state.  Third, transmission is person to person and thus does not involve a 
separate vector population or animal reservoir, i.e. mosquitos or sandflies.  
All three of these factors explain the serious challenges that remain for malaria control and eradication.  
There is no effective vaccine as of yet 26,27; the most studied malaria vaccine, RTS,S/AS01, remains poorly 
efficacious only preventing 47% and 26% of severe disease in 5-17month olds and newborns respectively 
26.  Malaria disease state is more complicated than smallpox.  Sub-clinical infections persist especially in 
areas of endemic or hypo-endemic transmission 28-31 and reactivation of latent disease is possible, especially 
in areas where P. vivax and P. ovale are active 32,33.  Both sub-clinical and reactivated infections can 
continue to transmit disease leading to resurgence of malaria in regions previously free of clinical disease 
and transmission.  And third, malaria is a vector born disease transmitted by a multitude of mosquito 
species. Thus, the lack of a vaccine, the ability to have continued transmission without clinical disease, and 
the transmission of the disease by mosquitos have flouted many heroic attempts at malaria disease 
eradication. 
The discovery of “rods” in the salivary glands of mosquito fed on malarias birds by Ronald Ross in 1898 
established mosquito transmission of malaria and commenced a new approach in malaria control 34.  The 
era of malariology was born as a discipline focused around malaria as a mosquito vector-born infectious 
disease.  Encouraged by the effectiveness and endurance of the newly discovered insecticide dichloro-
diphenyl-trichloroethane (DDT), The World Health Organization (WHO) spearheaded the Global Malaria 
Eradication Programme (GMEP) in1955.  The control and eradication efforts of GMEP relied on indoor 
residual spraying with DDT.  From the outset of the programme, it followed a strict timeline for progression 
from endemic disease to eradication 35.  Fourteen years later, the GMEP was plagued by malaria resurgence 
in many countries that had previously interrupted transmission and it was recognized that eradication of 
malaria was infeasible in a short-term campaign. The WHO abandoned the goal of worldwide malaria 
eradication and refocused on disease control. 
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1.4 DRUG RESISTANCE    
 A major cause of the failure of the Global Malaria Eradication Program was acquired resistance of the 
mosquito vector and the Plasmodium parasite itself.  For the sake of this work, we will focus largely on 
acquired drug resistance of Plasmodium parasites.  First line drugs for malaria have changed over time due 
to clinical drug resistance.  First in the form of Cinchona Bark and later reformulated as a tablet, quinine was 
the first and only effective therapy. Quinine was then replaced with the synthetic derivative chlororquine.  
More recently, the combination folate pathway inhibitor sulfadoxine-pyrimethamine replaced chlororquine, 
only now to be shelved for artemisinin-combination therapies.  The constant evolution of drug resistance 
necessitated switching chemotherapies (Table 1.4.1).  
Table 1.4.1: Time to resistant parasites in clinical use of Antimalarial drugs 
Antimalarial drug Introduced First reported resistance Difference (years) 
Quinine 1632 1910 278 
Chloroquine 1945 1957 12 
Proguanil 1948 1949 1 
Sulfadoxine-
pyrimethamine 
1967 1967 0 
Mefloquine 1977 1982 5 
Atovaquone 1996 1996 0 
Artemisinin 1994 2008*   
 
Based upon data from 36 *Delayed clearance, but not flagrant, resistance has been witnessed 37 
Two predominant resistance mechanisms have been witnessed in malaria research.  The first is pump-based 
efflux of a drug away from its subcellular location of activity.  In the case of Plasmodium falciparum 
Chloroquine Resistance Transporter (PfCRT), the gene product sits in the membrane of the digestive vacuole 
(Figure 1.4.1).   Chloroquine is hypothesized to inhibit detoxification of the heme functional group released 
during hemoglobin degradation 38.  Thus, certain ‘resistant’ alleles of PfCRT displace chloroquine from its 
site of action and allow for phenotypic drug resistance.  Another example of pump-mediated resistance is 
the Plasmodium falciparum multi drug resistance gene 1(PfMDR1) also know as P-glycoprotein (Pgph1).  The 
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product of PfMDR1 also sits in the digestive vacuolar membrane and is hypothesized to pump cytosolic-
acting drugs into the digestive vacuole 39  (Figure 1.4.1). 
 
Figure 1.4.1: Common drug resistance mechanisms of Intra-erythrocytic Plasmodium falciparum 
parasites39 
The second class of drug-resistance mechanisms in Plasmodium species are target site mutations. Both folate 
pathway and mitochondria-targeting drugs have selected for single nucleotide polymorphisms (SNPs) in their 
biochemical target.  In response to sulfadoxine-pyrimethamine pressure in vitro and clinically, mutations in 
dihydrofolate reductase (DHFR) and dihydropteroate synthetase (DHPS) evolved as resistance adaptations.  
In the mitochondria, bc1 complex inhibitors, such as atovaquone, rapidly select for resistant parasites in 
vitro with SNPs in cytochrome bc1.  During clinical trials of atovaquone of malaria cases in the United 
Kingdom, 6 out of 8 patients treated with 500mg dose had recrudescent malaria with in vitro resistance to 
the drug 40. 
The above-discussed mechanisms of drug resistance have only been described as single genetic markers and 
single event molecular mechanisms.  There is significant evidence that evolution of drug resistance is not a 
single event.  The evolution of chloroquine resistance, when dissected, makes a convincing case that drug 
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resistance in P. falciparum occurs in discrete and sequential steps.  Unlike target-site driven resistance 
mechanism that have taken days to months to evolve and fix in patient populations, chloroquine resistance 
was first observed after 12 years of clinical use and has evolved independently in more than four distinct 
geographic locations worldwide.  In Sub-Saharan Africa, resistance was first observed after almost 30 years 
of use and involves multiple mutations in linkage disequilibrium between PfMDR1 and PfCRT 41.  All of 
these observations argue for multiple genetic steps to achieve chloroquine resistance. 
1.5 EVOLUTION OF DRUG RESISTANCE – FITNESS MAXIMIZATION  
Many lines of evidence indicate drug resistance mutations impart selective advantages to parasites under 
drug pressure, but are also detrimental in absence of that drug 41.  Much work has been done in bacterial 
and viral biology to understand the fitness costs of drug resistance.  A common model employed to 
understand the evolution of drug resistance and its fitness costs is that of compensatory mutation: evolution 
of drug resistance results in decreased fitness in the absence of drug pressure.  Over time, later mutations 
accumulate in the drug-resistant lines that rescue the fitness defects; these mutations are termed 
compensatory mutations 42,43. 
One complication of investigating selective fitness in P. falciparum is the multi-host multi-stage lifecycle.  
Each environment will have a different fitness landscape and favor different alleles and variants.  Therefore, 
a drug resistance allele with superior fitness in the presence of the drug in the intraerythrocytic stage, may 
not have increased fitness within the mosquito midgut or within human hepatocytes during the liver stage of 
human infection.  From a cross-sectional study in Zambia, Mharakurwa et al. found that pyrimethamine-
resistant P. falciparum parasites were underrepresented in the midguts of Anopheles arabiensis vector 
mosquitoes when compared to their prevalence in human infections.  In contrast, cycloguanil-resistant 
parasites were more highly enriched in the midguts of A. arabiensis than in the human populations.  These 
observations built a convincing case that the pyrimethamine-resistant parasites were less fit and cycloguanil-
resistant parasites were more fit in the mosquito vector 44. 
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There is a great deal of evidence that drug-resistance mutations in P. falciparum do have significant fitness 
costs.  A great example of such a mutation is the chloroquine resistance haplotype at PfCRT.  After Kenya 
and Malawi discontinued use of chloroquine as their first-line antimalarial therapy, the prevalence of PfCRT 
resistance mutations in each country dropped significantly 45.  Another strongly studied pair of drug and drug 
resistance mechanisms leading to decreased fitness is atovaquone and cytochrome bc1. The 1000-fold 
atovaquone resistant strain with mutations M133I and G280D also had a 5-9% fitness cost and in 
competitive growth in the absence of atovaquone was out-competed by its parent line, 46.  Additionally, the 
cytochrome b Y268S mutation observed in an atovaquone-resistant isolate from Thailand led to decreased 
enzymatic function of the bc1 complex 47,48. 
The evidence that compensatory mutations can rescue malaria drug-resistance strains is much weaker.  Most 
epidemiological evidence demonstrating the decline in prevalence of drug-resistance alleles after the 
withdrawal of clinical use of the corresponding drug suggests that on a population basis compensatory 
mutations do not predominate and rescue the fitness costs of deleterious resistance mutations before they are 
removed.  However, laboratory-based experiments have suggested that compensatory mutations can rescue 
the fitness cost of drug resistance.  Experimentation with pyrimethamine-resistant P. chabaudi parasites 
supports the notion that compensatory mutations 49 can rescue an otherwise growth deficient strain.   
1.6 CURRENT REGIMEN FOR TREATMENT AND CONTROL OF MALARIA AND THE NEED FOR NEW ANTIMALARIALS 
In response to the continued evolution of drug resistance to mono-therapies, malaria pharmaceutical 
development has shifted focus to developing 2 drug combinations.  Drug combinations for malaria have 
been devised based on pharmacokinetic compatibilities. Artemisinin, a drug with a half-life of 2 to 5 hours 
50, has been combined with previously clinically used monotherapies with significantly longer half-lives in 
order to decrease parasite recrudescence.  Based on the success of these artemisinin-based combination 
therapies (ACTs), the WHO has updated its guidelines to recommend ACTs for treatment of 
uncomplicated P. falciparum malaria 3.  The recommended treatment for severe malaria is intravenous 
artesunate.  Unfortunately, all second line therapies for uncomplicated malaria are other ACTs.  Currently no 
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drugs with novel mechanisms of action will be coming through the development pipeline in the next 5 years 
51.  When malaria evolves flagrant resistance to artemisinins, will we be left with any treatments? 
The foreboding loss of effective therapies for malaria motivates us to find drugs that work through novel 
targets in the parasite.  Ethnobotany is a great source of potential leads for drugs to treat human disease.  It 
has been an especially great source of antimalarials; most antimalarials, in fact, are natural products.  The 
first effective treatment for malaria was Jesuit bark, an herbal remedy from the quinine-rich bark of the 
cinchona tree in the Peruvian Amazon 52.  Western medical science isolated the active pharmacophore, 
quinine, and through rational-based drug design created a series of chemical derivatives including 
chloroquine.  Artemisinin itself, our last efficacious monotherapy, is a product of traditional Chinese 
medicine. Chinese physician Ge Hong identified the antipyretic effects of Artemisia annua in 340 AD in Si 
Ku Quan Shu (A Handbook of Prescriptions for Emergencies). Though modern Chinese medical science 
rediscovered this traditional cure for malaria in 1971, the specter of the Cultural Revolution and the Cold 
war halted investigation and use of artemisinin outside of the People’s Republic of China 53. The antimalarial 
properties and promise of artemisinin first received worldwide attention in the 1980s. 
1.7  FEBRIFUGINE DERIVATIVES AND HALOFUGINONE  
The promise of natural products for antimalarial drug development drew our attention to febrifugine 
derivatives – a family of small molecules derived from the active principle component of Dichroa febrifuga.  
Used as an antipyretic in traditional Chinese medical practice, extracts of D. febrifuga were shown to have 
antimalarial properties in 1945 54.  In the 1960s, the Walter Reed Army Institute of Research (WRAIR) 
developed halofuginone and other febrifugine analogues as part of a large antimalarial drug development 
program 52. 
 In parallel with our work on halofuginone in P. falciparum, our collaborators have investigated the anti-
inflammatory properties of halofuginone in human physiology.  Our collaborators demonstrated that 
halofuginone potently inhibits the differentiation of proinflammatory Th17 cells through activation of the 
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nutrient-sensing amino acid response pathway72.  Furthermore, they have recently identified the glutamyl-
prolyl-tRNA synthetase (EPRS) as the molecular targets of halofuginone in humans55,56.   
 
1.8  TRNA SYNTHETASES AND AMINO ACID SENSING 
Translation of the genetic code occurs with the two subunits of the ribosome. RNA enters the assembly line 
of protein synthesis and the charged tRNA molecules translate the triplets of RNA bases into single amino 
acids.  tRNA synthetase are the grammarians of the central dogma.  They charge the tRNA with the correct 
amino acids and then edit those that are mischarged to ensure fidelity of the translated protein.  On top of 
their function in protein synthesis, cells use tRNA synthetases as measurements of overall amino acid 
homeostasis.  Cells directly sense the amount of uncharged tRNAs and reprogram their behavior via a signal 
transduction pathway called the Amino Acid Starvation Response (AAR). 
Amino Acid Starvation Response (AAR) is a stress response pathway well appreciated in yeast and 
mammalian biology as part of the larger Integrated Stress Response (ISR).  The AAR reprograms cellular 
behavior in response to deprivation of available amino acids 57.  The aggregate affect of the AAR is to inhibit 
cell-wide protein synthesis and selective translation of stress-response proteins.  Despite redundant amino 
acid supplies, recent work in the Wirth lab has confirmed that the parasite remains vulnerable to amino acid 
starvation. In fact, in vitro experimentation has demonstrated that growing parasites in media lacking 
isoleucine activates the AAR 58,59. 
1.9  AMINO ACID HOMEOSTASIS, NEW PERMEABILITY PATHWAY, AND THE CLAG GENE FAMILY 
The malaria parasite has a dual amino acid supply in the erythrocytic stage.  Within the red blood cell, P. 
falciparum parasites digest human hemoglobin.  Theoretically, P. falciparum could receive all of its amino 
acid for protein synthesis from hemoglobin degradation except for isoleucine.  However, P. falciparum also 
imports amino acid from the extracellular milieu, at least in in vitro culture. Proline is one of seven amino 
acids that are essential ingredients in media used for in vitro cultivation of P. falciparum 60.  Very little is 
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known about how amino acid homeostasis is achieved and maintained in Plasmodium species.  Because of 
the unique sources of amino acids and unique challenges of intracellular parasitism, much of the molecular 
machinery is likely to be the genus-specific. 
The malaria field has known for many years that the new permeability pathway (NPP), an increased 
permeability to various solutes that plasmodium parasites induce during erythrocytic parasitism.  The NPP, 
also know as the Plasmodium-specific anion current, increased influx of many amino acids 61 including 
proline 62.  Clag 3 has been identified as a genetic determinant of the PSAC channel 20.  Two groups recently 
found clag3 expression was suppressed by treatment with toxic substrates of the PSAC channel; both found 
that P. falciparum parasites downregulated clag 3 expression in response to blasticidin S treatment 63,64. 
1.10  SUMMARY OF CHAPTERS AND AIMS 
The focus of this thesis is to further the development of antimalarials and better understand the evolution 
machinery that empowers P. falciparum to develop resistance to the drugs used to treat it.  We chose to 
focus on derivatives of febrifugine, a plant derived antimalarial identified from the traditional Chinese 
pharmacopoeia, because it represented a probe for a novel mechanism of anti-parasitic activity.  Much of 
the work was carried out with the febrifugine chemical derivative halofuginone. 
In Chapter 2, we used forward genetic approaches to identify the cytoplasmic prolyl tRNA synthetase (cPRS) 
as the Plasmodial target of halofuginone.  To validate the clinical relevance of cPRS as a pharmacological 
target we devised halofuginol, an in vivo active antimalarial that retains the potency and target of 
halofuginone without the host-toxicity. 
In Chapter 3, we look deeper into the evolution of drug resistance to halofuginone with metagenomic 
sequencing of two in vitro evolution experiments.  We identify epigenetic-driven resistance to halofuginone 
that involved clag gene-overexpression and increased cytosolic proline.  This is the first of a three step 
evolutionary trajectory on the acquisition of halofuginone resistance. 
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In Chapter 4, we used a reverse genetic approach to confirm the halofuginone resistance phenotype we 
associated with the two cPRS mutations we found in Chapter 2.  Rather, we found that both cPRS mutations 
are epistatic with clag gene expression and can only confer halofuginone resistance in a background of clag 
gene overexpression.  Taken together, this reverse genetic approach demonstrated that cPRS drug resistance 
mutations could only take place as a second evolutionary step. 
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CHAPTER 2: PLASMODIUM PROLYL-TRNA SYNTHETASE: A 
DRUGGABLE NEXT GENERATION DUAL-STAGE TARGET FOR 
MALARIA ELIMINATION 
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2.2  INTRODUCTION 
Almost one-third of the world’s population is susceptible to malaria, with the highest burden of 
disease focused on poverty stricken nations in Asia, South America, and Africa. The World Health 
Organization estimates that malaria parasites infect over 200 million people each year, killing approximately 
600,000 people – mostly young children and pregnant women in sub-Saharan Africa - while many more 
suffer from permanent disabilities65. Independent evaluations paint an even grimmer picture, estimating the 
death toll at 1.2 million6,66. In addition to the human costs of severe morbidity and mortality, malaria 
imposes an enormous burden on the economic growth of developing countries as a result of lost 
productivity. In Africa alone, the WHO TDR estimates that malaria is responsible for 10% of the continent’s 
disease burden and an annual cost of $12 billion through death and disability 9.  
The causative agents of malaria are protozoan parasites of the genus Plasmodium that are 
transmitted between human hosts by mosquitoes. In humans, parasite evolve through a liver stage, a 
symptomatic intra-erythrocytic (asexual) stage and a sexual blood stage (gametocytes), which is responsible 
for malaria transmission.  
Current approved antimalarial drugs are limited to a few parasite targets and most drugs are only 
efficacious against the blood stage, which is sufficient for the treatment of acute malaria, however, of limited 
use for prophylaxis, transmission blocking, and eradication efforts67-69. In addition, the emergence and 
spread of clinical resistance to mainstay drugs, including artemisinis, is the major limitation for the use of 
current antimalarials70-72. Thus the discovery not only of novel chemical classes, but also novel druggable 
targets and pathways is essential73,74.   Developing therapies that act on unexploited vulnerabilities in the 
Plasmodium parasite is necessary to maintain the effectiveness of malarial therapy for the renewed 
worldwide efforts to eradicate malaria. 
Aminoacyl tRNA synthetases (aaRSs) and associated pathways have been proposed as attractive 
targets for chemotherapeutic intervention in malaria75 . However, the exploration of tRNA synthetase 
inhibitors in malaria has been scarce. While some tRNA synthetase inhibitors that were identified in other 
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organisms display antimalarial activity, validation of actual on target mechanism has been elusive58,76,77.  The 
repertoire of aaRSs in Plasmodium diverges from other organisms because of the need to carry out protein 
synthesis in multiple subcellular compartments77. 
Following our previous work demonstrating that halofuginone potently inhibits the differentiation of 
proinflammatory Th17 cells through activation of the nutrient-sensing amino acid response pathway we 
have recently identified the glutamyl-prolyl-tRNA synthetase (GPRS) as the molecular targets of halofuginone 
in humans55,56.  Halofuginone is a synthetic derivative of the natural product febrifugine, which constitutes 
the curative ingredient of an ancient Chinese herbal remedy that has been used for over 2000 years for the 
treatment of fevers and malaria54.  
Halofuginone had originally been developed in an unsuccessful effort to identify derivatives with 
improved pharmacological properties to overcome the severe side effects observed with febrifugine that 
preclude the compound from safe clinical use as an antimalarial 78. Subsequent identification of the broad-
spectrum antiprotozoal activity of halofuginone led to the approval in veterinary medicine. This in turn 
resulted in the recognition of the potent anti-fibrotic and immunomodulatory activity of halofuginone in 
metazoans and investigation as a therapeutic for cancer and fibrotic diseases 79,80.  
The exceptional antimalarial potency and unique activity profile of halofuginone has prompted our interest 
to better understand the molecular basis of halofuginone’s anti-parasitic activity with the aim to provide a 
well-defined and practical path forward to next-generation antimalarials.  To accomplish this goal it was 
critical to develop small molecule inhibitors lacking the dose-limiting toxicity of previously reported 
febrifugine derivatives, and to identify and validate the therapeutic potential of halofuginone’s target in P. 
falciparum. 
2.3  METHODS 
P. FALCIPARUM CULTURE 
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Dd2 is a chloroquine resistant in vitro cultured parasite cloned from the Laos derived W2-MEF parasite.  
Malaria culture was performed as described by Trager et al. 81. 
P. FALCIPARUM ERYTHROCYTIC STAGE IN VITRO DOSE-RESPONSE AND ANALYSIS 
A SYBR green method was performed as described in Johnson et al. 82. EC50 values were calculated in 
Graphpad Prism using a four-parameter nonlinear regression curve fit from three assays, each with 12-point 
drug dilution curves. 
DRUG-RESISTANCE CORRELATION ANALYSIS 
We used a set of 31 culture adapted P. falciparum isolates from Senegal previously published in Park et 
al.(45) In vitro EC50 values were determined, as described above, for 12 standard antimalarials and 
halofuginone.  Included standard antimalarials represent a diverse set of targets including the mitochondria, 
the folate pathway, and the heme detoxification pathway.  Pearson correlation between the EC50 values was 
determined with Graphpad.  A heatmap matrix of correlation coefficients (R^2) was generated in GENE-E 
(http://www.broadinstitute.org/cancer/software/GENE-E/). Absolute correlation of drug resistance between 
two antimalarials (R^2=1) is colored red.  Lack of correlation of drug resistance between two drugs (R^2=0) 
is colored blue. 
STEP-WISE ARTIFICIAL SELECTION FOR DRUG RESISTANCE 
Resistance selection under intermittent drug pressure was performed over six months time as reported earlier 
83.  
DILUTIONAL CLONING 
We performed limited dilution of ring stage parasites at concentrations of 0.8 and 0.2 parasites per well to 
isolate individual parasite clones as reported by Rosario 84.  
WHOLE GENOME SEQUENCING 
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DNA was isolated from cultures with QIAamp DNA Blood Kit (Qiagen). Whole genome sequencing of Dd2 
and halofuginone resistant cloned parasites was performed by Illumina 75bp sequence read technology on 
GAIIx machines to at least 80x coverage on Illuminia HiSeq machines.  Single nucleotide polymorphisms 
between each halofuginone resistant strain and its Dd2 parent were called using GATK and Samtools 85,86. 
We compiled the intersection of both sets of nonsynonomous SNPs into a final set of hits. The SNPs called 
between resistant and parental strains are deposited in dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/) 
and their respective sequences will be deposited at NCBI’s Sequence Read 
Archive http://www.ncbi.nlm.nih.gov/sra.  Sanger sequencing was performed by Genewiz (South Plainview, 
NY). 
HIGH RESOLUTION MELT 
We developed a highly-sensitive high-throughput assay for the region containing the SNP found at 
nucleotide 1445 of PFL0670c in HFGR I.  To genotype the halofuginone selection timepoints, we used a 29-
mer probe identical to the WT PFL0670c sequence, 5’CATCTCATTATCTTGGAACAAATTTTGC’3-block and 
with forward primer 5’TGGAAGAGCCATACAAGCAG3’ and reverse primer 
5’GTTTAACTTCATTTTCATCTTCAAATTCAA3’.  Amplification was undertaken with a forward to reverse 
primer ratio of 0.5 mM to 2.5 mM with LightScanner Master Mix (HRLS-ASY-0003, Idaho Technology. Inc., 
Salt Lake City UT).  We ran forty-five cycles of amplification with an annealing temperature of 60 °C. The 
HRM genotyping was performed with the LightScanner® System (Idaho Technology. Inc., Salt Lake City UT). 
PCR SEQUENCING 
Primers were designed to amplify the PFL0670c gene and validate the SNPs identified in whole-genome 
sequencing.  PCR products were purified by ExoSAP-IT treatment per the manufacturer’s directions (USB 
Scientific, USA) and sequenced using big dye termination chemistry (ABI prism automated sequencer) from 
both the forward and reverse strands (Genewiz, USA).  Raw sequence data was evaluated and aligned to the 
wt reference sequence.  SNPs were identified using SeqMan Pro and the Clustal algorithm in MegAlign 
(DNAStar).   
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P. FALCIPARUM WHOLE CELL LYSATE WESTERN BLOT 
Dd2 parasites were allowed to grow to asynchrony for 7 replicative generations.  800 mLs of 8% 
asynchronous, asexual Dd2 parasites were pooled, washed twice with PBS, and 100 mL aliquots were 
exposed to the experimental treatments for 90 minutes.  Drug treated cells were incubated in the presence of 
small molecule inhibitors in standard RPMI media (GIBCO).  Control samples were incubated with a 
corresponding amount of DMSO with either complete RPMI media or RPMI media lacking amino acids 
(RPMI-AA, US Biological). The RPMI-AA culture served as a positive control for AAR 59. Protein lysates from 
each of the 100 mL cultures were prepared by first lysing infected erythrocytes with 0.1% saponin (Sigma) 
and the resultant parasite pellets were lysed in 1x Laemmli Sample Buffer (Bio-Rad) supplemented with 5% 
beta-mercaptoethanol and 2% NP40 (G-Biosciences). All lysis buffers contained 1x Complete protease 
inhibitor cocktail (Roche) and 1x phosphatase inhibitor cocktail PhosStop (Roche).  Western blots were 
probed with a phospho-specific eIF2a pAb raised to a Toxoplasma gondii peptide antigen 
MSDERLpSKRRFRS, an eIf2a pAb raised to T. gondii peptide KGYIDLSKRRVS which recognizes total 
eIF2a  protein (47), and a histone-H3 rabbit pAb (Abcam ab1791).  
YEAST STRAINS AND MEDIA 
The PfProRS gene PFL0670c was optimized for yeast codon preference (see below) and cloned into the 
Gateway entry plasmid pDONR221 by GenScript. Yeast gene YHR020w was selected from the Flexgene 
library in pBY011 and cloned into pDONR221 using the Gateway BP reaction (Invitrogen) 87. Point 
mutations found in P. falciparum halofuginone resistance selections were introduced to the pDONR221-
PFL0670c plasmid following manufacturer’s directions using the QuikChange Site Directed Mutagenesis Kit 
(Stratagene). All destination vectors were taken from the pAG vector collection and destination constructs 
were made using the Gateway LR reaction (Invitrogen) 88.  
The yeast strain BY4743 (his3Δ1/his3Δ1 leu2Δ0/leu2Δ0 met15Δ0/+ lys2Δ0/+ ura3Δ0/ura3Δ0) heterozygous 
for the deletion of essential gene YHR020w from a yeast heterozygous deletion library (OpenBioSystems) 
was transformed with pAG416-YHR020w using a standard lithium acetate method 89.  This strain was 
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sporulated for five days at 23°C and tetrads were dissected as described 90. Tetrads were replica-plated onto 
YPD (1% yeast extract, 2% peptone, 2% glucose, 2% agar (yeast media reagents were from BD unless 
otherwise noted) + 200 µg/mL G418 (Invitrogen) to identify those spores that had the chromosomal deletion 
of YHR020w marked by the KanMX cassette.  For deletion of PDR1, the LEU2 cassette was amplified from 
pUG73 with primers in the genomic region flanking the gene (yeastdeletion.stanford.edu/) 91.  Yeast were 
transformed and selected on SD-Leu plates (0.67% yeast nitrogen base, 2% glucose, 2% agar, supplemented 
with complete amino acid mix minus leucine (Sunrise  Science Products)).  Colonies able to grow on Leu- 
media were tested for the pdr1 deletion using PCR and primers as described on the Saccharomyces Genome 
Deletion Project webpage. The pdr1∆::LEU2 mutants were subsequently deleted for pdr3 using the same 
methods with the hygromycin B cassette amplified from pAG32 92.  
The resulting strain (wildtype or -pdr1∆::LEU2, pdr3∆::Hyg) was transformed with pAG413-YHR020w, 
pAG413GPD-PFL0670c, or point mutants of pAG413GPD-PFL0670c. Strains were selected on 5-FOA for 
loss of the pAG416-YHR020w plasmid and loss of the plasmid was confirmed by lack of growth on Ura- 
media 87.   
YEAST GROWTH ASSAYS 
Yeast strains were grown overnight in assay media (0.17% yeast nitrogen base without amino acids, without 
ammonium sulfate (Bio101), 0.1% glutamic acid, 2% glucose supplemented with complete amino acid mix 
minus histidine (Sunrise Bioproducts)) at 23 °C to maintain log growth phase. The OD600 of cultures was 
measured and yeast strains were diluted to 0.01 OD600 in assay media with indicated concentrations of 
drugs or a corresponding volume of DMSO (Sigma). In indicated experiments, media was supplemented 
with 1 mg/mL proline (Sigma). Cells were grown in 100 µL of media in covered 96-well Nunc Edge assay 
plates at 30°C with interval shaking every 15 minutes in a ThermoScientific Multiskan GO instrument that 
read OD600 every 15 minutes. 
YEAST WESTERN BLOTS 
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Pump-deleted yeast strains were grown overnight in assay media at 23°C, after which either 25 mM 
halofuginone or a corresponding volume of DMSO was added to cultures, which were then grown at 30°C 
for six hours. Yeast pellets were washed with water and resuspended in lysis buffer (100 mM Tris, pH 8.0, 
20 mM NaCl, 2 mM MgCl2, 50 mM b-mercaptoethanol, 0.025 U/ml benzonase, 1% Triton X-100, 2 x Halt 
protease inhibitor (Sigma-Aldrich), 1x Halt Phosphotase Inhibitor (Thermo-Fisher) and acid-washed beads 
and bead beaten for five minutes at 4°C. Supernatants were collected and normalized for protein content 
using a BCA assay (Pierce). Proteins were resolved and transferred using standard techniques, and 
membranes were blotted for p-eIF2a mAb (Ser51) #3398 or total eIF2a pAb #9722 (Cell Signaling 
Technology). 
IN VIVO P. BERGHEI ASSAY 
Liver stage: Male C57BL/6 mice, aged 6–8 wk and weighing 20–22 g were purchased from Charles River 
and housed in the pathogen-free facilities of the Instituto de Medicina Molecular, Lisbon.  
Liver infection was initiated by intravenous injection of 10^4 P. berghei ANKA sporozoites. Parasite liver 
load was measured 42–44 h after infection by qRT-PCR of P. berghei 18S rRNA. 
Blood stage: For blood infection, mice were inoculated with 10^6 red blood cells infected with GFP-
expressing P. berghei ANKA- (iRBCs). Blood parasitaemia was accessed by FACS analysis and thin blood 
smear count. 
Halofuginol was administered 1 hour or 1 day after infection with sporozoites or iRBCs, respectively. 
Halofuginol was diluted to the final concentration in drinking water for oral administration or saline solution 
for intra-peritonal injection. Mice received 200 µL of compound solution and control groups received an 
equivalent amount of vehicle.  
All in vivo protocols were approved by the Animal Care Committee of the Instituto de Medicina Molecular 
and were performed according to the regulations of the European guidelines 86/609/EEG. 
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MODELING STUDIES 
Homology models of prolyl tRNA synthetase for S. cerevisiae, P. falciparum and H. sapiens (prolyl tRNA 
synthetase domain of GPRS) were constructed using Prime (54), the protein prediction structure software of 
Schroedinger Suite2010, using the available structure of T. thermophilus (pdb code 1H4S)  and H. sapiens 
(pdb code 4HVC) as the templates.  Halofuginone was docked in the resulting structures using Glide, 
version 4.5. 93,94.  The protein structures were previously prepared using the Protein Preparation Module, 
whereas the Ligprep module was used to obtain energy minimized 3D halofuginone structures, which were 
then docked in the respective grids using the extra precision scoring algorithm (XP mode). 
The resulting structures served as starting point for the molecular dynamics (MD) simulations, which were 
carried out in analogy to our previously validated protocol using the PMEMD version included in the 
AMBER10 suite of programs, 95 after careful relaxation of the system using minimization and equilibration 
procedures. The ionizable residues were set to their normal ionization states at pH 7. The protein atoms, as 
well as all the water molecules of the crystal structure, were surrounded by a periodic box of TIP3P 96 water 
molecules that extended 10 Å from the protein. Na+ counterions were placed by LEaP 97 to neutralize the 
system. 
The ff03 version of the all-atom AMBER force field was used to model the protein, and the GAFF force field 
for ATP and the organic ligand98,99.  Atom-centered partial charges were derived by using the AMBER 
antechamber program (RESP methodology) 100, after geometry optimization at the B3LYP/6-31G* level 101.  In 
the molecular dynamics simulation protocol, the time step was chosen to be 2 fs, and the SHAKE algorithm 
102 was used to constrain all bonds involving hydrogen atoms. A non bonded cutoff of 10.0 Å was used, and 
the non bonded pair list was updated every 25 time steps. Langevin dynamics was used to control the 
temperature (300 K) using a collision frequency of 1.0 ps-1, with isotropic position scaling to maintain the 
pressure (1 atm)103.  Periodic boundary conditions were applied to simulate a continuous system. Long-range 
interactions were treated by the Particle-Mesh-Ewald (PME)104,105 method was used with a grid spacing of  ~1 
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Å combined with a fourth-order B-spline interpolation to compute the potential and forces in between grid 
points. The trajectories were analyzed using the PTRAJ module of AMBER10. 
MULTIPLE SEQUENCE ALIGNMENT 
The Prolyl-tRNA synthetase (ProRS) class II core catalytic domain of PfcPRS was identified with NCBI’s 
Conserved Domain Database search v3.1, a position-specific scoring matrix based approach 106.  This 
methodology identified the CDD domain cd00778.  All prolyl-tRNA synthetase sequences were aligned by 
ClustalW.  Using Macvector, we built a neighbor joining tree of the class II core domain based upon 
bootstrapping through 1000 replicates. 
SYNTHETIC PROCEDURES HALOFUGINOL 
207mg (0.5mmol) MAZ1310 were suspended in 10mL methanol and 3 mL THF. Following cooling to 0°C 
10mg (0.3mmol) NaBH4 were added and the clear reaction mixture was stirred for additional 60min. Upon 
stirring at 0C the desired product precipitated from solution as white solid. The solid was isolated by 
filtration and recrystallized from methanol to afford racemic Boc-protected halofuginol (142mg, 68%).  
200uL HCl (4M in dioxane) were added to a solution of 10mg Boc-protected halofuginol in 2ml 
methanol/THF (1:1). The reaction mixture was stirred over night at room temperature. The desired product 
was obtained following removal of the solvent under reduced pressure in quantitative yield without the need 
for further purification as white powder as the hydrochloride salt.  
Individual halofuginol and halofuginol enantiomers were synthesized from enantiomerically pure MAZ1310, 
which was obtained following the procedure reported previously by Linder et al. 107. Epi-halofuginol was 
synthesized adapting the procedure for febrifugine reported by Kikuchi et al. 108.  
2.4  RESULTS 
FEBRIFUGINE DERIVATIVES ARE NOT CROSS-RESISTANT TO TRADITIONAL ANTIMALARIALS.  
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Lack of cross-resistance to clinically used antimalarials is a critical prerequisite for new antimalarial drug 
candidates. Thus, we tested a panel of 31 P. falciparum clinical isolates with diverse drug resistance profiles 
for their dose-response to halofuginone and a representative set of 12 antimalarials that cover the major 
classes of malaria chemotherapies. Halofuginone did not show significant cross-resistance with any of the 
tested antimalarials (see SFigure 2.5.1), consistent with the profile of a drug with a distinct mechanism. 
HALOFUGINOL IS ACTIVE AGAINST THE ERYTHROCYTIC STAGE OF MALARIA IN VITRO AND IN VIVO. 
We speculated that the observed side effects of halofuginone and febrifugine could be independent from 
inhibition of the host EPRS and caused by off-target effects originating from the compounds’ reported ability 
to epimerize in solution through formation of a reactive intermediate 109.  This undesired feature, which is 
also likely the reason for poor stability in aqueous buffer at physiological pH, can be attributed the central 
ketone common to febrifugine and halofuginone. Previously reported efforts to remove this functionality 
have resulted in loss of activity. We reasoned that formal reduction of the ketone to yield a secondary 
alcohol would retain the potential to form critical hydrogen bonds within the target complex while 
eliminating the ability to form a reactive Michael-acceptor. Introduction of the alcohol also introduces an 
additional stereocenter and consequently results in two possible diastereomers, one of which has already 
been reported for febrifugine to result in significant loss of activity. (24) We therefore established a synthetic 
approach to access both epimers (Figure 2.4.1a) derived from halofuginone as racemates for in vitro and in 
vivo profiling.  
We next tested both epimers for in vitro activity against the asexual P. falciparum 3D7 parasite. As expected, 
the epimer matching the relative stereochemistry of the previously reported febrifugine analog was 
approximately 1000-fold less active than halofuginone 108.  However, the other stereoisomer, which we 
termed halofuginol, demonstrated low nanomolar potency (EC50 = 5.8 nM) comparable to febrifugine 
(4.0nM) (SFig 2.5.1b). Importantly, the principle activity is attributed to one enantiomer with the same 
absolute configuration of the piperidyl substituent as febrifugine and the active enantiomer of halofuginone 
(see SFigure 2.5.2). 
	   28	  
Encouraged by these findings, we next evaluated halofuginol’s tolerability and activity against the 
erythrocytic stage of malaria in a P. berghei mouse model. Using an adapted version of Peters’ suppressive 
test 110,111, we found that halofuginol dosed at 10mg/kg intraperitoneally over 4 days inhibits P. berghei in 
vivo with an efficacy of >99% (Fig 2.4.1C) without observation of any adverse effects that have been 
reported for febrifugine and halofuginone at efficacious doses 110,111.  
 
 
Figure 2.4.1: Halofuginol is active against the erythrocytic and liver stages of malaria  
(A) Chemical structures of febrifugine, halofuginone (relative stereochemistry), halofuginol (relative 
stereochemistry), epi-halofuginol (relative stereochemistry) and MAZ1310 (relative stereochemistry). (B) In 
vitro activity of halofuginone, febrifugine, MAZ1310, halofuginol, and epi-halofuginol against P. falciparum 
strain 3D7 erythrocytic stage parasites. Growth inhibition was quantified after 72 hours by SYBR green 
staining. (C) Blood parasitemia at day 5 after infection. Mice were treated 24hr post inoculation with 10^6 
red blood cells infected with GFP-expressing P. berghei ANKA with 10mg/kg/day halofuginol (i.p.) or vehicle 
alone for 4 days. Blood parasite levels were analyzed by FACS. (D) In vitro dose-response of luciferase-
expressing P. berghei ANKA liver stage parasites to halofuginol infecting HepG2 cells. (E) In vivo potency of 
halofuginol in P. berghei infection model.  Relative parasitemia in mouse livers 44 h after infection with P. 
berghei sporozoites. Mice were treated 1hr post infection with halofuginol (5mg/kg i.p. and 10mg/kg p.o.) 
and vehicle, respectively. Parasite load was quantified relative to vehicle control by qRT-PCR of P. berghei 
18S rRNA. Data are displayed as mean relative to vehicle treated control, with the mean of the control 
group set to 100%. p values (***p < 0.001, ****p < 0.0001) were calculated from multiple animals by 
ordinary one-way ANOVA (Graphpad PRISM).   
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Activity against liver stages of malarial is critical for the next generation of antimalarials for use in global 
efforts to eliminate and eradicate malarial disease.  Following our recent work identifying halofuginone as 
potent inhibitor of the P. berghei liver stage in vitro, we investigated the activity of halofuginol 112. 
Halofuginol demonstrated potent inhibition (EC50 = 14 nM) of P. berghei ANKA liver stage parasites in vitro 
(Figure 2.4.1d). Supported by the good tolerability, activity against blood stage parasites and the 
confirmation of in vitro liver stage activity, we next investigated the in vivo activity of halofuginol in a P. 
berghei sporozoite challenge model 111.  As shown in Figure 2.4.1e, halofuginol reduced the growth of liver 
stage parasites by >99% following a single 5 mg/kg i.p. dose.  Importantly, similar efficacy was observed 
with a single oral bolus of 10 mg/kg that resulted in 95% reduced parasite load, indicative of oral 
bioavailability of halofuginol (Figure 2.4.1e) 113.  
Halofuginol Maintains the Antimalarial Potency but Lacks the Toxicity of Halofuginone in Mice. 
Gastrointestinal toxicity observed in mice has prevented halofuginone’s development as an antimalarial. 
Further clinical trials exploring halofuginone for cancer treatment have established nausea and fatigue as 
dose limiting 114, which is consistent with the well-documented emetic effects of febrifugine. Previous 
studies have reported significant toxicity in mice with an oral dose > 1mg/kg 113. Thus, we set out to 
compare halofuginone and halofuginol at therapeutically relevant doses. Consistent with previous findings, 
poor tolerability of halofuginone was evident at the efficacious doses of 0.5mg/kg p.o., and 1 mg/kg resulted 
in pronounced gastrointestinal toxicities (4/5) and lethality (1/5) (SFigure 2.5.3).  In contrast, treatment with 
halofuginol at the efficacious dose of 10 mg/kg p.o. reduced infection by >95% without evidence for 
gastrointestinal or other side effects from gross pathological assessment (Figure 2.4.1e). 
FORWARD GENETIC APPROACH CONFIRMS CYTOSOLIC PROLYL-TRNA SYNTHETASE (PFL0670C) AS MOLECULAR TARGET 
OF HALOFUGINOL IN P. FALCIPARUM 
The identification of the molecular mechanism of febrifugine derivatives in Plasmodium is of paramount 
interest for a comprehensive understanding of the antiprotozoal activity of this compound class and critical 
for the rational development of next generation antimalarials. We previously identified the bifunctional 
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glutamyl-prolyl-tRNA synthetase (EPRS) as the target of febrifugine analogs in metazoans 56.  However, the 
tRNA synthetase machinery differs greatly between humans and P. falciparum.  In humans the EPRS is the 
only enzyme with prolyl tRNA synthetase activity. EPRS forms the central framework of the multi-subunit 
complex (MSC) that is involved in a diverse number of biological processes 115.  In contrast, P. falciparum 
expresses two prolyl tRNA synthetases, one targeted to the apicoplast and one targeted to the cytoplasm.  
Due to the difference in tRNA synthetase machinery and large evolutionary distance between alveolates and 
metazoans, we selected an unbiased approach to identify the target of febrifugine derivatives in 
plasmodium.  
We chose a select-seq experimental design based on multiple independent drug resistance selection 
followed by whole genome sequencing to identify the acquired genetic mutations.  We carried out 
independent stepwise resistance selections under intermittent drug pressure with halofuginone (IC50 = 0.5 
nM) (Fig 2.4.1b) 83.  P. falciparum strains with decreased sensitivity to halofuginone were subjected to 
increased drug pressure until stable resistance was achieved (Figure 2.4.2A, B). 
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Figure 2.4.2: Identification and Validation of cPRS as target of Halofuginone in P. falciparum 
(A) Resistance selection under intermittent and dose-adjusted drug pressure allowed for generation of 
parasite strains with stepwise increased resistance to halofuginone. (B) Independent selection experiments 
starting from the Dd2 lab strain yielded two highly resistant clones. (C) Whole genome sequencing 
identified nonsynonomous mutations in HGFRI and HGFRII that map to the same amino acid codon (L482) 
in PfcPRS (PFL0670c). (D) Target Confirmations using a heterologous yeast model. +/-YHR020w 
heterozygous S. cerevisiae was transformed with a YHR020w-containing plasmid and haploid spores were 
selected for genomic deletion of YHR020w. The intermediate strain was transformed with a second plasmid 
with an orthogonal selection marker and YHR020w, codon optimized PFL0670c and mutant PFL0670c, 
respectively, and further selected for loss of the first plasmid. (E) Only transgenic S. cerevisiae expressing 
wild type PfcPRS (green) displayed dose-dependent sensitivity to halofuginone, while strains expressing 
ScPRS (blue) or the L482H PfcPRS mutant (red) were insensitive to halofuginone treatment up to 100uM (all 
strains are pdr1,3 deleted). In addition, MAZ1310 does not affect growth of PFL0670c expressing yeast 
(gray).    
 
We sequenced the full genome of two highly resistant parasite strains that were independently selected 
(HFGR-I (IC50 = 180 nM), HFGR-II (IC50 = 30 nM)) along with the parental Dd2 strain to identify the genetic 
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loci that contribute to halofuginone resistance 85,86. The only gene with nonsynonymous SNPs identified in 
multiple independently selected resistant strains was PFL0670c, which has been assigned as putative 
cytoplasmic proline amino acyl tRNA synthetase (PfcPRS) 116.  Importantly, both transversion mutations 
occurred in the same codon of PfcPRS (Figure 2.4.2C) translating in a L482H (HFGR-I) and L482F (HFGR-II) 
amino acid change, respectively.  The missense mutations were independently confirmed with a High 
Resolution Melting genotyping assay (SFigure 2.5.4) and verified by Sanger sequencing.  
Of the two prolyl tRNA synthetases in the P. falciparum genome, our forward genetic approach identified 
the ProRS that shares a high level of similarity with the human orthologue. The class II tRNA synthetase 
domains of EPRS and PfcProRS share 78% similarity.  These results suggest that the primary target of 
halofuginone and febrifugine is the P. falciparum cytoplasmic prolyl tRNA synthetase. This hypothesis is 
further supported by the observation that addition of exogenous proline to the in vitro culture media 
reversed the growth inhibition in a dose-dependent manner (SFigure 2.5.5). 
Furthermore, we found that the HFGR-I line was also resistant to febrifugine and halofuginol (SFigure 2.5.2), 
confirming that the molecular target identified for halofuginone, PfcPRS, is shared by all of our febrifugine 
derivatives.  
REPLACEMENT OF S. CEREVISIAE PRS BY PFCPRS CONFERS SENSITIVITY TO HALOFUGINONE AND HALOFUGINOL IN YEAST 
Saccharomyces cerevisiae PRS (ScPRS, YHR020w) is very similar to the P. falciparum cPRS and H. sapiens 
EPRS. Within the core Class II catalytic domains, the yeast PRS shares 77% and 70% similarity with human 
and plasmodium enzymes, respectively.  Despite the high similarity we discovered that S. cerevisiae was not 
sensitive to halofuginone.  This allowed us to use a yeast model for both target confirmation of halofuginone 
and validation of the resistance phenotype of the mutant alleles identified in our drug resistance selections. 
First, we performed a complementation test of PfcPRS in S. cerevisiae. We deleted the chromosomal copy of 
ScPRS, an essential gene and the only locus that codes for a prolyl tRNA synthetase in S. cerevisiae.  We 
found that episomal expression of PfcPRS   could complement the ScPRS knock-out strain.  Next, we 
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generated transgenic yeast strains that would express only ScPRS or PfcPRS , respectively (Figure 2.4.2d). 
While both strains exhibit comparable growth characteristics, only the PfcPRS-expressing strain displayed a 
dose-dependent sensitivity to halofuginone treatment (Figure 2.4.2e, SFigure 2.5.6). The sensitivity of the 
PfcPRS strain was attenuated by addition of free L-proline (SFigure 2.5.7).  
To validate the resistant allele L482H, we generated a yeast strain expressing L482H PfcPRS.  This strain was 
viable both in the presence and absence of halofuginone consistent with the L482H mutation conferring 
resistance to halofuginone (Figure 2.4.2e).  Similar activity was observed for the L482F mutant. None of the 
tested yeast strains were susceptible to inhibition by the control compound MAZ1310 55.  Halofuginol 
displayed an equivalent activity profile when tested against the wild-type and mutant yeast strains (SFigure 
2.5.8). 
MOLECULAR CHARACTERIZATION OF THE LIGAND-TARGET INTERACTION 
To provide a molecular rational for the experimental results, we modeled the binding dynamics of the 
Plasmodium falciparum PRS to ATP and halofuginone based on the recently published structure of ternary 
human PRS complex (PDB: 4HVC) 117.  Our model shows that the N- protonated hydroxypiperidine moiety 
of halofuginone is strongly stabilized by a network of hydrogen bonding interactions (Figure 2.4.3a), which 
cannot be formed by MAZ1310. As is to be expected from the high similarity (77%) of the Plasmodium 
falciparum PRS core catalytic domains including the complete identity of the active site residues, the 
interactions between halofuginone, ATP and PRS are essentially identical to the one discussed for the case of 
human PRS 117.  
Next, we investigated the L482H PfcPRS mutant to understand the experimentally observed insensitivity of 
this mutant; the Molecular Dynamics simulations revealed that the position of E361 changes from 
coordination to halofuginone (shown in white in Figure 2.4.3b) to a position where it is coordinated to S508 
and Y365. We hypothesize this structural change is due to the hydrogen bond that the mutant H482 residue 
establishes with S508, thus re-orienting S508 to hydrogen bond with E361. The experimental observation 
that the L482H mutant is less strongly inhibited by halofuginone thus underscores again the critical 
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importance of this interaction. The L482F mutation, on the other hand, induces steric repulsion with 
residues nearby, again disrupting the interactions in the binding pocket (SFigure 2.5.9).  
 
 
Figure 2.4.3: Models of the ternary complex of PfcPRS with ATP and halofuginone 
Comparison of wild-type (A) and L482H mutant (B) 
 
HALOFUGINOL, FEBRIFUGINE AND HALOFUGINONE INDUCE THE AMINO ACID STARVATION RESPONSE IN P. 
FALCIPARUM 
Following validation of PfcPRS as the molecular target of febrifugine and analogs, we turned our interest to 
understanding how the parasite senses amino acids and how halofuginol dysregulates these mechanisms.  
Like direct amino acid deprivation, inhibition of AARSs results in the accumulation of uncharged tRNA, 
which in turn binds and activates the eIF2α kinase GCN2 as the central control element of the conserved 
Amino Acid Starvation Response (AAR) pathway (SFigure 2.5.10) 118.  Recent research has confirmed the 
existence of a functional AAR in P. falciparum’s intraerythrocytic stage and demonstrated the 
phosphorylation of eIF2α in response to isoleucine starvation (the sole amino acid that can be fully depleted 
as it is the only amino acid that is absent from hemoglobin) 58,59.  However, treatment with isoleucine tRNA 
synthetase inhibitors unexpectedly did not induce eIF2α phosphorylation58.   
To probe for the induction of the AAR, we have treated asynchronous Dd2 cultures with halofuginol, 
halofuginone, febrifugine, or MAZ1310 and quantified the amount of eIF2α and p-eIF2α by Western blot 
analysis relative to amino acid deprivation. (2'R,2R,3S)-halofuginol (RRS-HFol), the active halofuginol 
enantiomer (see SFigure 2.5.2), halofuginone, and febrifugine treatment significantly increased eIF2α 
A B 
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phosphorylation in a dose dependent manner comparable to amino acid starvation (Figure 2.4.4a,b, SFigure 
2.5.11).  DMSO and MAZ1310-control treatments failed to increase levels of eIF2α phosphorylation.  
 
Figure 2.4.4: Halofuginol and Halofuginone Induce eIF2α Phosphorylation 
Western blot analysis of p-eIF2α and total eIF2α protein in drug-treated asynchronous Dd2 (A) cultures and  
3D7 (B) cultures relative to an amino acid starved reference (histone H3 serves as a loading control).  Each 
blot is representative of two independent replicates.  Halofuginone and febrifugine (A) and (2'R,2R,3S)-
halofuginol (active enantiomer) (B) induce phosphorylation of eIF2α after 90 minutes treatment. (C) 
Halofuginone treatment induces pronounced eIF2a phosphorylation in PFL0670c but not in YHR020w-
expressing S. cerevisiae.     
 
The amino acid starvation response pathway is well characterized in yeast and, as in the P. falciparum 
pathway, eIF2α is phosphorylated in response to amino acid starvation 59.  To further probe the underlying 
mechanism of growth inhibition by halofuginone we investigated the effect of drug treatment on eIF2α 
Ser51-phosphorylation levels in both PfcPRS and ScPRS expressing yeast strains. Only the halofuginone-
sensitive PfcPRS expressing strain exhibited robust induction of p-eIF2α in response to compound exposure 
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(Figure 2.4.4c), while no differential levels of eIF2α-phosphorylation were observed in the ScPRS expressing 
strain. 
2.5  DISCUSSION  
The need for new targets for anti-malarial drug development is universally recognized, and many have been 
proposed. However, well-defined, pharmacologically practical paths forward to new classes of drugs remain 
scarce.  Many traditional druggable targets such as kinases proved challenging to yield promising candidate 
targets 119. Febrifugine has been identified over 60 years ago as the active principle of one of the oldest 
known antimalarial herbal remedies. However, despite extensive efforts the underlying mechanism of 
febrifugine’s antiparasitic activity remained a mystery. Furthermore, poor tolerability has prevented the 
clinical use of the natural product as a mainstay antimalarial and medicinal chemistry efforts, which were 
hampered by the unknown mode of action, have failed to identify viable alternatives. 
We here report halofuginol, a novel halofuginone analog developed by our group, retains excellent in vivo 
activity against both human relevant malaria stages.  Dual-stage activity is essential for antimalarial drugs 
that will be used to eliminate and eradicate human malaria. Importantly, halofuginol, unlike febrifugine and 
halofuginone, was very well tolerated in vivo when dosed orally or intraperitoneally at pharmaceutically 
relevant concentrations and did not induce any signs of toxicity even after 4 days of treatment. This 
attractive pharmacological profile makes halofuginol a promising candidate for further preclinical 
development. 
Furthermore, we identify P. falciparum cytoplasmic Prolyl-tRNA-Synthetase (cPRS), one of two Prolyl-tRNA-
Synthetases encoded in the Plasmodium genome, in an unbiased target-ID approach as the functionally 
relevant target of halofuginone, halofuginol and febrifugine (Reviewed in 120 ). We support our findings by 
target validation in an orthogonal transgenic yeast model and provide a mechanistic rational for drug action 
on a molecular level. 
Previous reports have suggested that tRNA synthetases represent attractive targets for the treatment of 
malaria. However, there has been little exploration of tRNA synthetase inhibitors in malaria and the 
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validation of on-target mechanism has been elusive. Past efforts have primarily focused on isoleucine 
utilization, as it represents the sole amino acid that the parasite cannot obtain from hemoglobin digestion. 
Recently the isoleucyl tRNA synthetase inhibitors mupirocin and the isoleucine analog thiaisoleucine have 
been shown to kill blood stage parasites at mid-nanomolar and low micromolar concentrations, 
respectively. However, neither compound was capable of inducing the phosphorylation of eIF2α, which is a 
sensitive indicator of the starvation response and a hallmark of isoleucine withdrawal. Deepening the 
puzzle, isoleucine starvation, which would also be expected to act through limitation of isoleucyl tRNA 
synthetase activity, is not acutely toxic to the parasite but induces in a hibernatory state. Our work 
demonstrates that P. falciparum also senses restriction of proline with great sensitivity, which possibly further 
expands the field to study utilization of other amino acids. 
Our findings not only identify the first small molecule tRNA synthetase inhibitor that induce the amino acid 
starvation response in viable Plasmodium parasites, validating valuable chemical tools for chemogenomic 
approaches to study this pathway in P. falciparum and S. cerevisiae, but also establishes amino acyl tRNA 
synthetases as attractive targets for the development of new classes of antimalarials active against both the 
red blood cell and liver stages of malaria. The transgenic yeast strain in combination with halofuginone will 
further prove invaluable to mechanistically dissect nutrient deprivation signaling pathways.  These tools 
enable studies in S. cerevisiae to understand the independence/interrelatedness of the nutrient sensing of the 
AAR and the TOR pathways 121. 
The potent in vivo activity of halofuginol against both human relevant life-cycle stages is very encouraging 
and demonstrates that well tolerated and efficacious halofuginone analogs can be developed. Our findings 
that halofuginol also binds to the human EPRS suggests that the side effects observed with halofuginone and 
febrifugine are indeed caused by off-target effects. However, more detailed studies that are beyond the scope 
of this work will be required to rule out that the excellent tolerability is not only the result of a favorable 
pharmacokinetic profile.  
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We speculate that the broad-spectrum antiprotozoal activity of halofuginone could be due to conservation 
of the prolyl tRNA synthetase.  Halofuginone is currently approved in veterinary medicine to treat 
coccidiosis in poultry (caused by Eimeria tenella) and cryptosporidiosis in cattle (caused by Cryptosporidium 
parvum) 122-124.  Molecular phylogenetics of the catalytic domain of the ProRS confirmes that the ProRS of 
both veterinary parasites, E. tenella and C. parvum, displays 81 and 86 % similarity respectively to that of P. 
falciparum (SFigure 2.5.12). Furthermore, these agents may be effective against other human malarias such 
as P. vivax, which shares 95% conservation of the active site of the cPRS, and a wide swath of infectious 
diseases caused by protozoan parasites including toxoplasmosis and cryptosporidiosis.   
Combined with our recent identification of the human EPRS as the host target, the computational 
mechanistic study here provides a detailed understanding of the ligand-protein interaction with atomic 
resolution in both the human and parasite enzyme, establishing a clear path forward to the design of new 
inhibitors with dual-stage activity in humans that selectively target the malaria parasite. Given the excellent 
efficacy and excellent tolerability, halofuginol represents an attractive lead candidate for preclinical 
development.  
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CHAPTER 3:  
SEQUENTIAL EVOLUTION OF RESISTANCE TO HALOFUGINONE: 
EVIDENCE FOR GENETIC AND EPIGENETIC REGULATION 
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J.D.H. designed and performed HFGRII and HFGRIII in vitro selections. J.D.H. characterized selections and 
clones. E.M. aligned WGS data to a reference genome.  D.P.R called SNPs and performed the trajectory-
based sequencing analysis.  J.D.H performed additional sequencing analysis of CNVs.  J.D.H. designed and 
prepared samples for metabolite profiling experiments.  A.D. ran and quality-controlled the mass-spec 
analysis of metabolites.  C.C. and J.D.H. analyzed metabolite experimental data. J.D.H. designed and 
performed the HFG-induced resistance and clag expression experiments. 
 
3.2 Introduction 
We have previously described two mutations in the cytoplasmic prolyl tRNA synthetase (cPRS) that confer 
resistance to halofuginone.  We describe here the evolutionary trajectory of resistance of two independent 
drug resistance selections.  We show that non-genetic adaptation to halofuginone precedes mutation or 
amplification of the cPRS gene.  P. falciparum first rewires its proline homeostasis in response to 
halofuginone pressure through overexpression of the PSAC determinants cytoadherence-linked asexual gene 
(clag) 2 and clag 3.2.  By tracking the evolution of two drug resistance selections with by whole genome 
sequencing, we demonstrate that the cPRS locus accounts for the majority of genetic adaptation to 
halofuginone in P. falciparum.  We further validate that, in addition to mutations in the cPRS locus, copy-
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number variations also contribute to halofuginone resistance.  Finally, we provide a three-step model for 
multi-locus evolution of drug resistance via genetic and non-genetic adaptations in P. falciparum. 
3.3  MATERIALS AND METHODS 
METAGENOMIC WHOLE GENOME SEQUENCING OF HFG POPULATIONS SELECTED IN VITRO  
Genomic DNA extracted from bulk population cultures of the two independent lines selected for 
halofuginone resistance was extracted and sheared with a Covaris S220 Focused-ultrasonicator (Covaris 
Woburn, MA).  Illumina-compatible libraries were prepared on the Apollo 324 (WaferGen Biosystems 
Fremont, CA) and sequenced on an Illumina HiSeq 2000 (Illumina San Diego, CA).  P. falciparum 
populations were sequenced with the goal of reaching  over 60x average fold-coverage across the genome. 
Metagenomic Time Series Analysis to Identify Segregating Sites 
We used a two-stage process to distinguish real mutations from sequencing and alignment errors in the 
metapopulation time-series sequence data. First, we used the GATK (Broad Institute Cambridge, MA) to 
obtain a permissive list of candidate loci and the number of supporting reads for each allele in each time-
point. We used the haploid mode of GATK’s UnifiedGenotyper with a minimum confidence threshold phred 
score of 4 to obtain a permissive set of SNPs and small INDELs.  We further filtered this set of candidates 
based on two fundamental assumptions: first the two independent replicate populations should not share the 
exactly the same mutations. Second, the frequencies of a real mutation should be correlated through time 
(positive autocorrelation), while sequencing errors should be uncorrelated at different time points (negative 
or zero autocorrelation).  
Thus we 1) discarded all sites with an average coverage depth less than 10x across the time points, 2) 
discarded all sites with an average frequency above 1% in the non-focal population 3) I discarded all sites 
with a negative or zero autocorrelation. 4) Further, we noticed that the frequencies of alternate alleles at 
HFGRII time point 2-30x were aberrant despite deep coverage and we discarded this time point from the 
analysis due to potential contamination. 
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METAGENOMIC TIME SERIES ANALYSIS TO IDENTIFY SELECTIVE SWEEPS  
We took the unfiltered list of candidate loci called by the Unified Genotyper (GATK) and looked for 
mutations that began at a frequency near zero at the first time point and ended at a frequency near one at 
the last time point.  
METAGENOMIC TIME SERIES ANALYSIS TO IDENTIFY HITCHHIKING MUTATIONS ALONG WITH CPRS MUTATION IN 
HFGRII 
We searched for mutations that hitchhiked with the known mutation at the C1444T cPRS in HFGRII. To find 
hitchhiking mutations, we sorted the unfiltered list of candidate loci called by the Unified Genotyper (GATK) 
by the Euclidean distance between their allele frequencies trajectories and the frequency trajectory of the 
focal mutation.  
QPCR – COPY NUMBER ANALYSIS 
Genomic DNA was prepared from saponin-lysed P. falciparum parasites using the Qiagen Blood Mini- or 
Midi Kits (Qiagen Venlo, Limburg).  qPCR analysis was performed on an Agilent 7900HT Fast Real-Time 
System (Agilent Technologies Santa Clara, CA). System using unlabeled primers and Power SYBR Green 
master mix and.   Primers used for copy-number analysis are in Table 3.3.1 (target locus primers) and Table 
3.3.2 (control locus primers).  Copy number was calculated using the ΔΔCt method included in the SDS 
version 2.3.2 as described in the Applied Biosystems User Bulletin 2. 
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Table 3.3.1: qPCR Control Primers 
Gene Name Direction PlasmoDB ID Sequence (5’ to 3’) 
fructose-bisphosphate 
aldolase Forward PF3D7_1444800 TGTACCACCAGCCTTACCAG 
fructose-bisphosphate 
aldolase Reverse PF3D7_1444800 TTCCTTGCCATGTGTTCAAT 
B-tubulin Forward PF3D7_1008700  CGTGCTGGCCCCTTTG 
B-tubulin Reverse PF3D7_1008700  TCCTGCACCTGTTTGACCAA 
Seryl tRNA Synthetase 
Forward PF3D7_0717700  
TATCATCTCAACAGGTATCTACATC
TCCTA 
Seryl tRNA Synthetase 
Reverse PF3D7_0717700  
TTTGAGAGTTACATGTGGTATCAT
CTTTT 
 
Table 3.3.2: qPCR Primers for cPRS Target 
Gene Name 
Region of 
Gene Direction PlasmoDB ID Sequence (5’ to 3’) 
Prolyl tRNA 
synthetase (cPRS) 5' Forward PF3D7_1213800  
TGCTATAAGACCAACAA
GTGAAACA 
Prolyl tRNA 
synthetase (cPRS) 5' Reverse PF3D7_1213800  
ACGTACCACAGTATTCC
ATTGATTT 
Prolyl tRNA 
synthetase (cPRS) 3' Forward PF3D7_1213800  
CCAAACAAACAGTGAAA
CGACAT 
Prolyl tRNA 
synthetase (cPRS) 3' Reverse PF3D7_1213800  
TAGGTGGTTGATCTAAC
GGGATAC 
 
 
IN VITRO DRUG SENSITIVITY AND DOSE-RESPONSE ANALYSIS BY SYBR GREEN STAINING 
The SYBR Green I method was used as previously described82.  In brief, we grew P. falciparum parasites for 
72 hours in 384-well plates at 1% hematocrit and 1% starting parasitemia.  Growth was assessed by SYBR 
Green staining of parasite DNA.  All dose-response assays were carried out with twelve-point curves in 
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technical triplicate.  DMSO stocks of drugs used were dispensed by HP D300 Digital Dispenser (Hewlet 
Packard Palo Alto, CA).  Fluorescence measurements were collected on a SpectraMax M5 (Molecular 
Devices Sunnyvale, CA) and analyzed on GraphPad Prism version 5 (GraphPad Software La Jolla, CA) and 
EC50 values were determined with the curve-fitting algorithm log(inhibitor) vs. response – Variable slope. 
IN VITRO DRUG SENSITIVITY AND DOSE-RESPONSE ANALYSIS BY TRITIATED HYPOXANTHINE ASSAY 
Halofuginone dose-response assays were performed as described by Desjardins et al. using the initial drug-
resistance selected HFGRII parasites125. 
PARASITE CULTURE  
Malaria culture was performed as described by Trager et al. 81.  Dd2 is a chloroquine resistant in vitro 
cultured parasite cloned from the Laos derived W2-MEF parasite obtained from MR4 (ATCC Manassas, 
Virginia).  
FLOW CYTOMETRY 
Flow cytometry of P. falciparum infected erythrocytes was carried out based on SYBR Green I staining of 
parasite nuclei as previously described 126.  Modifications to the Bei et al. protocol include staining of iRBC 
with SYBR Green I at a 1:2000 concentration, acquisitions of non-single cells were pre-filtered for cells that 
fell on the y=x line in a plot of forward scatter area vs. height. All Flow Cytometry was collected on a 
MACSQuant Flow Cytometer (Miltneyi Biotec Inc. San Diego, CA) and analyzed with MacQuantify and 
FlowJo 8.8.6 software (Tree Star Ashland, OR). 
LC-MS ANALYSIS OF AMINO ACIDS AND POLAR METABOLITES  
Highly synchronous (within 4 hours) early schizonts were magnetically purified with MACS CS columns 
(Miltenyi Biotec). A small aliquot was also made for flow cytometry.  The rest of the purified samples were 
divided into two equal volumes: one for saponin lysis (0.025%) and one for whole iRBC extraction.  Each 
sample was washed 2x in PBS, and then suspended in 10 uL PBS.  Polar metabolites were extracted using 
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nine volumes of 74.9:24.9:0.2 (v/v/v) acetonitrile/methanol/formic acid containing stable isotope-labeled 
internal standards (0.2 ng/µL valine-d8 (Isotec); and 0.2 ng/µL phenylalanine-d8 (Cambridge Isotope 
Laboratories)). Profiles of amino acids were measured using LC-MS as described previously127.  Briefly, 
positive ionization, multiple reaction mode (MRM) data were acquired using a 4000 QTRAP triple 
quadrupole mass spectrometer (AB SCIEX) coupled to an 1100 Series pump (Agilent) and an HTS PAL 
autosampler (Leap Technologies). Cell extracts (10µL) were injected onto a 150 x 2.1 mm Atlantis HILIC 
column (Waters). The column was eluted isocratically at a flow rate of 250 µL/min with 5% mobile phase A 
(10 mM ammonium formate and 0.1% formic acid in water) for 1 minute followed by a linear gradient to 
40% mobile phase B (acetonitrile with 0.1% formic acid) over 10 minutes. The ion spray voltage was 4.5 kV 
and the source temperature was 450°C. MultiQuant 1.2 software (AB SCIEX) was used for automated peak 
integration and metabolite peaks were manually reviewed for quality of integration and compared against a 
known standard to confirm identity.  Stable isotope-labeled internal standards were used to eliminate 
samples with poor data quality.  Metabolite peaks signals were normalized by flow cytometry-determined 
cell counts and compared to PBS and uninfected red blood cell control measurements.  Pearson correlation 
analysis was performed in prism and heat maps were generated with Gene-e (Broad Institute). 
QPCR – GENE EXPRESSION ANALYSIS 
Total RNA was extracted using Trizol (Life Technologies Carlsbad, CA) according to manufacturer 
instructions, DNAse-treated, and re-purified with Qiagen RNeasy mini columns ((Qiagen Venlo, Limburg)).  
First strand cDNA synthesis was performed using SuperScript III (Life Technologies) following manufacturer 
instructions. The absence of contaminating DNA and the success of the reverse transcriptase reaction were 
confirmed by comparing qPCR of Rt+ and Rt- with the control Seryl tRNA synthetase primer set in 
quadruplicate; samples were run on and ABI 7900 HT and fold-expression calculated using the ABI software 
suite SDS 2.3.2. cDNA concentrations were normalized to SerRS Ct values to minimize biases in PCR 
efficiency.  Samples were run in quadruplicate with two control primer sets for validation of expression 
analysis.  PCR amplification was performed as follows: 15 minutes at 95 °C followed by 40 cycles of two-
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step amplification of 94 °C for 30 s and 52 °C for 30 s. All primers used for expression analysis (Table 3.3.3 
and 3.3.4) were validated for specificity and efficiency under the same PCR conditions. 
Table 3.3.3: qPCR primers for clag gene family expression analysis 
Gene Name Direction PlasmoDB ID Sequence (5’ to 3’) 
Clag 2 Forward PF3D7_0220800 CTCTTACTACTTATTATCTATCTCTCA 
Clag 2 Reverse PF3D7_0220800 CCAGGCGTAGGTCCTTTAC 
Clag 3.1 Forward PF3D7_0302500 ACCCATAACTACATATTTTCTAGTAATG 
Clag 3.1 Reverse PF3D7_0302500 TCTGAACTAGGAGGCCAACC  
Clag 3.2 Forward PF3D7_0302200 ACCCATAACTACATATTTTCTAGTAATG 
Clag 3.2 Reverse PF3D7_0302200 TTCAGCAGCAAGTCCGTGA 
Clag 8 Forward PF3D7_0831600  GTTACTACAACATTCCTGATTCAG  
Clag 8 Reverse PF3D7_0831600  AATGAAAATATAAAAATGCTGGGGGAT 
Clag 9 Forward PF3D7_0935800 TACCATTAGTGTTTTATACACTTAAGG 
Clag 9 Reverse PF3D7_0935800 CCAAAATATGGCCAAGTACTTGC 
 
3.4  Results 
TRACKING IN VITRO EVOLUTION OVER TIME BY WHOLE GENOME SEQUENCING 
From our previous work to identify the target of halofuginone, we performed end-point whole genome 
sequencing on three in vitro evolution experiments: HFGRI, HFGRII, and HFGRIII.  For two of these 
selections, HFGRII and HFGRIII, we collected phenotypic data and genetic material from multiple time-
points .  At cycle 40, we performed whole genome sequencing of HFGRII and HFGRIII though we continued 
our selection for another 15 generations.  In Chapter 2 we identified a L482F mutation in the cytoplasmic 
Proline tRNA Synthetase (cPRS) in HFGRI selection and an L482H mutation in the cPRS of HFGRII selection. 
In this paper, we present a genomic look at the step-wise evolution of halofuginone resistance in HFGRII 
and HFGRIII.  We independently selected two populations with increasing intermittent drug pressure that till 
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we obtained parasites capable of growing in 140 nM halofuginone, which is 200-times the EC50 of the 
parental Dd2 line.  We performed whole genome sequencing of the entire evolving population to track the 
rise and fall of mutant alleles over 50 generations (HFGRII) and 58.5 generations (HFGRIII) as displayed in 
Tables 3.4.1 and 3.4.2. 
Table 3.4.1: Sequenced time points from the HFGRII in vitro evolution experiment 
HFGRII 
Population 
Time Points 
Sequence 
Generations 
Drug 
Pressure 
(EC50) 
Drug 
Pressure 
(nM) 
Fold 
Coverage 
HFGRII 2-10x 18 2-10x 7 185 
HFGRII 1-30x 23 1-30x 21 263 
HFGRII 2-30x 27 2-30x 21 141 
HFGRII 2-60x 34 2-60x 42 
 
232 
HFGRII 1-200x 41 1-200x 140 
  
235 
HFGRII 2-200x 50 2-200x 140 181 
 
Table 3.4.2: Sequenced time points from the HFGRIII in vitro evolution experiment 
 
HFGRIII 
Population Time 
Points Sequence 
Generations 
Drug 
Pressure 
(EC50) 
Drug 
Pressure 
(nM) 
Fold 
Coverage 
HFGRIII 2-10x 18 2-10x 7 12 
HFGRIII 1-30x 23 1-30x 21 263 
HFGRIII 1-60x 32 1-60x 42 241 
HFGRIII 2-60x 36 2-60x 42 246 
HFGRIII 1-200x 45 1-200x 140 240 
HFGRIII 2-200x 55 2-200x 140 92 
HFGRIII 3-200x 58.5 3-200x 140 92 
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A VIEW OF A GENOME EVOLVING WITH FEW MUTATIONS FIXING IN THE POPULATION 
We used our time-course data from HFGRII and HFGRIII to distinguish true mutations from sequencing or 
alignment-introduced error.  From this analysis framework, we found a paucity of genomic mutations over 
time.  To our surprise, most of the genetic adaptation during our evolution experiments occurred at the cPRS 
locus.  With this method, we confirmed the evolution of the L482F cPRS mutation in HFGRII.  The L482F 
mutation first appeared at 27 generations at a 0.6% allele frequency; we manually verified that the 2 out of 
332 reads supporting this call were high quality and ruled out sequencing artifact.  However, the cPRS 
mutation in HFGRII did not proceed to fixation as we would have assumed.  It reached a maximum allele 
frequency of 57%.  After 20 additional generations, the L482F mutation was competed out and disappeared 
from the population (Figure 3.4.1a).  In contrast, we found that no SNPs proceeded to fixation in HFGRIII 
over the course of the experiment.   
Outside of the cPRS, we found one other mutation that passed through our filters in HFGRII: 
Pf3D7_1402700, a pre-mRNA splicing factor on chromosome 14. From generation 41 to generation 50 of 
HFGRII, the A->T mutation went from 3 to 51% of aligned reads.  However, this was only supported by 3 
and 21 reads respectively and could possibly be remaining artifact.  Using the same filtering methodology in 
HFGRIII, we did not find a single segregating SNP that was not subtelomeric.  Although such subtelomeric 
mutations could be an alignment error, they often occur in repeated gene families that recombine more 
frequently.   
As orthogonal approaches to our filtering approaches, we also looked for mutations that would have went to 
fixation over the course of the selection or any that hitchhiked with the HFGRII cPRS mutation.  Both 
analytic approaches did not find any candidate mutations that either fixed during the selection or were 
tightly linked to the HFGRII cPRS mutation.  Without mutations sweeping to fixation, drug resistance might 
be achieved in these populations by multiple mutations in independent lineages or may not be due to SNPs 
or small INDELs and thus could have been missed by this metagenomic sequencing approach. 
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A SEARCH FOR NON-GENETIC ADAPTATIONS TO HALOFUGINONE DURING EARLY ADAPTATION 
It was evident from our whole genome sequencing data that copy number variation (CNV) at the cPRS locus 
played a role in developing halofuginone resistance.  We tracked the cPRS amplification in the two 
selections with qPCR relative quantification.  We found that the cPRS gene amplification occurred by 
generation 50 in HFGRII and generation 32 in HFGRIII.   
 
Figure 3.4.1: cPRS copy number and mutational variation of in vitro evolution experiments  
Copy number was determined by ΔΔCt qPCR with SerRS as an endogenous control and allele balance was 
determined by analysis of next generation whole genome sequencing data from the HFGRII (a) and HFGRIII 
(b) in vitro evolution experiments. 
From genetic analysis, we can identify adaptations at the cPRS locus from generation 32 and on, in both in 
vitro evolution experiments.  However, acquisition of halofuginone resistance preceded cPRS copy 
expansion (Figure 3.4.1a,b).  By cycle 27 in HFGRII, the bulk population had 18-fold decreased sensitivity to 
halofuginone (Figure 3.4.2). 
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Figure 3.4.2: The acquisition of halofuginone resistance precedes genetic adaption in HFGRII 
Resistance is quantified as the fold-increase in EC50 of the total population over the EC50 of the Dd2 
parental line. The red arrow points to cycle 32, where the cPRS mutation first reaches an allele frequency of 
0.57.  EC50s were determined by a tritiated hypoxanthine incorporation dose-response assay. 
To validate this phenomenon, we recreated the early steps of our evolution experiments but evaluated them 
much earlier on in the process of adaptation.  We put wild type (WT) Dd2 parasites under constant 
halofuginone pressure (2.8nM).  Within 8-9 generations, both replicate-treated Dd2 lines were more than 
20-fold resistant compared to an untreated Dd2 line (Figure 3.4.3a).  Since this Dd2 parasite line was the 
same used for our in vitro evolution experiment, we replicated these results in the unrelated parasite line 
3D7 (Figure 3.4.3b). From here on we will refer to this phenomena as induced resistance. 
  
Figure 3.4.3: Short-term treatment of wild-type parasites results in immediate induction of halofuginone 
resistance 
(a) Dd2 and (b) 3D7 induced parasites have increased halofuginone EC50 values determined by SYBR Dose-
Response Assay. 
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INCREASED PROLINE CONCENTRATION RESULTS IN ABRUPT INDUCTION OF HALOFUGINONE RESISTANCE  
Surprised that 20-fold resistance could be acquired only over 8 generations of exposure we conceived of 
two possible explanations for the results: non-genetic adaptation or fixation of prior-existing genetic 
diversity.  We first investigated amino acid homeostasis in our induced parasites based on our knowledge of 
their effects on cell-based responses to halofuginone.  In Chapter 2 we found that increased environmental 
proline can alter halofuginone dose-response (Herman et al. submitted).  Furthermore, proline is the only 
one of the three cPRS substrates that we believe competes with halofuginone for the cPRS binding pocket.  
 
Figure 3.4.4: Induced Parasites Specifically Upregulate Intracellular Proline Concentration 
(a)(b) Amino acid levels of purified Dd2 untreated and induced P. falciparum parasites (a) and total P. 
falciparum infected erythrocytes (iRBC) (b) Amino acid measurements are expressed as the integrated peak 
intensity per 105 cells.   
(c) Fold-increase in amino acid concentration upon induction is expressed as a ratio of halofuginone pre-
exposed over unexposed concentrations. 
(d) Parasite and iRBC proline concentration in both biological-replicate induced parasites. 
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Of the 19 amino acids we measured with our LC-MS approach, proline was uniquely upregulated in 
induced parasites (Figure 3.4.4a) and total infected erythrocytes (iRBC) (Figure 3.4.4b); our iRBC 
measurements represent magnetically-purified red blood cells and thus represent the sum of both parasite 
and erythrocyte cytoplasmic proline pools.  Induction produced a 3-5 fold increases in iRBC proline and 19-
32 fold increases in purified parasites proline levels (Figure 3.4.4c).  Our biological replicate inductions of 
Dd2 parasites showed similar increases in parasite and iRBC proline (Figure 3.4.4d). 
ABRUPT INDUCTION OF HALOFUGINONE RESISTANCE OCCURS THROUGH CLAG GENE OVEREXPRESSION 
Among 19 amino acids measured in induced and un-induced Dd2 parasites, we saw higher correlation 
between other amino acids and proline levels in the total iRBC samples than in purified parasites (Figure 
3.4.5a). The three amino acids most highly correlated with proline were tyrosine, methionine, and 
isoleucine.  Since all three amino are essential exogenous nutrients for in vitro growth 60 we thought a more 
general amino acid importation mechanism on the surface of the red blood cell could be involved.  Thus, 
we chose to determine if the parasite-specific anion current (PSAC) that is responsible for the increased 
permeability of Plasmodium-infected erythrocytes was involved in induced halofuginone resistance.  To 
probe this, we investigated the expression of the NPP/PSAC-associated clag gene family in induced parasites.  
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Figure 3.4.5: Stronger Correlation of Other Amino Acids with Proline in iRBC Leads us to Clag 
Overexpression  
(a) Heatmap of R^2 correlation coefficients between proline concentration and a second amino acid in 
measurements of Dd2 untreated and Induced parasites.  Correlation of amino acid fluctuations was 
examined separately for purified parasites and iRBCs. *P(two-tailed)<0.05. P-values for amino acids 
statistically significantly correlated with proline levels in iRBCs: Methionine p=0.0237, Isoleucine p=0.0379. 
(b) Expression analysis of the Clag gene family in highly synchronous induced and untreated Dd2 early 
schizonts.  FBP-Aldolase is included as a second control. SerRS was the endogenous control primer set used 
for ΔΔCt analysis. 
We found that Clag 2 and Clag 3.2 expression to be robustly upregulated in Dd2 parasites with 
halofuginone-induced resistance.  Clag 8 was also upregulated in both replicate Dd2 induced parasites, but 
to a lesser extent (Figure 3.4.5b).  
INDUCED HALOFUGINONE RESISTANCE IS UNLIKELY TO HAVE A GENETIC CAUSE 
Over three months, induced halofuginone resistance has been a stable phenotype. Both Dd2 and 3D7 
parasites have remained resistant over these three months without halofuginone drug pressure.  To address 
the possibility that preexisting genetic diversity could have been selected upon and fixed in 8 generations, 
we performed whole genome sequencing of Dd2 untreated and two biological replicate inductions of Dd2.  
We are still awaiting the sequencing results. 
However, we have been able to characterize the cPRS locus of Dd2 induced and untreated strains. 
Resequencing of the entire cPRS gene did not identify any cPRS mutations in the induced parasites (Figure 
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3.4.6a).  Similarly, we found no significant change in cPRS expression in Dd2 induced parasites (Figure 
3.4.6b).   
 
Figure 3.4.6: Induced Dd2 parasites have no evidence of genetic modifications at cPRS locus 
(a) Sanger sequencing across the cPRS allele revealed that induced and untreated Dd2 strains have WT cPRS 
alleles.  The codon where HFGRI (T14445A) and the HFGRII (C1444T) mutations occurred is highlighted in 
yellow. 
(b) Expression of cPRS in synchronous early schizonts is invariant between untreated and induced Dd2 
parasite lines.  
 
LIKE DD2-INDUCED LINES, HFGII, AND HFGRIII IN VITRO EVOLVED LINES HAVE UNIQUELY INCREASED PROLINE 
POOLS 
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Figure 3.4.7: HFGRII and HFGRIII in vitro Evolved Halofuginone Resistant Lines Have Increased Proline 
Concentration 
(a)(b) Concentration of 19 measured amino acids in (a) purified parasites and (b) infected RBCs from the 
parental Dd2 line and clones from in vitro selected lines HFGRII and HFGRIII.  Data is displayed as 
integrated peak intensity per 105 cells. 
(c) Relative proline concentration in clones from in vitro selected HFGR lines. Concentrations are relative to 
the parental Dd2 line. 
 
We found that purified parasites cloned from the 2-200x selection time point (50 and 55 generations 
respectively) of HFGRII and HFGRII in vitro selected lines had dramatically increased proline concentration 
in purified parasites (Figure 3.4.7a) and iRBC (Figure 3.4.7b). Similar to induced Dd2 parasites, in vitro 
evolved lines showed similar amino acid selectivity for increased proline and far greater enrichment of 
proline in purified parasites than total iRBCs (Figure 3.4.7c). 
COPY NUMBER VARIATION AT CPRS LOCUS CONTRIBUTES TO HFG RESISTANCE 
Intrigued by our observations of cPRS locus amplification from whole genome sequencing, we confirmed 
this observation with qPCR over the span of the in vitro evolution experiments.  While we verified the 
amplification of the cPRS locus in HFGRII (Figure 3.4.1a) and HFGRIII (Figure 3.4.1b), we also found an 
interesting difference in the temporality of this amplification.  HFGRIII, the culture without cPRS mutations, 
had evidence of amplification 18 generations before HFGRII. 
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Although the HFGRIII 2-200x (Generation 55) parasite clones are from the same genetic background and 
grew in parallel in the same in vitro evolution experiment, we wanted to eliminate the chance that genetics 
factors beyond the cPRS locus could account for the HFG drug resistance.  We are currently performing 
whole genome sequencing on the three clones and are still awaiting the sequencing results. 
To explore the effect that cPRS copy number variation plays in resistance to halofuginone, we cloned by 
dilution the end point HFGRIII parasite population, HFGRIII 2-200x.  We obtained 14 clonal lines and found 
an allele frequency spectrum dominated by parasites with 3 copies of cPRS (Figure 3.4.8).  We chose 3 
parasite clones with 1, 2, or 3 copies of cPRS (Figure 3.4.9a).  We found that halofuginone resistance in our 
SYBR dose-response assay increased with the number of copies of cPRS (Figure 3.4.9b).  Furthermore, the 
correlation between cPRS copy number and drug resistance was limited to halofuginone and not to any of 
10 other antimalarial compounds we tested (Table 3.4.3). 
 
Figure 3.4.8: Copy number variation frequency spectrum at cPRS locus in HFGRIII 2-200x cloned parasites  
 
Figure 3.4.9: Amplification of cPRS confers resistance to halofuginone 
(a) Copy Number variation determined by qPCR of three clones investigated for sensitivity to HFG using the 
3’ cPRS assay. (b) SYBR assay confirms that more cPRS copies desensitize parasites to HFG. 
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Table 3.4.3: Correlation between cPRS copy number and drug resistance 
Antimalarial Compounds R^2 
Amodiaquine 0.1811 
Artemisinin 0.01341 
Atovaquone 0.01929 
Dihydroartemisinin 0.008082 
Doxycycline 0.7748 
Geldanamycin 0.3254 
Guanabenz 0.2477 
Halofuginone * 0.9963 
Mefloquine 0.01006 
Mg132 0.08533 
WR 99210 0.04343 
R^2 Pearson correlation coefficients of the relationship between cPRS copy number and the EC50 values of 
11 antimalarial compounds.   The parasites used for this analysis were HFGRIII 2-220x Clone H3 (1 Copy), 
H6 (2 Copies), and A8 (3 Copies). * Two-tailed t-test P-value <0.05. 
3.5  Discussion 
TRNA SYNTHETASE INHIBITORS AND AMINO ACID HOMEOSTASIS 
The past three years has seen an upswing in interest in tRNA synthetases as drug targets in eukaryotic 
parasites 128.  Exciting new work has demonstrated that small molecules that can inhibit isoleucine tRNA 
synthetase 58 lysine tRNA synthetase 129,130 and threonine tRNA synthetase 131, and proline tRNA synthetase 
(Chapter 2) in P. falciparum.  This work has focused on target identification and validation of these inhibitors 
and has neglected the complex genus-specific mechanisms of amino acid homeostasis that greatly affect the 
potency and clinical future of antimalarials that target tRNA synthetases. 
The malaria parasite has a dual proline supply in the erythrocytic stage.  Within the red blood cell, P. 
falciparum parasites digest human hemoglobin, which is 4.9% proline.  P. falciparum also imports amino 
acid from the extracellular milieu.  There are several lines of evidence that support that P. falciparum uses 
both. Proline is one of seven amino acids that must be in the media used for in vitro cultivation of P. 
falciparum 60.  In addition, the new permeability pathway (NPP) / parasite-specific anion current (PSAC) that 
is responsible for the selective increase in permeability of early trophozoite infected red blood cells 
increases flux of many amino acids 61 including proline 62. 
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GENETIC FACTORS EXPLAIN PART BUT NOT ALL OF OBSERVED RESISTANCE 
We approached the question of how the parasite evolves resistance to halofuginone from a conservative 
perspective.  By observing two independent populations, we were able to see snap-shots of evolution.  
Within the cPRS locus, we saw two different genetic mechanisms of drug resistance: mutation and 
amplification.  In Chapter 2, we identified the nonsynonymous C1444T mutation in the cPRS gene that arose 
during the HFGRII in vitro selection.  In both HFGRII and HFGRIII we saw amplification of the cPRS locus.  
Here, we have shown that amplification of the cPRS locus results in increased halofuginone resistance 
(Figure 3.4.9, Table 3.4.3).   
However, these two genetic pieces of evidence only partially explained the acquisition of resistance we 
mapped in our in vitro evolution experiments.  We saw a 20-fold increase in halofuginone dose-response 
(Figure 3.4.2) before the SNP in HFGRII or amplification in HFGRIII reached a high enough frequency to be 
detected by our deep-coverage whole genome sequencing or qPCR CNV assay. 
We adopted two approaches to explore other mechanisms for the acquisition of drug resistance: one genetic 
and one non-genetic.  Looking for additional genetic contributors outside of the cPRS locus, we performed 
whole genome sequencing of snap-shots taken along the course of two evolution experiments.  We found 
that no SNPs or small INDELs fixed in HFGRII or HFGRIII over the selection.  Also, in HFGRII we found that 
no SNPs or small INDELs hitchhiked also with the C1444T cPRS.  Using a series of filters to distinguish 
segregating SNPs and INDELs from noise regardless of fixation in the population, we found one other 
mutation in HFGRII that only occurred in the last two genetic snap-shots.  Thus, a potential mutation in 
PF3D7_1402100 could further explain the high level resistance we found at the end of HFGRII, but not the 
early adaptation unexplained by genetic adaption at the cPRS locus. 
The second approach assumed that epigenetic adaptations could explain the ‘missing resistance’ from our 
genetic story.  To probe the early evolutionary dynamics we had yet to understand in our long-term 
evolutionary experiments, we treated wild-type strains Dd2 and 3D7 with 2.8nM (4xEC50) halofuginone.  
We found both acquired halofuginone drug resistance within 8-9 generations (Figure 3.4.3a,b).   
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The abrupt adaptation itself implies a non-genetic phenomenon is the most likely explanation.    The initial 
population size of 109 parasites in each of these induction experiments argues against the possibility that a 
novel mutation (present at an allele frequency of 1/109) arising in the first generation would have enough 
fitness advantage become fixed in the population after 7 additional generations.  Additionally, acquisition of 
this induced resistance phenotype in two separate strains argues against pre-existing parasite sub-
populations with a HFG-resistance trait that could fix and cause the rise in halofuginone resistance we have 
observed.  To rule out the pre-existing or de-novo mutation hypotheses, we are performing whole genome 
sequencing of the two induced Dd2 lines and their parental strain. 
Using our induced resistance parasite lines, we sought to understand the non-genetic acquisition of 
resistance to halofuginone.  Our attention turned to amino acid homeostasis because proline is one of the 
three substrates of cPRS.  We knew from previous testing that increased proline levels in culture media 
increased halofuginone EC50 in SYBR dose-response assays (Chapter 2).  Based on this evidence we 
measured intracellular amino acid levels in our Dd2 parasites with induced halofuginone resistance. 
INTRACELLULAR PROLINE CONCENTRATION LINKED TO HALOFUGINONE RESISTANCE 
We measured the concentration of 19 amino acids in induced and untreated Dd2 parasites and found 
proline to be uniquely upregulated.  We examined the metabolomics picture of these parasites by measuring 
both purified P. falciparum parasites and P. falciparum infected erythrocytes.  This provided further insight 
into the dynamics of proline accumulation that may contribute to induced halofuginone resistance.  Both 
purified parasite and total iRBC showed increased proline concentrations upon induction (Figure 3.4.4 a,b). 
 However, total iRBC samples from induced parasites show slightly upregulated levels of multiple amino 
acid; these concentrations correlated with more strongly with proline in iRBC than purified parasites (Figure 
3.4.5a).  The magnitude of proline enrichment is also substantially different between purified parasites and 
iRBC; induction resulted in a 3-5 fold increase in iRBC proline and a19-32 fold increase in parasite proline . 
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To validate that the increased proline pools observed in our halofuginone-induced parasites also occurred in 
our in vitro evolution experiments, we measured levels of the same 19 amino acids in end point clones of 
HFGRII and HFGRIII selections.  We confirmed our suspicion that clones from both halofuginone evolved 
lines had elevated proline levels (Figure 3.4.7 a, b).  
Based on the parasite’s two sources of proline, we created two working models to explain the underlying 
mechanisms of observed amino acid homeostasis alterations.  In the first, halofuginone induction modulates 
hemoglobin degradation regulation.  Following this hypothesis, the parasite would have to upregulate 
hemoglobin degradation to increase the parasite proline pool. However, to achieve the proline-specific 
enrichment that we have observed, the parasite would have to specifically efflux non-proline amino acids 
into the erythrocyte and then from the erythrocyte into the extracellular environment.  Amino acid efflux 
transporters have been identified in prokaryotes such as Corynebacterium glutamicum and Escherichia coli 
132 but have yet to be described in eukaryotes or Apicomplexa specifically.  Additionally, the selective 
advantage for P. falciparum to contain non-proline amino acid efflux machinery remains to be 
demonstrated.  Thus, we view this first model as unlikely. 
Our second working model is based on increased and selective importation of proline from the extracellular 
milieu.  The difference between iRBC and parasite measurements in selectivity and magnitude of proline 
enrichment supports a two-step model of proline import. In this model, a subset of amino acids, including 
proline, are transported across the erythrocyte membrane by a P. falciparum-altered mechanism.  Then, 
proline is transported across the parasitophorous vacuole and parasite membrane.  This model is consistent 
with two separate transport or transport-effector mechanisms activated by halofuginone-induced resistance. 
CLAG OVEREXPRESSION LINKED TO INDUCTION OF HALOFUGINONE RESISTANCE 
Based on this model, we investigated the expression of clag genes in our parasite with induced resistance.  
Clag 3 has been identified as a genetic determinant of the PSAC channel 20.  Pillai et al. reported up 
regulation of a larger clag repertoire (Clag 3.2 and Clag 2) when they selected for Clag 3.2 expression by 
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growing Dd2 parasites in custom media and clag 3.1-inhibitor ISPA-28 133.  Two groups recently found clag 
3 expression to be down regulated in P. falciparum parasites resistant to blasticidin S 63,64. 
We found that clag 2 and 3.2 had strongly increased expression in parasites with halofuginone induced-
resistance (Figure 3.4.5 b).  Our observations demonstrate that Plasmodium parasites use clag genes to 
regulate amino acid transport as a mechanism of drug resistance.  More strikingly, these results implicate 
clag 2 and clag 3.2 genes in regulation of PSAC importation specificity that has not been reported before. 
We hypothesize that upregulation of clag gene expression in response to halofuginone causes increased 
intracellular proline, which inhibits the halofuginone activity at the cPRS.  We recognize that it is unlikely 
that only clag 2, 3.2, and 8 are responsible for the proline-specific regulation of importation at the red blood 
cell surface.  It remains to be shown whether non-clag effectors of the PSAC channel or of other erythrocyte 
surface receptors are involved in HFG-induced resistance.  We also recognize that we not addressed the 
mechanism of parasite surface proline import.  There is a large diversity of amino acid transporters; there are 
over 2-dozen families and superfamilies recognized with greatly varying specificity and selectivity for amino 
acids and their derivatives 134.  We have identified nine P. falciparum genes with homology to different 
families of amino acid transporter proteins (AATs).  We will address both outstanding issues with RNA-seq 
based expression studies we are currently undertaking of Dd2 parasites with HFG-induced resistance. 
The amino acid homeostatic mechanisms witnessed in these halofuginone experiments have demonstrated 
that proline levels are regulated in response to external pressures.  It is possible that this complex epigenetic 
regulation of intracellular solutes could be unique to proline-focused drug pressure.  However, it is more 
likely a general mechanism of drug-resistance to tRNA synthetase inhibitors including mupriocin and 
cladosporin. 
GENERAL MODEL OF MULTI-STEP EVOLUTION OF RESISTANCE TO HALOFUGINONE 
At first glance our 50 plus generation halofuginone in vitro evolution experiments and the rapid induced 
resistance we found after 18 days appear discordant.  However, our in vitro evolution experiments used 
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much higher concentrations of halofuginone.  This created an entirely different fitness landscape under 
which the malaria parasites adapted and resulted in different magnitudes of resistance.  After the full course 
of in vitro evolution, strains are as much as 300-fold resistant to halofuginone.  However, induced Dd2 or 
3D7 parasites show only 20-fold resistance. 
To explain the multistep mechanisms of halofuginone drug resistance, we propose a multi-step adaptation 
process that maximizes fitness in increasing concentrations of halofuginone.  In the first phase of our in vitro 
evolution, resistance is acquired by altering cellular amino acid homeostasis; specifically, intracellular and 
intraerythrocytic proline concentration are adapted in response to halofuginone pressure.  This phenomenon 
is analogous to the induced resistance phenotype we found with low-dose constant drug treatment.   
The second phase of drug resistance represents alterations in the cPRS in mutually exclusive ways.  We have 
witnessed either target site mutations or early target amplification in this second temporal phase. 
However, the third phase of drug resistance encompasses amplification of the WT target loci in the presence 
of increasing selective drug pressure regardless of prior mutation (Figure 3.5.1).   
We stress the sequential acquisition nature of these adaptations; a target site mutation in cPRS may provide 
increased fitness only in the presence of halofuginone with elevated intracellular proline.   
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Figure 3.5.1: A Model of Step-wise Acquisition of Halofuginone Drug Resistance 
Mapping resistance mechanisms is essential to furthering malarial drug discovery.  Identifying resistance 
mechanisms inform the future usefulness of an antimalarial compound.  Further, this model of halofuginone 
resistance will inform the rational design of combination therapy.  The most obvious of which is the 
combination of febrifugine derivatives with PSAC channel inhibitors. 
IMPLICATIONS OF EVOLUTIONARY TRAJECTORY ON THE FITNESS OF COMPETING ALLELES 
Genomic sequencing of time points along the HFGRII evolution trajectory revealed a mutation in the cPRS 
that increased in the prevalence from 0.6% in cycle 27 to 57% in cycle 34.  However, instead of fixing in 
the population, the allele remained at an intermediate frequency for another 7 generations before being out 
competed by a parasite with an amplified WT cPRS locus.  The anticorrelation of the HFGRII cPRS SNP and 
CNV implies clonal competition and argues that cPRS amplifications are more fit at higher halofuginone 
drug pressures than the HFGRII cPRS mutant allele. 
 
 
	   64	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HALOFUGINONE RESISTANCE MUTATIONS AT THE CPRS LOCUS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   65	  
4.1  ATTRIBUTION 
 
Authors:  Jonathan D. Herman1,2, Daniel P. Rice3,4, Ulf Ribacke2, Amy Deik1, Huihao Zhou6, Eli Moss1, Paul 
Schimmel9, Michael Desai3,4, Clary B. Clish1, Ralph Mazitschek1,2,7, and Dyann F. Wirth*1,2 
 
Affiliations: 
1 The Broad Institute, Infectious Diseases Initiative, Cambridge, MA 02142, USA 
2 Harvard School of Public Health, Department of Immunology and Infectious Disease, Boston, MA 02115, 
USA  
3 Department of Organismic and Evolutionary Biology, Harvard University, Cambridge MA 02138 
4 FAS Center for Systems Biology, Harvard University, Cambridge MA 02138 
5 Department of Cell and Molecular Biology, Microbiology, Uppsala University, 751 24 Uppsala, Sweden 
6 The Skaggs Institute for Chemical Biology, Department of Molecular Biology, The Scripps Research 
Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, USA. 
7 Massachusetts General Hospital, Center for Systems Biology, Boston, MA 02142, USA 
 
We gratefully acknowledge financial support for this work by the Gates Foundation (DFW and RM) and the 
National Institute of Health (DFW) (AI084031). 
 
J.D.H. designed and performed HFGRII and HFGRIII in vitro selections. J.D.H. characterized the three 
selections and their clones.  J.D.H. and U.R. designed the cloning scheme for transgenic parasites. J.D.H. 
cloned the constructs, transfected and cycled the parasites, and phenotypically characterized them.  U.R. 
and J.D.H. designed the Allelic Discrimination assay and competitive growth assays.  J.D.H. performed and 
analyzed the data from the competitive growth assays.  J.D.H. designed and prepared the samples for the 
metabolite profiling experiment.  A.D. ran and quality-controlled the mass-spec analysis of metabolites.  
C.C. and J.D.H. analyzed the metabolite experimental data. J.D.H. designed and performed the HFG 
induced resistance and clag expression experiments. 
 
 
 
4.2 INTRODUCTION 
We have previously described two mutations found from drug-resistance selections in the cytoplasmic prolyl 
tRNA synthetase (cPRS), HFGRI and HFGRII that confer halofuginone drug resistance in a yeast heterologous 
system.  Here we describe the two-step process necessary for evolution of the HFGRI and HFGRII 
halofuginone resistance mutation.  Using a reverse-genetic approach we found that HFGRI on its own leads 
to halofuginone hypersensitivity in P. falciparum.  However, AR-HFGRI’s hypersensitivity was lost when 
exposed to sufficiently high (>=2.8nM) halofuginone pressure during a competition assay or before a SYBR 
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dose-response assay.  Upon overexpressing clag 2 and clag 3.1, AR-HFGRI parasites halofuginone EC50 
increased 40-fold.  We found a similar upregulation of clag 2 and 3.2 in AR-HFGRII parasites exhibiting 
resistance to halofuginone.  Thus from identifying an epistatic relationship between cPRS drug resistance 
alleles and clag gene expression we have found evidence for a two-step process for the evolution of drug 
resistance mutations in P. falciparum. 
4.3  MATERIALS AND METHODS 
WHOLE GENOME SEQUENCING OF TRANSFECTED PARASITES 
Genomic DNA extracted from bulk population cultures of the two independent halofuginone resistance 
selected lines was extracted and sheared with a Covaris S 220.  Illumina-compatible libraries were prepared 
on the IntegenX Apollo 324 and sequenced on an Illumina HiSeq 2000.  All sequenced populations 
included in this analysis reached average fold-coverage across the P. falciparum genome greater than 60x.  
QPCR – COPY NUMBER ANALYSIS 
Genomic DNA was prepared from saponin-lysed P. falciparum parasites using the Qiagen Blood Mini- or 
Midi Kits.  qPCR analysis was performed on an Agilent 7900HT Fast Real-Time PCR. System using unlabeled 
primers and Power SYBR Green master mix and.   Primers used for copy-number analysis are in Table 4.3.1 
(target locus primers) and Table 4.3.2 (control locus primers).  Copy number was calculated with the ΔΔCt 
method according to the Applied Biosystems user bulletin 2.  
Table 4.3.1: qPCR Control Primers 
Gene Name Direction PlasmoDB ID Sequence (5’ to 3’) 
fructose-bisphosphate aldolase Forward PF3D7_1444800 TGTACCACCAGCCTTACCAG 
fructose-bisphosphate aldolase Reverse PF3D7_1444800 TTCCTTGCCATGTGTTCAAT 
B-tubulin Forward PF3D7_1008700  CGTGCTGGCCCCTTTG 
B-tubulin Reverse PF3D7_1008700  TCCTGCACCTGTTTGACCAA 
Seryl tRNA Synthetase 
Forward PF3D7_0717700  
TATCATCTCAACAGGTATCTACAT
CTCCTA 
Seryl tRNA Synthetase 
Reverse PF3D7_0717700  
TTTGAGAGTTACATGTGGTATCAT
CTTTT 
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Table 4.3.2: qPCR Primers for cPRS Target 
Gene Name 
Region 
of Gene Direction PlasmoDB ID Sequence (5’ to 3’) 
Prolyl tRNA 
synthetase (cPRS) 5' Forward PF3D7_1213800  
TGCTATAAGACCAACAAG
TGAAACA 
Prolyl tRNA 
synthetase (cPRS) 5' Reverse PF3D7_1213800  
ACGTACCACAGTATTCCAT
TGATTT 
Prolyl tRNA 
synthetase (cPRS) 3' Forward PF3D7_1213800  
CCAAACAAACAGTGAAAC
GACAT 
Prolyl tRNA 
synthetase (cPRS) 3' Reverse PF3D7_1213800  
TAGGTGGTTGATCTAACG
GGATAC 
 
IN VITRO DRUG SENSITIVITY AND DOSE-RESPONSE ANALYSIS BY SYBR GREEN 
The SYBR Green I method was used as previously described82.  In brief, we grew P. falciparum parasites for 
72 hours in 384 well plates at 1% hematocrit and 1% starting parasitemia.  Growth was assessed by SYBR 
Green staining of parasite DNA.  All dose-response assays were carried out with twelve-point curves with 
technical triplicate.  DMSO stocks of drugs used were dispensed by the HP D300 Digital Dispenser.  
Fluorescence measurements were collected on a SpectraMax M5 (Molecular Devices) and analyzed on 
GraphPad Prism version 5 and EC50 values were determined with the curve-fitting algorithm log(inhibitor) vs. 
response – Variable slope. 
PARASITE CULTURE AND TRANSGENESIS 
Malaria culture was performed as described by Trager et al. 81.  Dd2 is a chloroquine resistant in vitro 
cultured parasite cloned from the Laos derived W2-MEF parasite obtained from MR4.  
To generate transfection plasmids for 3’ allelic replacement, we PCR amplified 1209:2241 nucleotides of 
PfcPRS from Dd2, and two halofuginone-resistant in vitro HFGRI and HFGRII evolved lines with the primers 
5’GGACCGCGGCCGCAGAATTTTTATGGCAAGAAG’3 and 
5’GGACCCTCGAGTTAATAACTTCTACCAAATAAAC’3.  These 3’ fragments were subcloned into a 
pGEM3Z-based (Promega) plasmid with hDHFR selectable marker driven by a CAM promoter, PfHSP 86 
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3’UTR.  The 3’ fragment of cPRS was inserted at NotI and XhoI sites such that it is not transcribed 
episomally.  3D7 parasites were electroporated with pcPRSWT, pcPRSHFGRI, or pCPRSHFGRI plasmids and 
transgenic parasites were selected via homologous recombination by cycling on and off WR99210 drug 
pressure until integration was confirmed by PCR and transcription of the correct allele was confirmed by 
Allelic Descrimiation qRtPCR. 
INTEGRATION-SPECIFIC PCR 
The plasmid-specific amplicon was amplified using Plasmid-Forward and Plasmid-Reverse primers.  The un-
integrated chromosomal locus was amplified using Chromosomal-Forward and Chromosomal-Reverse.  The 
Integrated chromosomal locus was amplified using Chromosome-Forward and Plasmid-Reverse.  The 
primers are described in Table 4.3.3 and the PCR scheme is described in Figure 4.4.1. 
PCR Conditions for the Integration-specific and plasmid-specific PCR reactions are as follows: 95°C for 4 
minutes and then 40 amplification cycles (95°C for 30s, 57°C for 30s, 68°C for 180s) and then a final 
extension at 68°C for 300s. Amplification of the unmodified chromosomal locus follows the same conditions 
except for the use of an annealing temperature of 48°C instead of 57°C. 
Table 4.3.3: PCR Primers for Analysis of 3' Allelic Replacement Transgenic Parasites 
Gene Name 
Type of Region 
Amplified Direction PlasmoDB ID Sequence (5’ to 3’) 
Prolyl tRNA 
synthetase (cPRS) 
Native 
Chromosomal 
Locus Forward PF3D7_1213800  
CAAACAACTTAAGAT
TTGTTGACGA 
Prolyl tRNA 
synthetase (cPRS) 
Native 
Chromosomal 
Locus Reverse PF3D7_1213800  
TGAATTTTAAATGAA
AAATGGGGTA 
Prolyl tRNA 
synthetase (cPRS) 
Unrecombined 
Plasmid Forward PF3D7_1213800  
AGGAAACAGCTATG
ACCATGATTAC 
Prolyl tRNA 
synthetase (cPRS) 
Unrecombined 
Plasmid Reverse PF3D7_1213800  
ATATTGGGGTGATGA
TAAAATGAAA 
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COMPETITION ASSAY AND ALLELIC DISCRIMINATION QPCR READOUT 
AR-WT #38, AR-HFGRI #25, and AR-HFGRII #71 clones were used in these fitness competition assays.  
Tightly synced parasites (10-14 hours post invasion) were mixed in a 1:1 ratio to achieve a 1% parasitemia 
culture and maintained in competition for 5 generations in quadruplicate.  Each cycle RNA was harvested, 
cultures were cut back to 1% parasitemia by flow cytometry, and drug pressure was maintained.  RNA was 
also harvested from individual transfectant parasites on Day 0.  RNA was extracted using RNeasy 96-well 
plate extractors, DNase treated, and then purified through a second set of plates.  First strand cDNA 
synthesis was made with SuperScript III (Life Technologies). Absence of contaminating DNA and the success 
of reverse transcriptase reaction was confirmed by comparison of Seryl tRNA synthetase Ct values of Rt+ and 
Rt- samples run in quadruplicate on ABI 7900 HT Fast Real-Time PCR machine.  Transcribed allele balance 
of each parasite was determined by analysis of the individual samples pre-mixture (Cycle 0) and parasite 
prevalence over the five generations was determined by cPRS Allelic Discrimination Assay. 
CPRS ALLELIC DISCRIMINATION QPCR ASSAY 
We custom designed two allelic discrimination genotyping assay at Codon 482 of cPRS to differentiate 
between two SNPs we previously identified to confer resistance to halofuginone (Table 4.3.4). MGB-binding 
probes (Life Technologies) were designed to either the WT allele or two MT alleles (HFGRI and HFGRII). 
To calibrate the assay artificial mixtures of plasmid DNA with WT and MT cPRS alleles were mixed in a 
decrement of 10% to make an eleven-sample set spanning 100% of each allele. Six ten-fold dilutions were 
made of the set of mixtures and were used to calibrate the Allelic Discrimination qPCR assay with each 
point of this matrix run in duplicate.  The primers and probes used in the Allelic Discrimination assay to 
track WT versus HFGRI and WT versus HFGRII are described in Table 4.3.4.   Choice of which dilution of 
the calibration curve to use was made for each individual sample basis on a Euclidian distance minimization 
algorithm.  Allele balance of sample was calculated based on the log transformation of the ratio of 
fluorescence signal intensities of the chosen calibration curve.  Allelic discrimination assays were run with 
TaqMan Universal PCR Master Mix with no AmpErase UNG (Applied Biosystems) on an ABI 7900 HT Fast 
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Real-Time PCR machine with the amplification conditions as follows: 95°C for 10 minutes, followed by 40 
cycles of a two-step amplification of 95°C for 15 seconds and 60°C for 1 minute. 
Table 4.3.4: cPRS allelic discrimination assay primers and probes 
Primers/Probe Direction Fluorophore Sequence (5’ to 3’) 
cPRS Locus Amplification 
Primer Forward   
AAAATGGAAGAGCCATACAAGCA 
cPRS Locus Amplification 
Primer Reverse   TACAACCCCATGATGTTTGATGA 
WT Probe   FAM      TCATTATctTGGAACAAA 
HFGRI Allele (L482F) Probe   VIC     TCATTATcaTGGAACAAA 
HFGRII Allele (L482H) 
Probe   VIC 
TCTCATTATttTGGAACAAA 
 
FLOW CYTOMETRY 
Flow cytometry of P. falciparum infected erythrocytes was carried out as based on SYBR Green I staining of 
parasite nuclei as previously described 126.  Modifications to the Bei et al. protocol include staining of iRBC 
with SYBR Green I at a 1:2000 concentration, acquisitions of non-single cells were pre-filtered by for cells 
that fell on the y=x line in a plot of forward scatter area vs. height. All Flow Cytometry was collected on a 
MACSQuant Flow Cytometer (Miltneyi Biotec) and analyzed with MacQuantify and FlowJo 8.8.6 software 
(Tree Star). 
LC-MS ANALYSIS OF AMINO ACIDS AND POLAR METABOLITES  
Highly synchronous (within 4 hours) early schizonts were magnetically purified with MACS CS columns 
(Miltenyi Biotec). A small aliquot was also made for flow cytometry.  The rest of the purified samples were 
divided into two equal volumes: one for saponin lysis (0.025%) and one for whole iRBC extraction.  Each 
sample was washed 2x in PBS, and then suspended in 10 uL PBS.  Polar metabolites were extracted using 
nine volumes of 74.9:24.9:0.2 (v/v/v) acetonitrile/methanol/formic acid containing stable isotope-labeled 
internal standards (0.2 ng/µL valine-d8 (Isotec); and 0.2 ng/µL phenylalanine-d8 (Cambridge Isotope 
Laboratories)). Profiles of amino acids were measured using LC-MS as described previously127.  Briefly, 
positive ionization, multiple reaction mode (MRM) data were acquired using a 4000 QTRAP triple 
quadrupole mass spectrometer (AB SCIEX) coupled to an 1100 Series pump (Agilent) and an HTS PAL 
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autosampler (Leap Technologies). Cell extracts (10µL) were injected onto a 150 x 2.1 mm Atlantis HILIC 
column (Waters). The column was eluted isocratically at a flow rate of 250 µL/min with 5% mobile phase A 
(10 mM ammonium formate and 0.1% formic acid in water) for 1 minute followed by a linear gradient to 
40% mobile phase B (acetonitrile with 0.1% formic acid) over 10 minutes. The ion spray voltage was 4.5 kV 
and the source temperature was 450°C. MultiQuant 1.2 software (AB SCIEX) was used for automated peak 
integration and metabolite peaks were manually reviewed for quality of integration and compared against a 
known standard to confirm identity.  Stable isotope-labeled internal standards were used to eliminate 
samples with poor data quality.  Metabolite peaks signals were normalized by flow cytometry-determined 
cell counts and compared to PBS and uninfected red blood cell control measurements.  Pearson correlation 
analysis was performed in prism and heat maps were generated with Gene-e (Broad Institute). 
QPCR – GENE EXPRESSION ANALYSIS 
Total RNA was extracted by the Trizol extraction method, DNAse treated, and re-purified with Qiagen 
RNeasy mini columns.  First strand cDNA synthesis was made with SuperScript III (Life Technologies). 
Absence of contaminating DNA and the success of reverse transcriptase reaction confirmed by comparison 
qPCR of Rt+ and Rt- with the control Seryl tRNA synthetase primer set in quadruplicate and was run on ABI 
7900 HT and fold expression was calculated. cDNA concentrations were then balanced by SerRS Ct to 
minimize PCR efficiency biases.  Samples were run in quadruplicate and run with two control primer sets for 
validation of expression analysis.  PCR amplification was performed as follows: 15 minutes at 95 °C 
followed by 40 cycles of two-step amplification of 94 °C for 30s and 52 °C for 30s. All primers used for 
expression analysis (Tables 4.3.5, 4.3.1, and 4.3.2) were validated for specificity and efficiency with these 
exact PCR conditions. 
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Table 4.3.5: qPCR primers for expression analysis of the clag gene family 
Gene Name Direction PlasmoDB ID Sequence (5’ to 3’) 
Clag 2 Forward PF3D7_0220800 CTCTTACTACTTATTATCTATCTCTCA 
Clag 2 Reverse PF3D7_0220800 CCAGGCGTAGGTCCTTTAC 
Clag 3.1 Forward PF3D7_0302500 ACCCATAACTACATATTTTCTAGTAATG 
Clag 3.1 Reverse PF3D7_0302500 TCTGAACTAGGAGGCCAACC  
Clag 3.2 Forward PF3D7_0302200 ACCCATAACTACATATTTTCTAGTAATG 
Clag 3.2 Reverse PF3D7_0302200 TTCAGCAGCAAGTCCGTGA 
Clag 8 Forward PF3D7_0831600  GTTACTACAACATTCCTGATTCAG  
Clag 8 Reverse PF3D7_0831600  AATGAAAATATAAAAATGCTGGGGGAT 
Clag 9 Forward PF3D7_0935800 TACCATTAGTGTTTTATACACTTAAGG 
Clag 9 Reverse PF3D7_0935800 CCAAAATATGGCCAAGTACTTGC 
 
 
 
 
4.4  RESULTS 
 
Table 4.4.1: Summary of cPRS mutations in drug resistance selected lines HFGRI and HFGRII 
Selected	  Line	  
Dd2	  Parental	  
Strain	   HFGRI	   HFGRII	  
Nucleotide	  Change	  
Observed	  in	  cPRS	  
-­‐	   A1445T	   C1444T	  
Amino	  Acid	  Change	  
Observed	  in	  cPRS	  
-­‐	   L482H	   L482F	  
Corresponding	  Allelic	  
Replacement	  (AR)	  
Strain	  	  
AR-­‐WT	   AR-­‐HFGRI	   AR-­‐HFGRII	  
 
HFGRII MUTATION AT THE CPRS CONFERS RESISTANCE TO HALOFUGINONE IN ALLELIC REPLACEMENT EXPERIMENTS  
We previously performed drug-resistance selections with halofuginone and found two mutations in the 
cytoplasmic prolyl tRNA synthetase (Chapter 2) and summarized in Table 4.4.1. We confirmed in a 
heterologous yeast model that cPRS mutant allele HFGRII, from drug resistance selected parasite HFGRII, 
conferred high-level resistance to halofuginone analogue halofuginol in is a dose-dependent manner 
(SFigure 2.5.8).  To validate the effect of these alleles in P. falciparum we set out to genetically engineer 
syngeneic parasites that only differed by their cPRS allele type.  To achieve this goal, we performed 3’ single 
crossover allelic exchange experiments as depicted in Figure 4.4.1a in wild type 3D7 P. falciparum 
	   73	  
parasites.  We confirmed integration in our cPRS cloned transfectants parasites by PCR (Figure 4.4.1b).  
Notably, our transection control parasites AR-WT #38 where we replaced the wild type chromosomal copy 
with the wild type allele validated that we can integrate a plasmid at the cPRS locus.  Furthermore, we 
verified that all allelic replacement AR-WT parasites had an indistinguishable dose-response to halofuginone 
from its 3D7 parental strain (Figure 4.4.1c). 
 
 
Figure 4.4.1: cPRS HFGRII transgenic parasites are more resistant to halofuginone 
(a) A model of 3’ allelic replacement transgenesis at cPRS via single homologous recombination. 
(b) PCR confirmation of integration and absence of unrecombined locus in AR-WT and AR-HFGRII clones 
with modified cPRS loci.  
(c) Halofuginone EC50s of AR-WT and AR-HFGRII clones. Error Bars reflect SD. 
 
 
In our transfectants with the cPRS HFGRII mutant allele, we confirmed integration by PCR (Figure 4.4.1b).  
We found that both AR-HFGRII clones we characterized had a five-fold increased resistance to halofuginone 
(Figure 4.4.2c) in our 1.5-cycle SYBR green-based growth inhibition assay. 
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Encouraged by the results with the HFGRII allelic replacements, we went forward with allelic exchange 
experiments with the cPRS HFGRI allele.  The HFGRI allele showed a stronger resistance phenotype in our 
heterologous yeast model (SFigure 2.5.8) so we hypothesized that AR-HFGRI parasites would be more 
resistant than AR-HFGRII parasites. 
 
 
Figure 4.4.2: cPRS HFGRI transgenic parasites are hypersensitive to halofuginone 
(a) PCR confirmation of integration and absence of unrecombined locus in AR-HFGRI clones with 
modified L482F cPRS locus. 
(b) Halofuginone EC50s for the transfectant parasite clones expressed in uM units. Halofuginone EC50s 
of 3D7 untransfected, AR-WT, and AR-HFGRII clones. Error Bars reflect SD. 
 
 
We first went forward and obtained one transfectant clone, AR-HFGRI #25.  We confirmed it had integrated 
the plasmid and lacked any unrecombined native locus (Figure 4.4.2a). When we investigated the 
halofuginone dose-response of our HFGRI transfectants, we found it was uniquely hypersensitive to 
halofuginone and no-other antimalarial tested including artemisinin, atovaquone, amodiaquine, 
dihydroartemisinin, doxycycline, mefloquine, and sulfadoxine.  Alarmed by this sensitization to 
halofuginone, we then went back to an early freeze of the bulk transfected line that yielded the AR-HFGRI 
#25 and re-selected with WR and obtained three additional clones that were PCR-positive for integration 
(Figure 4.4.2b): 5D, 7B, and 10F. 
We drug-phenotyped our additional AR-HFGRI clones and found they were all more sensitive to 
halofuginone than the wild type transfected and untransfected controls (Figure 4.4.1c).  Since this 
observation was inconsistent with the phenotype of the halofuginone resistance-selection parasites with 
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corresponding alleles, we set out to characterize the genetic changes leading to this surprising phenotype. 
First we looked at the cPRS RNA transcription levels in the transfectant parasites clones with qPCR probes to 
the 5’and 3’ untranslated regions of the cPRS locus. 
 
 
 
Figure 4.4.3: Expression analysis reveals co-allelic expression and amplification in AR-HFGRI not present 
in other transfectants  
(a) cPRS gene expression of untransfected Dd2 parasites and transfectants AR-WT #38,  AR-HFGRI #25 and 
AR-HFGRII #71 in Late Trophozoites (LT) stage parasites. 
(b) cPRS gene expression of untransfected Dd2 parasites and transfectants AR-WT #38,  AR-HFGRI #25 and 
AR-HFGRII #71 in Late Schizont (LS) stage parasites. 
(c) Expressed allele in transfectant parasites AR-WT#38, AR-HFGRI #25, and AR-HFGRII #71 parasites 
determined by allelic discrimination qrtPCR assay.  AR-WT#38 and AR-HFGRI #25 were analyzed with 
the WTvsHFGRI assay.  AR-HFGRII#71 was analyzed with the WTvsHFGRII assay.  
 
 
From previous experience with the 3’ single-strand break based modification strategies, we expected to see 
more 3’ RNA than 5’ RNA because of the 3’ cPRS fragment on the donor plasmid.  If the plasmid 
concatermizes as often occurs before integration, much more 3’ cPRS transcript can be made than 5’.  We 
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saw this pattern of 3’ transcript predomination in AR-WT and AR-HFGRII transfectants in both parasite 
stages investigated (Figure 4.4.3a,b).  However, we interestingly saw equal expression levels of 5’ and 3’ 
cPRS transcript in AR-HFGRI #25.  In addition, AR-HFGRI transfectants expressed between 2-3-times more 
full-length RNA than untransfected Dd2 parasites.  This furthered our suspicion that AR-HFGRI transfectant 
parasites might have amplified their cPRS locus. 
With the hypothesis in mind that AR-HFGRI #25 might have a duplicated locus, we next determined which 
cPRS allele our transfectants expressed with allelic discrimination qrtPCR.  As shown in Figure 4.4.3c, AR-
WT #38 and AR-HFGRII #71 each expressed 100% of the wild type and HFGRII mutant-type alleles 
respectively.  However, AR-HFGRI #25 expressed approximately equal amounts of wild type and HFGRI 
mutant-type cPRS alleles.  This evidence for co-allelic expression in AR-HFGRI #25 convinced us to look 
more deeply into the genomic architecture of the cPRS locus in these transfectants.   
At first, we took a southern blot approach to map the recombined locus but could not determine the details 
of the genetic map from multiple digestion schemes and two different probes.  As a second approach, we 
used qPCR to look for evidence of copy number variation at the cPRS locus. 
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Figure 4.4.4: Mapping the Recombined cPRS Loci in transfected parasites with qPCR 
(a) cPRS gene copy number analysis of untransfected 3D7 parasites along with transfectants AR-WT #38, 
AR-HFGRI #25, and AR-HFGRII #71 clones by qPCR relative to a 3D7 untransfected control.  SerRS was 
used as the endogenous control for ΔΔCt analysis. 
(b) Model of integrated locus with location of qPCR primers and the relative copy number of each region of 
the transfected locus in HFGRI resistance-selected line and the four cloned transfectant clones with the 
HFGRI cPRS allele.  The magenta outlined locus in the model represents plasmid-derived DNA; black-
outlined loci represent chromosome 12-derived material.  cPRS copy number was determined relative to 
3D7 untransfected control.  hDHFR copy number was determined in relation to an unrelated transfected 
parasite externally confirmed to have a single copy. All ΔΔCt analysis was performed with a SerRS 
endogenous control.   
(d) (e) A 30kB view of cPRS locus of AR-HFGRI #25 (d) and AR-HFGRI #10F (e) from whole genome 
sequencing data.  Read pile-ups were visualized with the Integrated Genome Viewer. 5’ of the gene is to 
the left, and 3’ of the gene is to the right.  The red and green lines represent the proportion of mutant-
type to wild type aligned reads at the T1445A locus.  The chromosomal coordinates for this view are 
Pf3D7_12_v3:587,476-595,131. 
 
From previous experience with the 3’ single-crossover based modification strategies, we expected to see 
more 3’ copies than 5’ copies as seen in the integration scheme in Figure 4.4.1a.  We found that both sets of 
clones from AR-WT and AR-HFGRII parasites had this expected pattern (Figure 4.4.2a): 1 copy of 5’ cPRS 
and >1 copy of 3’ cPRS.  This confirms that AR-WT and AR-HFGRII clones are single-integrant, single cPRS 
copy parasites.  However, AR-HFGRI #25 showed a surprising increase in both ends of the cPRS locus 
confirming that the cPRS has been amplified.  We confirmed the amplification of the cPRS locus of AR-
HFGRI#25 with whole genome sequencing (Figure 4.4.4d). 
We went back to the original HFGRI resistance selected parasite where we found the HFGRI L482H cPRS 
mutation and confirmed that it has a single copy of cPRS (Figure 4.4.4c). We realized that a transfectant 
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strain with both an amplification and change in allele type would complicate our understanding of how the 
HFGRI cPRS allele contributes to halofuginone resistance.  To investigate whether it is possible to get single 
cPRS copy AR-HFGRI transfectant, we first tried to transfect Dd2 WT parasites with the same plasmid used 
for the AR-HFGRI lines characterized above.  In both transfections, parasites failed to grow back after 70+ 
days.  As a second approach, we mapped the cPRS locus by-qPCR of the three other AR-HFGRI clones we 
obtained (Figure 4.4.2b).  We found that all of the AR-HFGRI clones amplified their cPRS locus but each had 
a unique amplification scheme  (Figure 4.4.4c). 
 P. FALCIPARUM PARASITES OVEREXPRESSING CPRS ALLELES COULD NOT BE PRODUCED 
Intrigued that all of the transfected HFGRI parasites that came up had amplified cPRS loci, we transfected 
parasites with HSP86-driven episomal overexpression plasmids with WT, HFGRI, or HFGRII alleles.  In all of 
our 3 transfections of each construct, parasites did not return after 70 days. 
COMPETITION ASSAY REVEALS THAT AR-HFGRI TRANSFECTANTS ACQUIRE RESISTANCE AT HIGH CONCENTRATIONS OF 
HALOFUGINONE  
We were still unsure how to reconcile the hypersensitive phenotype of HFGRI allelic replacement 
experiments with the drug-resistance selections and yeast allelic replacement data.  In parallel with our 
genetic dissection of the transfectant parasites, we looked for another approach beyond our 1.5 cycle growth 
assay to interrogate the halofuginone phenotype of these parasites.  We chose growth competition assays as 
an orthogonal approach to confirm the halofuginone hypersensitivity phenotype we saw with our AR-HFGRI 
transfectants.   
This second approach focused on explaining the selective advantage that cPRS alleles confer in competitive 
growth over 5 generations rather than the 1.5 generations of our previous assay.  We grew AR-WT #38 in 
competition with either AR-HFGRI #25 in the presence or absence of halofuginone at multiple 
concentrations.  Interestingly, AR-HFGRI #25 displayed a fitness disadvantage in low concentrations of 
halofuginone (1.4nM) as would be expected from our SYBR growth assays (Figure 4.4.3a); AR-HFGRI #25 
was less fit in the presence of 1.4nM than in the absence of halofuginone entirely.  However, when 
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presented with greater concentrations of halofuginone (4.2 nM and 7 nM) AR-HFGRI #25 parasites were 
strongly favored (Figure 4.4.3b).
 
Figure 4.4.5: HFGRI and HFGRII cPRS alleles confer advantage only in the presence of halofuginone 
(a) (b) Competitive growth assay of AR-WT #38 versus AR-HFGRI #25 transfected parasites in the presence 
and absence of low-dose halofuginone (1.4nM) (a) or high-dose halofuginone (b). Error bars in (a) and 
(b) represent standard error.   
(c) Competitive growth assay of AR-WT #28 versus AR-HFGRII #71 parasites in the presence and absence of 
halofuginone. Error bars in (a) reflect SD and in (b) represent SE.   
 
 
AR-HFGRII TRANSFECTANTS ARE RESISTANT TO HALOFUGINONE AT BASELINE IN COMPETITIVE GROWTH 
Due to the discrepancy we found between AR-HFGRI’s halofuginone fitness between our 1.5 and 5 
generation assays, we were curious to see if similar discrepancies existed for our AR-HFGRII line. We grew 
AR-WT #38 in competition with AR-HFGRII #71 transgenic parasites over 5 generations in the presence or 
absence of halofuginone. Confirming the 1.5-cycle growth assay (Figure 4.4.1b), AR-HFGRII #71 parasites 
proved more fit in the presence of halofuginone (Figure 4.4.5b).  We also performed similar competition 
experiments between AR-WT #38 and AR-HFGRII#71 at 4.2 and 7nM HFG but growth in replicate cultures 
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was fully inhibited. The HFGRII cPRS allele was mildly deleterious in the absence of halofuginone (normal 
unmodified RPMI).  Thus, we confirmed that AR-HFGRII parasites didn't require higher halofuginone 
concentrations to ‘awake’ a resistance phenotype. 
HFGRI BUT NOT HFGRII CPRS ALLELE REQUIRES HALOFUGINONE PRE-TREATMENT TO MAKE P. FALCIPARUM 
RESISTANT TO HALOFUGINONE 
To explain the conflicting data from the two different measurements of halofuginone phenotype, we 
employed a model of epistatic: HFGRI is a resistance mutation in one background and a sensitizing 
mutation in another and depending on time/dose of halofuginone exposure can convert from one to another. 
We were grappling with these AR-HFGRI transfectants at the same time that were came across the HFG-
induction phenotype described in Chapter 3. We hypothesized that the same conditions that cause the 
induction of resistance in wild-type Dd2 parasites could help us understand the epistatic control of the cPRS 
resistance mutation HFGRI.  The evidence that AR-HFGRI parasites need high concentrations of 
halofuginone to acquire resistance in a competitive growth assay (Figure 4.4.5b) further supported this 
hypothesis.  Thus, we treated both WT and HFGRI transfectant parasites with 2.8nM halofuginone.  As 
quickly as 3 generations after treatment, AR-HFGRI transfectants acquired dramatically increased resistance 
to halofuginone by our 1.5 cycle growth assay (Figure 4.4.6a).  All three clones of AR-HFGRI had greater 
than a 40-fold increase in halofuginone resistance whereas AR-WT experienced a 5-fold increase (Table 
4.4.2).  This acquired resistance has been stable over 60 days after removal of drug pressure from AR-HFGRI 
induced lines. 
When we performed the same induction experiments with AR-HFGRII transfectants, we saw no change in 
halofuginone resistance (Figure 4.4.6b and Table 4.4.2). This result was internally consistent with the 
competitive growth assays – AR-HFGRII’s halofuginone resistance pre-existed external drug pressures. 
	   81	  
 
 
Figure 4.4.6: Pre-Exposure of AR-HFGRI transfectants to halofuginone induces resistance but does not in 
AR-HFGRII 
(a) Halofuginone EC50s of AR-WT and AR-HFGRI transfectants with and without pre-exposure to 
2.8nM halofuginone. 
(b) Halofuginone EC50s of induced and un-induced AR-HFGRII #71 clone. Error Bars reflect SD. (c) Relative Copy Number of cPRS and MDR1 in Induced and untreated transfectants. B-tubulin is 
provided as an additional control.	  
 
Table 4.4.2: Fold-increase in HFG EC50 after pre-exposure with  
 2.8nM HFG in transfectants 
 	  	   Fold Increase in Halofuginone EC50 Upon 
Induction 
AR-WT #38 5 
AR-HFGRI #25 45 
AR-HFGRI #5D 53 
AR-HFGRI #10F 51 
AR-HFGRII #71 0.9 
 
We wanted to eliminate the possibility that the phenotypic change in resistance caused by our induction 
protocol was due to a change in the architecture of the cPRS locus.  With a similar qPCR-based 
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methodology we found that all four clones of AR-HFGRI showed no change in cPRS copy number upon 
halofuginone induction (Figure 4.4.4b).  We also eliminated MDR1 amplification, a common drug-
resistance mechanism in P. falciparum, as a potential explanation of the induction of resistance (Figure 
4.4.4b). 
PRE-EXPOSURE CAUSES THE OVEREXPRESSION OF MULTIPLE CLAG GENES AR-HFGRI 
Taking a page from our findings in Chapter 3, we preformed expression analysis of the clag gene family in 
our AR-HFGRI transfectants. Expression of the epigenetically regulated clag gene family are associated with 
the NPP/PSAC channel that is responsible for importation of many salts and nutrients including amino acid 
across the cell membrane of infected erythrocytes. 
We found that AR-HFGRI, a transgenic parasite from the 3D7 background, upregulated clag 2 and clag 3.1 
expression upon exposure to halofuginone (AR-HFGRI #25 – Uninduced vs. AR-HFGRI #25 – Induced in 
Figure 4.4.7).  Clag 8 and 9 expression on the other hand were not remarkably upregulated (Figure 4.4.7) 
upon halofuginone induction. 
 
Figure 4.4.7: Overexpression of clag 2 and clag 3.2 associated with halofuginone pre-treatment of AR-
HFGRI #25 parasites but not in AR-HFGRII #71 
(a) Replicate Expression Studies of Clag gene family in Halofuginone treated and naïve AR-HFGRI and AR-
HFGRII early schizont stage parasites. FBP-Aldolase is included as a second control and Dd2 is provided as 
untransfected control. SerRS was used as the endogenous control primer set used for ΔΔCt analysis. 
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AR-HFGRII PARASITES ENDOGENOUSLY UPREGULATE THEIR CLAG GENE EXPRESSION 
Next looking at clag gene expression in AR-HFGRII parasites, we found that un-induced AR-HFGRII 
parasites have already upregulated their expression of clag 2 and clag 3.2 (Figure 4.4.7).  When further pre-
treated with halofuginone, we did not witness any increase in clag expression of AR-HFGRII parasites.  Thus, 
both AR-HFGRII and AR-HFGRI parasites demonstrate epistasis between cPRS HFGR mutations and clag 
gene expression. 
 
4.5  DISCUSSION 
 
 
PREVIOUS EVIDENCE FOR CPRS HFGRI AND HFGRII MUTATIONS IN DRUG RESISTANCE 
In Chapter 2, we performed two drug-resistance selections with intermittent halofuginone pressure and 
found two mutations in the cytoplasmic prolyl tRNA synthetase.  We named the mutations for the selection 
in which they were first identified, HFGRI and HFGRII.  The nonsynonymous T1445A mutation in HFGRI 
was validated to be a halofuginone and halofuginol-resistance conveying mutation in a heterologous yeast 
system.  The nonsynonymous C1444T was also demonstrated to confer resistance to halofuginol in 
transgenic yeast.  Though nucleotide 1444 and 1445 are not in the tRNA charging domain of cPRS, our 
structural modeling identified it as proximal to the proline-binding pocket (Chapter 2).  Here in this paper, 
we sought to validate HFGRI as a halofuginone resistance mutation in P. falciparum and characterize the 
properties of parasites expressing the HFGRI cPRS allele. 
EVIDENCE FOR THE EPISTATIC NATURE OF HFGRI MUTATION FROM OUR ALLELIC EXCHANGE EXPERIMENTS 
We employed a 3’ allelic replacement single crossover approach typical in P. falciparum genetics to 
introduce HFGRI and HFGRII into a syngenic environment.  We quickly realized our monogenic model of 
cPRS mutations as the sole determinant of halofuginone resistance was an oversimplification from the AR-
HFGRI transfectants.  AR-HFGRI transgenic parasites took twice as long as AR-Dd2 to recrudesce after 
transfection.  When we characterized all three parasite lines, they had equivalent growth rates in semi-
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quantitative assays.  This indicated to us that a second adaptation/mutation likely had to be acquired for AR-
HFGRI to achieve normal growth in an in vitro environment.  When we characterized the recombined cPRS 
locus in our transfectant lines, we found one of these adaptations was amplification of the modified cPRS 
locus (Figure 4.4.4.a).   
Drug phenotyping of the three sets of transgenic parasites confirmed the multi-factorial nature of drug 
resistance.  Though AR-HFGRI parasites were more sensitive than AR-WT in our 1.5 cycle dose-response 
assay (Figure 4.4.2b), they were more resistant is a 5-cycle competitive growth assay only at higher doses of 
halofuginone (Figure 4.4.45a,b). Taken in total, these data indicated that the HFGRI cPRS allele is not 
sufficient to confer halofuginone resistance in P. falciparum.  Rather the HFGRI allele is part of a larger 
cellular program for resistance. 
HFGRI CPRS ALLELE HAS A STRONG AFFECT ON CELL PHYSIOLOGY 
As a counter-point AR-HFGRII parasites did not amplify their cPRS locus and did not have a halofuginone 
phenotype that was dependent on external stimuli.  This led us to believe that for reasons unappreciated, 
HFGRI had a much stronger effect on P. falciparum cell physiology than HFGRII.   
To understand whether the cPRS amplification was a rare event or necessity for our HFGRI allelic exchange 
experiments, we went back to an early freeze of the uncloned transfected AR-HFGRI line that yielded the 
AR-HFGRI #25 and re-selected with WR.  Each of the three clones we isolated was similarly hypersensitive 
to halofuginone and possessed an amplified cPRS locus.  If all of the AR-HFGRI parasites had the same 
amplification pattern, we could conclude that a single amplification event and the clones I obtained were 
unmodified progeny.  However, the organization of the amplified locus was unique in each clone.  This 
phenomenon would be consistent with multiple independent amplification or a single initial amplification 
and subsequent modification/de-amplifications by the individual progeny.  Either way, both models argue 
for the essentiality of copy number variation the cPRS locus of AR-HFGRI parasites and the strong effect the 
HFGRI has had on cell physiology in our transgenesis experiments. 
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ROLE OF CLAG EXPRESSION IN HFGRI-MEDIATED RESISTANCE TO HALOFUGINONE 
To elucidate the larger program necessary for HFGRI resistance, we set out to model the phenotypic change 
elucidated by our competitive growth assays (Figure 4.4.5a,b).  AR-HFGRI parasites were less fit in 1.4nM 
HFG, but strongly selected for in 4.2nM HFG and higher concentration.  We formulated two hypotheses 
based on this data.  The first was that exposure to a certain dose of halofuginone re-programed AR-HFGRI 
and created the cellular environment where HFGRI could contribute to resistance.  The second was that a 
sub-population of resistant AR-HFGRI parasites pre-existed the competition assay and were selected for only 
in exposure to high concentrations of halofuginone. 
To address the first hypothesis, we set out to replicate the phenotypic change in AR-HFGRI by pre-treating 
the cultures with halofuginone.  We estimated that the inflection point between a sensitive and resistant 
program was 2.8nM.  Pre-treated HFGRI transfectants with this mid-level concentration acquired 45-53-fold 
increase (Table 4.4.1), thus supporting our first hypothesis.  This acquired resistance was present in multiple 
clones of AR-HFGRI, thus decreasing the likelihood that fixation of a subpopulation could explain the 
acquisition of resistance.  Furthermore, we sequenced both the untreated and HFG treated AR-HFGRI #25 
clone and in the process of analyzing the sequences to identify any genetic polymorphisms that could differ 
between the two. 
It has been know for some time that the new permeability pathway (NPP) / parasite-specific anion current 
(PSAC) that is responsible for the selective increase in permeability of early trophozoite infected red blood 
cells increases flux of many amino acids 61 including proline 62.  More recently, clag 3 has been identified as 
a genetic determinant of the PSAC channel 20.  In Chapter 3, we found that overexpression of clag 2 and clag 
3.2 played an important in the acquisition of induced halofuginone resistance.  Based on this premise, we 
looked into whether pre-treatment of AR-HFGRI with halofuginone changed clag gene expression and found 
upregulation of clag 2 and clag 3.1 in two replicate studies.  This is congruent with recent findings by Pillai 
et al. who saw up regulation of a larger clag repertoire (clag 3.2 and clag 2) when they selected for clag 3.2 
expression by growing Dd2 parasites in custom media and clag 3.1-inhibitor ISPA-28 133. 
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HFGRII TRANSFECTANTS UPREGULATE CLAG EXPRESSION WITHOUT INDUCTION 
We wanted to investigate whether the epistatic we found between clag expression and cPRS allele 
phenotype in AR-HFGRI parasites is generalizable.  Thus, we set out to determine if induction phenotype, 
i.e. induction of halofuginone resistance we found in Chapter 3, in our AR-HFGRII transfectants.  When we 
induced AT-HFGRII transfectant parasites with halofuginone pre-treatment, we surprisingly saw no 
difference in dose-response. This lack of an induction phenotype distinguished AR-HFGRII from AR-HFGRI 
and wild type parasites.   
We wondered if that meant that the HFGRII mutation some how disentangled clag genes from their 
involvement in halofuginone resistance. By measuring the expression of AR-HFGRII of the clag family of 
genes, we determined that AR-HFGRII transfectants over-express clag 2 and clag 3.2 endogenously (Figure 
4.4.5a).  This observation further confirmed clag involvement in the halofuginone resistance of AR-HFGRII.  
Even further, the unaltered clag 2 and 3.2 expression levels in AR-HFGRII induced parasites provides better 
evidence clag overexpression is involved in phenotypic halofuginone resistance rather than just an 
associated phenomena triggered by HFG-treatment. 
HALOFUGINONE RESISTANCE MUTATIONS AT CPRS REQUIRES ELEVATED CLAG EXPRESSION  
The model we have built from our investigations of transgenic parasites with the HFGRI and HFGRII cPRS 
alleles is based upon multi-factorial resistance in which HFGRI is not the first but a second step.  From many 
unexpected observations that were not foretold by work in a yeast model system, we propose a model of 
epistasis between cPRS allele type and clag expression in our phenotype of resistance to halofuginone.  
AR-HFGRI parasites without altered clag gene expression are sensitized to halofuginone (Figure 4.4.5a) and 
a HFGRI cPRS mutation without second-site adaptation would never fix under the selective force of 
halofuginone (Figure 4.4.4a).  We have confirmed in our genetic experiments that upon clag -overexpression 
parasites with the HFGRI allele are strongly selected for by halofuginone (Figure 4.4.4b). 
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Thus, the genetic requirement of a pre-existing environment for cPRS resistance mutations is in direct 
agreement with the observation-based model of evolution of halofuginone resistance we presented in 
Chapter 3.  Synthesizing the two independently derived models of resistance, we posit a re-interpretation of 
our three steps:  First non-genetic re-regulation of clag expression predominates and importantly sets the 
stage for cPRS mutations to evolve. In step two, genetic adaptation occurs either through cPRS mutations 
that are selected for in a newly permissive environment or through cPRS amplification.  In the third step, 
cPRS amplification become more favored in ever-increasing halofuginone pressures and outcompetes cPRS 
mutations. 
RECONCILING THE DIFFERENCES BETWEEN AR-HFGRI AND AR-HFGRII 
At this point, we cannot experimentally explain certain differences that resulted during our transfection 
experiments.  It is not known why AR-HFGRI parasites needed an outside stimulus to upregulate clag 2 and 
clag 3.2 expression and AR-HFGRII parasites upregulated clag 2 and clag 3.1 expression de novo.  
Hopefully, whole genome sequencing of the transfectants will identify any mutations outside of the cPRS 
that were acquired to all parasites to proliferate with the HFGR cPRS alleles and give us the step towards 
understanding the more complex regulatory mechanisms at play. 
LARGER IMPLICATIONS AND LIMITATIONS OF CURRENT MECHANISTIC MODEL 
This two-step model for evolution of a drug resistance mutation in P. falciparum has two greater implications 
for the field of drug resistance.  First, it shows there are relevant markers of drug sensitization or pre-
resistance that could be used be used to track and intervene before permanent drug resistance fixes in a 
population.  Second, the multiple steps required to evolve drug resistance can inform the design of future 
rational drug combinations.  These experiments we present here argue that inhibitors of amino acid import 
would make the HFGRI and HFGRII mutants evolutionarily inaccessible. 
We do acknowledge that we have yet to provide a mechanistic link between clag gene overexpression and 
cPRS mutations in these transfectants.  Our underlying hypothesis is that clag gene overexpression is 
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involved with amino acid homeostasis regulation as we have seen in out wild type induced lines.  However, 
we are currently pursuing this approach to determine whether a proline-specific or non-specific re-
regulation of amino acid levels are responsible for the epistatic between cPRS and clag genes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   89	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 5: CONCLUSION AND FUTURE DIRECTIONS 
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4.1 CONCLUSIONS AND FUTURE DIRECTIONS 
 
Lack of an effective vaccine and recurrent drug resistance are the two main reasons a treatable 
disease such as malaria remains responsible for more than 1,238,000 deaths a year 6.  Despite 
much work to find new approaches to vaccine development, our greatest success in malaria 
vaccine development in 2014 is RTS,S/AS01: a vaccine with less than a 50% efficacy in children 
under 17 months old 26.  A big hindrance to our progress is that any malaria vaccine needs to 
outperform natural immunity. 
Drug development and abating drug resistance remains a promising direction for research and 
development to combat malarial disease and death.  This is why we have focused on identifying 
new drug targets and understanding the potential resistance pathways that may thwart this new 
class of drugs. 
To that end, we labored in Chapter 2 to discover a new target for antimalarial development – a 
druggable chokepoint in the parasite’s cellular physiology.  Through drug resistance selection with 
halofuginone, a derivative of an ancient Chinese medicinal remedy for fever, we found that the 
cytoplasmic prolyl tRNA synthetase (cPRS) is a new promising target for antimalarial development.  
Further, we have discovered a related molecule, halofuginol, is active in vivo against liver and red 
blood cell stages of malaria and lacks the gastrointestinal toxicity of halofuginone.  Thus, 
halofuginol proves that targeting the cPRS is a viable and promising route for future development 
of dual-stage anti-malarial drugs. 
To better support our argument that halofuginol is a promising in vivo active antimalarial, we need 
to more thoroughly explore the dosing regimens needed in our mouse model.  Specifically, we 
should explore the dose at which gastrointestinal toxicity similar to halofuginone occurs with 
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halofuginol and determine if it is possible to achieve a dose in our mouse model of erythrocytic 
infection that can provide a single dose radical cure (SERC). 
In the future, we hope to perform protein-based high-throughput screens to find additional small 
molecule scaffolds that target three of the enzymatic functions of cPRS: activation of proline, 
charging of proline onto proline tRNAs, and editing of mischarged proline tRNAs. 
In Chapter 3, we delve more deeply into the halofuginone resistance mechanisms that P. 
falciparum can evolve, but more generally into understanding the sequential, multi-step nature of 
the evolution of drug resistance in malaria.  In addition to the evidence that cPRS mutations 
contribute to halofuginone resistance in Chapters 2 and 4, in Chapter 3 we show that copy 
number variation at the locus is a drug resistance mechanism.  More significantly, we have found 
evidence that both genetic and non-genetic mechanisms are essential for halofuginone drug 
resistance.  We found that short-term treatment of P. falciparum parasites with halofuginone 
induced non-genetic resistance that led to the upregulation of clag family genes and increased 
proline levels within the parasite.  Interestingly, this is the first example of substrate-specific 
regulation of solutes that has involved the clag gene family.  Thus we have found evidence for a 
highly regulated amino acid homeostasis that can be perturbed by the cPRS inhibitor, 
halofuginone. 
Because of the recent and surprising nature of the results we present in Chapter 3, we have some 
experiments that were ongoing at the time of submission of this dissertation.  To further strengthen 
the evidence that cPRS confers halofuginone resistance, we want to ensure that loci outside of the 
cPRS could contribute to the resistance we saw in the three clones we characterized from HFGRIII 
2-200x.  Thus, we are currently performing whole genome sequencing of the three clones and will 
look for any SNPs or CNVs that differ among the trio.  A fundamental assumption of our three-step 
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model is that induction of halofuginone resistance via upregulation of clag gene family members 
and cytosolic proline occurs as a first step.  We base this assumption on three observations: first 
that parasites at the end of in vitro evolution replicates HFGRII and HFGRII have strongly 
upregulated cytosolic proline.  Our second piece of data is that induced wild type Dd2 parasites 
overexpress clag gene family members and upregulate cytosolic proline.  Third, induced wild type 
parasite had a similar level of drug resistance as observed in HFGRII before cPRS mutations or 
CNVs appeared.  To confirm this model, we need to thaw our early time points in both selections 
and validate the temporality of non-genetic resistance to halofuginone. 
Our current evidence shows the linkage of high cytosolic proline, clag family gene upregulation, 
and non-genetic abrupt development of drug resistance.  However, our model is still incomplete.  
First, we cannot yet prove that the elevated proline levels are due to increased proline importation, 
though this is hinted towards by the clag gene expression data.  Thus, we are planning on two 
experimental approaches:  first we will track proline importation in induced and untreated 
parasites with C14-labeled proline.  Second, we will use aspartic protease inhibitors to probe the 
involvement of hemoglobin degradation in induction of halofuginone resistance.  Also, we 
recognize that clag gene overexpression can only explain the increased proline levels in the 
erythrocyte cytoplasm.  We are hopeful that RNA-seq gene-expression studies that are ongoing 
will help elucidate the genes involved in parasite membrane and parasitophorous vacuole 
contribution to proline uptake in the parasite cytoplasm.   
The evidence of clag-mediated halofuginone resistance has caught us by surprise.  Certain 
questions that directly arise from our findings address the fundamental understanding we have of 
how clag genes contribute to and regulate PSAC–mediated transport.   
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The finding specific enrichment of proline through a clag-involved mechanism is very interesting 
and leads us to many follow up questions and observations.  We would like to understand how 
specific import of single amino acids is achieved by clag-involved PSAC machinery.  As of now, 
clag 3 and more recently clag 2 have been implicated as genetic determinants of PSAC 
importation.  However, the composition of the PSAC channel, its subunits, and its modifiers are 
still unexplored.  We feel that the specific enrichment of proline we have seen in the non-genetic 
induction of halofuginone resistance is a unique observation and can be utilized to further probe 
the specificity of PSAC and additional determinants of this specificity within and beyond the clag 
gene family. 
Our finding of clag involvement has opened up many future directions to further drug discovery 
and the approaches we combine antimalarials for clinical therapy.  We are very interested to know 
whether the clag-related resistance is a phenomena specific to proline regulation and selective 
pressures created by cPRS inhibitors, or is it more generalizable to inhibitors of other tRNA 
synthetase. 
We have created a three-step model of the evolution of drug resistance with clag-medicated non-
genetic and genetic mechanisms.  Our three replicate evolutions experiments HFGRI, II, and III 
have provided us with a three-step model.  However, we hope to pursue a much larger number of 
replicate experiments of artificial evolution to ensure the robustness of the N=3 conclusions.  In 
addition, in these future in vitro evolution experiments we will disentangle the acquisition of 
improved fitness from escalating selective pressure, i.e. elevated drug dose.  Thus by performing 
separate selections at constant drug pressures over time, we will be able to attribute any clonal 
competition to differential fitness in the same environment, rather than observing the selective 
fitness of mutants in environments other than those in which they arose. 
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In Chapter 4, we were able to show that cPRS drug resistance mutations found in halofuginone-
selected lines, HFGRI and HFGRII, are epistatic with clag gene overexpression and require 
preexisting cellular adaptation to confer resistance.  This finding further validates the model of 
drug resistance we have described in Chapter 3.  However, the recent nature of these findings has 
not allowed us to perform all of the follow experiments we need to connect the clag regulation we 
saw in Chapter 3 with our transfectants strains.  We need to perform metabolic studies of the WT, 
HFGRI, and HFGRII transfectants with and without induction to understand if amino acid levels 
are altered as a result of clag gene overexpression as we found in wild type Dd2 parasites.  
Additionally, we hope to shine more light on the genetic architecture of the cPRS locus in the AR-
HFGRI clones.  We are currently using the PRICE Genome Assembler to de novo assemble the 
cPRS locus and identify the number of full length amplifications that are likely transcriptionally 
active in each clone. 
We have confirmed that in the right cellular environment, cPRS mutations HFGRI and HFGRII 
confer resistance to halofuginone.  The deeper implications of our work with allelic exchange 
experiments in Chapter 4 arise from the requirement of specific cellular adaptations to allow cPRS 
mutations to confer resistance to halofuginone.  A common model employed to understand the 
evolution of drug resistance and its fitness costs is that of compensatory mutation: evolution of 
drug resistance results in organisms with decreased fitness in the absence of drug pressure 42,43.  
Additional ‘compensatory’ mutations are acquired to rescue the fitness of the drug-resistant 
organisms.  This was our null hypothesis going into our work with halofuginone.   
Once we identified that cPRS was the target of halofuginone, we looked with our metagenomic 
sequencing approach for additional mutations that would fix along or after fixation of the cPRS 
mutation in HFGRII.  Rather than finding post-cPRS  compensatory mutations, we found that 
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preexisting cellular adaptations were required for cPRS mutations to be selected for by 
halofuginone pressure.  In both AR-HFGRI and AR-HFGRII, halofuginone resistance was 
epistatically linked with clag gene overexpression.  AR-HFGRI parasites with normal clag 
expression patterns were even less fit in the presence of halofuginone than wild type.  Thus, we 
have created a model of pre-adaptation of cellular environment that allows the evolution and 
fixation of a cPRS resistance allele that is otherwise deleterious.  This model has larger 
implications for understanding the initial steps of evolutionary adaptation that is required for later 
and more permanent genetic events.   
In terms of drug discovery, our findings from Chapter 3 and 4 are very informative for re-orienting 
rational based drug discovery and drug combination design.  From my first pass analysis of the 
evolutionary trajectory of halofuginone resistance, I surmised that this fine mapping of evolution 
showed us that combining PSAC inhibitors and halofuginone would be an apt approach.  
However, it took me a while to realize the new approach implicit in this statement.  A newly 
developing theme of much cancer and infectious disease research is to focus on developing 
therapies that will target the common resistance pathways with mutant specific drugs; this 
approach has been investigated in P. falciparum with DHODH and pfCRT inhibitors 135 and has 
been extensively explored in clinical treatment of imatinib-resistant chronic myeloid leukemia 
with second-generation BCR-ABL kinase inhibitors (Reviewed in Weisenberg et al) 136.   
Our findings in Chapter 4 show that pre-conditioning of the cellular environment via clag gene 
family overexpression is essential for the drug resistance evolution of cPRS mutations.  Thus, by 
combining cPRS and PSAC inhibition we are suggesting that we can block the early non-genetic 
adaption that precedes the evolution of genetic resistance.  Thus rather than targeting the resistant 
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enzyme and making it less fit, we are proposing to eliminate the evolutionary path that would lead 
to target site mutations at the cPRS. 
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6.1 SUPPLEMENTARY FIGURES AND TABLES FROM CHAPTER 2 
 
2.5 SUPPLEMENTARY MATERIALS 
 
 
SFigure 2.5.1: Halofuginone is not cross-resistant with common anti-antimalarials 
Linear correlation of EC50 values among 31 culture adapted P. falciparum isolates from Senegal found little 
relationship between in-vitro resistance to halofuginone and resistance to 12 standard antimalarials.  
Correlations are represented by R^2 values in a heatmap matrix (R^2=1 is red, highly correlated; R^2=0 is 
blue, uncorrelated).   
 
 
 
SFigure 2.5.1: Enatiomer-Specific Potency of Halofuginone and Halofuginol 
(A) Structures of halofuginone and halofuginol enantiomers. (B) EC50 values of febrifugine and analogs for 
erythrocytic stage Dd2 wild-type and halofuginone-resistant strains.  Values are representative of three 
replicate SYBR dose-response assays.  
 
Artemisinin
Dihydroartemisinin
Halofantrine
Lumefantrine
Mefloquine
Primaquine
Amodiaquine
Piperaquine
Halofuginone
Chloroquine
Quinine
Atovaquone
Pyrimethamine
A
rte
m
is
in
in
D
ih
yd
ro
ar
te
m
isi
ni
n
H
al
of
an
tri
ne
Lu
m
ef
an
tri
ne
M
ef
lo
qu
in
e
P
rim
aq
ui
ne
A
m
od
ia
qu
in
e
P
ip
er
aq
ui
ne
H
al
of
ug
in
on
e
C
hl
or
oq
ui
ne
Q
ui
ni
ne
A
to
va
qu
on
e
P
yr
im
et
ha
m
in
e
N
N
O
O HN
Cl
Br
OH
N
N
O
O HN
Cl
Br
OH
N
N
O
HO HN
Cl
Br
OH
N
N
O
HO HN
Cl
Br
OH
(2R,3S)-Halofuginone (RS-HF)
(2S,3R)-Halofuginone (SR-HF)
(2’R,2R,3S)-Halofuginol (RRS-HFol)
(2’S,2S,3R)-Halofuginol (SSR-HFol)
EC50 (nM) 95% CI EC50 (nM) 95% CI
Halofuginone 0.81 0.73 - 0.89 252 211 - 301
(2R,3S)-Halofuginone 0.197 0.187 - 0.208 78.3 66.7 - 91.8
(2S,3R)-Halofuginone 3.6 3.48 - 3.73 1075 949 - 1218
Halofuginol 5.839 5.390 - 6.325
(2'R,2R,3S)-Halofuginol 3.05 2.87 - 3.25 >1000 -
(2'S,2S,3R)-Halofuginol 142 140 - 149 18300 4725 - 70890
epi-Halofuginol ~ 576.3 -
Febrifugine 2.37 1.87 - 2.33 987 904 - 1482
MAZ1310 86 80.9 - 91.4 >100000 -
Strains
Dd2 HFGR I
Antimalarial 
A
B
	   99	  
 
SFigure 2.5.3: In vivo potency of halofuginone in liver stage P. berghei infection model 
Relative parasitemia in mouse livers 44 h after infection with P. berghei sporozoites. Mice were treated 1hr 
post infection with halofuginone (0.5mg/kg p.o. and 1mg/kg p.o.) and vehicle, respectively. Parasite load 
was quantified relative to vehicle control by qRT-PCR of P. berghei 18S rRNA. Data are displayed as mean 
relative to vehicle treated control, with the mean of the control group set to 100%. p values (**p < 0.01, 
****p < 0.0001) were calculated from multiple animals by ordinary one-way ANOVA (Graphpad PRISM). 
 
 
 
SFigure 2.5.4: High resolution melt assay of PfcPRS identifies mutant loci 
A high-resolution melt genotyping assay identified two different mutant alleles within the Class II core tRNA 
synthetase domain of PfcPRS in the drug-resistance selected lines. 
 
 
 
SFigure 2.5.5: Dose dependent inhibition of P. falciparum growth is dependent on the concentration of 
free proline 
Proline concentration relative to RPMI media. Error bars reflect s.d. of triplicate experiments. 
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SFigure 2.5.6: Transgenic S. cerevisiae expressing wild type PfcPRS is sensitivity to halofuginone 
Representative growth curves for -/-YHR020w S. cerevisiae recombinantly expressing PfcPRS (A), ScPRS (B) 
and mutant (L482H) PfcPRS (C) in presence of varying concentrations of halofuginone. 
 
 
SFigure 2.5.7: Dose dependent inhibition of PfcPRS-expressing yeast growth by halofuginone is abolished 
by addition of proline  
% Growth was normalized to untreated control. Error bars reflect s.d. of triplicate experiments. 
 
 
 
SFigure 2.5.8: Dose dependent inhibition of S. cerevisiae expressing wild type PfcPRS by halofuginol 
Representative growth curves for -/-YHR020w S. cerevisiae recombinantly expressing ScPRS, PfcPRS, 
PfcPRS(L482H) and PfcPRS(L482F) PfcPRS in presence of varying concentrations of respective halofuginol 
enantiomers.  
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SFigure 2.5.9: Molecular models of Leu482 resistant mutatations 
Effect of the mutation of Leu482 (A) to histidine (B) and phenylalanine (C), on the interactions of 
halofuginone (gray sticks) in the active site of cPRS. Residue 482 is shown in sphere representation. Leu482 
is directly adjacent to the proline binding pocket, and although it does not directly participate in the 
hydrogen bonding network formed between halofuginone and the respective PRS, it does support the 
binding geometry of the interacting amino acid residues. The histidine in L482H mutant provides an 
alternative hydrogen bonding acceptor, thus destabilizing the network. Mutation to phenylalanine, on the 
other hand, induces steric repulsion with residues nearby, again disrupting the interactions in the binding 
pocket. 
 
 
SFigure 2.5.10: Amino Acid Response Pathway 
Aminoacyl tRNA (aaRS) synthetases charge unloaded tRNAs with their cognate amino acids (AA), which in 
turn are used as substrates by the ribosome during protein biosynthesis. Inhibition of aaRS (or lack of amino 
acids) results in accumulation of uncharged tRNAs that bind and activate GCN2.  Active GCN2 
phosphorylates the a-subunit of the eukaryotic initiation factor eIF2. Phosphorylated eIF2α can no longer 
initiate the ribosome assembly, resulting in inhibition of translation.  
 
 
!
!
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SFigure 2.5.11: Quantification of peIF2α protein levels in the western blots from Figure 2.4.4a  
Western blots in Figure 2.4.4a were of  asynchronous Dd2 cultures treated with halofuginone and 
febrifugine (A) and from Figure 2.4.4b of 3D7 asynchronous cultures treated with halofuginone and 
(2'R,2R,3S)-halofuginol (RRS-HFol).  Protein abundance is represented as relative to untreated control 
(DMSO) after normalization to the histone H3 loading control. 
 
 
SFigure 2.5.12: Multiple protein sequence alignment of the Class II Core Domains of Proline tRNA 
Synthetases from diverse species 
(A) Sequences of the class II core tRNA synthetase domains were aligned by a ClustalW algorithm.A Black 
arrow indicates the conserved residue L482. (B) A neighbor joining tree assembled of the class II core 
domains.  Tree metrics represent an unrefined P value calculated by a bootstrapping algorithm with 1000 
replicates. 
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Residence within a customized vacuole is a highly successful
strategy used by diverse intracellular microorganisms. The para-
sitophorous vacuole membrane (PVM) is the critical interface
between Plasmodium parasites and their possibly hostile, yet
ultimately sustaining, host cell environment. We show that tor-
ins, developed as ATP-competitive mammalian target of rapamy-
cin (mTOR) kinase inhibitors, are fast-acting antiplasmodial com-
pounds that unexpectedly target the parasite directly, blocking
the dynamic trafﬁcking of the Plasmodium proteins exported
protein 1 (EXP1) and upregulated in sporozoites 4 (UIS4) to the
liver stage PVM and leading to efﬁcient parasite elimination by
the hepatocyte. Torin2 has single-digit, or lower, nanomolar po-
tency in both liver and blood stages of infection in vitro and is
likewise effective against both stages in vivo, with a single oral
dose sufﬁcient to clear liver stage infection. Parasite elimination
and perturbed trafﬁcking of liver stage PVM-resident proteins are
both speciﬁc aspects of torin-mediated Plasmodium liver stage in-
hibition, indicating that torins have a distinct mode of action com-
pared with currently used antimalarials.
host-parasite interactions | malaria | protein trafﬁcking | P. falciparum
The population at risk for developing malaria is vast, com-prising some 3.3 billion people particularly in sub-Saharan
Africa and Southeast Asia, with mortality estimates ranging from
655,000 to 1,200,000 (1). Widespread resistance has limited the
therapeutic utility of most existing antimalarial drugs, and artemisi-
nin, the highly efﬁcacious cornerstone of artemisinin combination
therapies, appears to be at risk for the same fate (2). The need for
new antimalarial chemotherapeutic strategies is thus acute.
Plasmodium spp., the causative agents of malaria, have a complex
life cycle with alternating motile-nonreplicative and sessile-replica-
tive forms in both mammal and mosquito. In the mammalian host,
Plasmodium invades and replicates inside two very distinct cell
types: hepatocytes and red blood cells (RBCs). In mammals, the
Plasmodium life cycle is initiated by a motile sporozoite that invades
a hepatocyte, where it resides for 2–14 d, multiplying into >10,000
merozoites in a single cycle (3). Once released into the bloodstream,
each of these motile merozoites will infect an RBC and, within 1–3
d, generate 10–30 new merozoites, which will contribute to the
continuous cycle of blood stage infection that causes the symptoms,
morbidity, and mortality of malaria.
These two stages of mammalian infection, despite taking place
in distinct cell types and having an orders-of-magnitude difference
in parasite replication, do share common features. In both, the
motile “zoite” invades the host cell through formation of a para-
sitophorous vacuole (PV). Both stages grow and replicate exclu-
sively within the conﬁnes of the PV, and the parasitophorous
vacuole membrane (PVM), which is populated with parasite pro-
teins, constitutes the physical host–parasite interface throughout
development. Unlike the vacuoles of many intracellular pathogens
including Leishmania, Chlamydia, Mycobacteria, and Legionella
(4, 5), the Plasmodium vacuole, like that of Toxoplasma gondii,
does not fuse with host lysosomes and is not acidiﬁed (6). This is
not unsurprising in the context of Plasmodium development in an
RBC, which lacks endomembrane system trafﬁcking and, indeed,
lysosomes. The highly polarized hepatocyte, however, has exten-
sive vesicular transport networks (7) and can target intracellular
pathogens residing in a vacuole (8), suggesting that the exo-
erythrocytic form (EEF) may need to resist host cell attack.
Although the PVM is thought to be critical for Plasmodium
growth in both the hepatocyte and the RBC contexts, its cellular
roles remain elusive. The importance of several Plasmodium
PVM-resident proteins, however, has been conclusively demon-
strated in both blood and liver stages. Attempts to generate
exported (exp)1 and Plasmodium translocon of exported protein
(ptex)150 knockout parasites in Plasmodium falciparum failed (9,
10), revealing that these are both essential proteins for the blood
stage, whereas Plasmodium berghei and Plasmodium yoelii
mutants lacking up-regulated in sporozoites (uis)3 or uis4 fail to
complete liver stage development (11, 12). These PVM-resident
proteins, and thus the PVM itself, are performing functions that
are crucial for Plasmodium growth, but delineating the functions
of individual PVM-resident proteins has proven as difﬁcult as
identifying the cellular processes mediated by the PVM.
Signiﬁcance
Plasmodium parasites have two distinct intracellular growth
stages inside the mammalian host—the ﬁrst stage, which is
clinically silent, in liver hepatocytes, and the second, which
causes the symptoms of malaria, in red blood cells. This study
reports the discovery of a class of antimalarial compounds
called torins, which are extremely potent inhibitors of both
intracellular stages of Plasmodium. We show that torins block
trafﬁcking of liver stage parasite proteins to the physical host–
parasite interface, called the parasitophorous vacuole mem-
brane (PVM), and that without continuous trafﬁcking of PVM-
resident proteins, the parasite is subject to elimination by its
host hepatocyte.
Author contributions: K.K.H., D.F.W., and M.M.M. designed research; K.K.H., K.B., M.P.,
J.D.H-O., M.R., and W.L.B. performed research; A.S.R. and R.M. contributed new reagents/
analytic tools; K.K.H., K.B., M.P., J.D.H-O., M.R., W.L.B., D.F.W., T.H., M.M., and M.M.M.
analyzed data; and K.K.H. and M.M.M. wrote the paper.
The authors declare no conﬂict of interest.
*This Direct Submission article had a prearranged editor.
Freely available online through the PNAS open access option.
1To whom correspondence may be addressed. E-mail: khanson@fm.ul.pt or mmota@fm.
ul.pt.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.
1073/pnas.1306097110/-/DCSupplemental.
www.pnas.org/cgi/doi/10.1073/pnas.1306097110 PNAS Early Edition | 1 of 10
M
IC
RO
BI
O
LO
G
Y
PN
A
S
PL
US
	   104	  
 
 
 
 
 
The one process in which both the centrality of the PVM is
known and evidence for the participation of speciﬁc PVM pro-
teins exists is the export of parasite proteins to the RBC. A cohort
of parasite proteins that are involved in extensive physiological
and structural modiﬁcations of the infected RBC (iRBC) is
exported into the iRBC cytoplasm and beyond (13). Five proteins
have been identiﬁed as components of PTEX, the proposed ex-
port machinery at the iRBC PVM (9). Although liver stage
protein export has been shown for the Circumsporozite (CS)
protein (14) and PTEX components are expressed in P. falcipa-
rum EEFs (15), a role for parasite protein export into the he-
patocyte remains speculative; the host hepatocyte may not
require the extensive structural remodeling that the iRBC does.
Conversely, however, the hepatocyte, with its extensive vesic-
ular transport network, intuitively constitutes a more hostile host
environment than the RBC, and there is evidence that the liver
stage PVM may play a crucial role in preventing host cell-
mediated parasite killing, as it does in Toxoplasma gondii (16).
Support for a protective role for the liver stage PVM comes from
knockout parasites that fail in the earliest steps of PVM for-
mation and remodeling. Sporozoites lacking the p52/p36 gene
pair invade hepatocytes successfully, but fail in PVM formation
(17, 18) and are severely reduced in abundance midway through
liver stage development. Parasites lacking slarp/sap (19, 20), a
regulator of early liver stage development, fail to express UIS4
and exported protein 1 (EXP-1), along with other parasite pro-
teins, and are also eliminated at the beginning of infection.
Acquisition of resources from the host-cell environment, an
unambiguous requirement for an obligate intracellular parasite
like Plasmodium, is a function ascribed to the PVM in both
mammalian stages. The PVM allows the free passage of molecules
(21, 22), presumably through proteinaceous pores, which may
contribute to acquisition of host nutrients and disposal of parasite
waste products. Members of the early transcribed membrane
protein (ETRAMP) family, single-pass transmembrane proteins
conserved among Plasmodium spp., which are highly expressed
and developmentally regulated in both blood and liver stage par-
asites (23, 24), could be candidates for mediating uptake of host
resources. Such a role in lipid uptake has indeed been proposed for
the P. berghei ETRAMP UIS3 on the basis of its interaction with
host-cell L-FABP (liver fatty acid binding protein) (25).
Although Plasmodium parasites must use host resources to
support their own growth in both mammalian stages, the single
cycle replicative output of the liver stage parasite is vastly greater
than that of the blood stage, which may reﬂect a similarly increased
need for host resources. In this respect, the hepatocyte constitutes
far superior “raw material” compared with the RBC; hepatocytes
are not onlymetabolically active, but also highly versatile cells, which
are capable of altering uptake, storage, production, and degradation
of a wide array of macromolecules in response to cellular and or-
ganismal requirements. The presence of a growing Plasmodium
parasite is sensed by the host hepatocyte, which responds with acti-
vation of cellular stress responses and altered metabolism (26, 27).
The mammalian target of rapamycin (mTOR) kinase integrates
signals from amino acids, stress, oxygen, energy, and growth factors
and responds by altering cellular protein and lipid synthesis, as well
as autophagy (28). As such, we sought to determine how inhibition
of host mTOR signaling would affect Plasmodium liver stage de-
velopment. Here we show that torins, a single structural class of
mTOR inhibitors, are highly potent antiplasmodial compounds
targeting both mammalian stages in vitro and in vivo. Independent
of host-cell mTOR, torins impair trafﬁcking of Plasmodium liver
stage PVM-resident proteins, revealing the fast turnover of these
proteins at the liver stage PVM, and provoke elimination of liver
stage parasites.
Results
Torins Potently Inhibit Plasmodium Liver and Blood Stages. We ﬁrst
tested whether Plasmodium infection could be modulated by
inhibition of host mTOR signaling using two unrelated mTOR
inhibitors (see Table S1 for structures, reviewed in ref. 29):
rapamycin, a naturally occurring macrolide that is an allosteric
mTOR inhibitor, and Torin1, a tricyclic benzonaphthyridinone
developed through medicinal chemistry efforts as an ATP-com-
petitive inhibitor (30). We plated two human hepatoma cell lines,
Huh7 and HepG2, and infected the cells with GFP-expressing
P. berghei sporozoites. Two hours after infection, by which time
sporozoite invasion is completed, cells were switched into me-
dium containing 250 nM of either rapamycin or Torin1. Control
cells were treated with DMSO alone (vehicle control). Infection
parameters were quantiﬁed by ﬂow cytometry 48 h after sporo-
zoite addition. In both cell lines, the effects of the two mTOR
inhibitors were strikingly different. Treatment with rapamycin led
to a modest increase in the proportion of infected cells (number
of GFP+ cells) (Fig. 1A), or parasite development (Fig. 1B), as
indicated by the geometric mean of the GFP signal intensity,
which correlates with parasite development (31). Treatment with
Torin1, however, eliminated the vast majority of parasites in both
cells lines (Fig. 1A; HepG2 P < 0.0001) and blocked the develop-
ment of those few that remained (Fig. 1B; HepG2 P < 0.0001).
These results were conﬁrmed by microscopy, and representative
examples of control, rapamycin-treated, and the rare remaining
Torin1-treated EEFs are shown in Fig. 1C.
A Torin1 analog with properties more amenable to large-scale
synthesis and in vivo use was recently reported (32). We next
synthesized and tested this analog, Torin2, for antiplasmodial ac-
tivity. Dose–response analysis revealed that Torin2 is an∼100-fold
more potent an inhibitor of Plasmodium liver stage growth than
Torin1; the calculated cellular EC50 of Torin1 and Torin2 for
parasite development was 106 nM 95% conﬁdence interval (CI)
101–107 nMand 1.1 nM (95%CI 0.95–1.33 nM), respectively (Fig.
1D). Furthermore, a single dose of 10 mg/kg Torin2, administered
to mice 2 h after infection with 10,000 sporozoites, led to a highly
signiﬁcant reduction inPlasmodium liver load (Fig. 1E,P< 0.0001)
40 h postinfection. In a controlled physiological infection model
with infection initiated by 500 P. berghei-GFP sporozites, the same
10 mg/kg dose of Torin2 was curative. Control mice became blood
stage positive by ﬂow cytometry detection of GFP from day 4 to 6
postinfection, but none of the Torin2-treated animals ever de-
veloped blood parasitaemia by day 11 (Fig. 1F). Theﬂow cytometry
data were conﬁrmed by microscopic examination of thin blood
smears for all of the Torin2-treated animals.
The discrepancy between the extremely potent inhibition of
P. berghei EEFs by the torins and the slight (and opposing) effects
of rapamycin led us to wonder whether the antiplasmodial activity
of the torins was really mediated by host mTOR. As a ﬁrst step in
addressing this, we tested if the inhibitory effects of the torins
would extend to P. falciparum asexual blood stages, as the mature
enucleate RBCs in which P. falciparum replicates have no cata-
bolic capacity for mTOR to stimulate. Torin1 (200 nM) and
Torin2 (10 nM) were added to synchronized P. falciparum 3D7
ring stages, and parasite replication and reinvasion were assessed
by ﬂow cytometry 48 h later. iRBCs were identiﬁed based on
SYBR green labeling of P. falciparumDNA. Strikingly, both Torin1
and Torin2 blocked parasite development and completely pre-
vented reinvasion, as evidenced by the static parasitemia, compared
with the DMSO-treated control (Fig. 2A, P < 0.0001 for both
Torin1 and Torin2 vs. control). Using a different cytometry-based
assay and the P2G12 clone of P. falciparum 3D7 (33), we performed
dose–response assays and determined the Torin2 EC50 for asexual
blood stages to be 1.4 nM (95% CI 1.31–1.59 nM) (Fig. 2B). Torin2
is also highly potent against early gametocytes, with a slightly lower
EC50 of 6.62 nM (95% CI 4.59–9.54 nM). (Table S1). We next
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tested whether Torin2 would be capable of antimalarial activity
against the blood stage of P. berghei in vivo. C57BL/6 mice
infected with P. berghei-GFP iRBCs were treated with a single
oral dose of 10 mg/kg Torin2 on day 4 after infection when the
parasitaemia had reached 3%. All control mice succumbed to
experimental cerebral malaria by day 7, whereas the majority of
the Torin2-treated group did not (Fig. 2C), a highly signiﬁcant
difference in survival (P < 0.0001). The single Torin2 dose also led
to a highly signiﬁcant blunting of parasitaemia (Fig. 2D, P <
0.0001). Overall, our data demonstrate that torins are similarly
effective and potent against both blood and liver stage Plasmodium
parasites in vitro and in vivo. Thus, the mediator of the antimalarial
activity must be present in both of these host–parasite settings.
Inhibition of Host mTOR Signaling by Other Means Does Not
Phenocopy the Antiplasmodial Effects of Torins. The ability of torins
to potently target both liver and blood stages of Plasmodium in-
fection suggested a direct effect on the parasite and not on host
mTOR. We sought to further test this hypothesis using chemical
and genetic means to reduce host mTOR activity in hepatoma cells.
First, we evaluated the ability of PP242, another highly speciﬁc
ATP-competitive mTOR inhibitor that is structurally unrelated
to the torins (34), to inhibit Plasmodium liver stages. Treatment
with 2.5 μM PP242 [concentration showing complete inhibition
of mTORC1 and mTORC2 signaling in cellular assays (34)] did
not reduce either infected hepatocyte number or Plasmodium
liver stage growth (Fig. 3 A and B). Likewise, addition of PP242
to P. falciparum-synchronized 3D7 ring stages had no impact on
blood stage development and reinvasion (Fig. 3C).
We next turned to siRNA knockdown of mTORC1 components
in hepatoma cells. siRNA oligonucleotide pools targeting human
mTor or raptor transcripts were introduced by reverse transfection
and the knockdown cells infected with GFP-expressing P. berghei
sporozoites 48 h later. siRNA-mediated knockdown of neither
mTOR nor raptor could phenocopy the dramatic reduction of
infected cells or parasite development observed with Torin2
treatment (Fig. 3 D and E). EEF morphology 24 h after infection
was also comparable across the control, mTOR, and raptor knock-
down cells (Fig. 3F). Taken together, our data strongly suggest that
the target mediating the antiplasmodial effects of torins is not the
host cell mTOR kinase, but rather is parasite-encoded.
Torin2 Is Not Permissive to Generation of Drug-Resistant Parasite
Lines in Vitro. To identify the target of Torin2, we attempted
to generate drug-resistant mutants in P. falciparum blood stage
parasites. We ﬁrst determined that the multidrug-resistant
Dd2 strain of P. falciparum retained Torin2 sensitivity, with an
EC50 of 0.7 nM (95% CI 0.48–1.02 nM) in asexual blood stage
growth assays (35). We then performed resistance selection with
clonal Dd2 ring stage parasites, exposing them to 10× EC50
(7 nM) Torin2 for 8 d. When parasites failed to recrudesce 60 d
after this treatment, we varied the length of selection to opti-
mize the mutation-selection window. We achieved parasite re-
crudescence in 4 of 32 independent selection attempts and only
with exposure times of 48 h or less (summarized in Table 1).
Remarkably, the four selected strains all failed to display any
resistance phenotype by SYBR dose–response or decrease in
time to recrudescence in subsequent repetitions of the selection
protocol (Table 1). We, and others, have used these selection
Fig. 1. Torins are antiplasmodial compounds with nano-
molar potency against Plasmodium liver stages and are
capable of curing infection. (A–C) Effect of mTOR inhib-
itors, rapamycin, and Torin1 on P. berghei liver stage in-
fection. HepG2 or Huh7 cells infected with P. berghei-GFP
sporozoites on the day after seeding. Torin1, rapamycin,
or DMSO (vehicle as control) were added 2 h after in-
fection and remained present until 48 h after sporozoite
addition, when samples were processed for ﬂow cytom-
etry (A and B) or microscopy (C). Data from technical
triplicates of the DMSO control were averaged, and the
mean was set to 100%; all samples were then normalized
to this value. Mean ± SD from one representative experi-
ment is shown. (A) The number of GFP+ events detected
represents the number of infected cells. (B) The geometric
mean of the GFP signal, known to correlate with parasite
growth, represents EEF development. (C) Representive
confocal images. Huh7 cells were ﬁxed and labeled with
anti-PbHSP70 (P. berghei heat shock protein 70) (EEF,
green) and DAPI (nuclei, blue). (D) Dose-dependent effects
of Torin1 and Torin2 on P. berghei liver stage infection.
HepG2 cell infection analyzed by ﬂow cytometry 48 h later,
as in B. Each data point represents n = 3 biological tripli-
cates. Four-variable curve ﬁtting was carried out using
GraphPad Prism. (E) Effect of a single Torin2 oral dose on
parasite liver load. C57BL/6 mice were infected i.v. with
10,000 Pb-GFP sporozoites and given 10 mg/kg Torin2 sus-
pended in sunﬂower oil or an equivalent dose of sunﬂower
oil alone 2 h after infection. Each point represents a single
animal (n = 3 independent experiments); mean ± SD is in-
dicated for each group. (F) Effect of a single Torin2 oral dose
on prepatency period. C57BL/6 mice were infected i.v. with
500 Pb-GFP sporozoites and given 10 mg/kg Torin2 sus-
pended in sunﬂower oil or an equivalent dose of sunﬂower
oil alone 2 h after infection. Animals were monitored daily
for appearance of parasitaemia in the blood by ﬂow
cytometry. Data are from three independent experiments
with a total of 12 animals in each group.
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methodologies to raise resistance to antimalarials that act on
a variety of targets within the parasite’s cytosol and mitochon-
dria (36, 37). In contrast, Torin2 pressure has thus far failed to
induce a stable resistance phenotype after varied, repeated
attempts, suggesting that additional unbiased approaches will be
necessary to elucidate the drug target(s).
Plasmodium Growth Is Inhibited by Torin2 Throughout Liver Stage
Development. With the evidence leaning toward torins acting di-
rectly on Plasmodium spp., we sought to gain insight into the killing
mechanism by asking when the target(s) of Torin2 antiplasmodial
activity are present in liver stages. We ﬁrst varied compound
treatment windows to target different stages of parasite invasion
and development during liver stage infection. Initially, we
checked whether Torin2 treatment of HepG2 cells 2 h before
sporozoite addition could impact either sporozoite invasion or
EEF development. Torin2 pretreatment did not alter either
parasite numbers or development, as assayed 24 h after infection
(Fig. S1A). We next tested if Torin2 treatment concomitant
with sporozoite addition would affect parasite invasion and again
found no effect; comparable amounts of cells were infected
(GFP+) after 2 h, demonstrating that sporozoite invasion occurs
normally in the presence of Torin2 (Fig. S1B). Next, sporozoites
were allowed to complete invasion of HepG2 cells, and then 10
nM Torin2 was added for varying time periods (as schematized in
Fig. 4A) corresponding roughly to “early PVM remodeling” (2 h),
trophozoite (6 h), and schizont (24 h) stages of intrahepatocyte
development. Infection was analyzed 50 h after sporozoite addi-
tion by ﬂow cytometry, and none of the Torin2 treatment periods
was found to signiﬁcantly increase HepG2 cell death (Fig. S1C).
As previously shown, continuous incubation of infected cells with
10 nM Torin2 after sporozoite invasion results in near-complete
parasite elimination (Fig. 4A). Remarkably, a mere 4-h in-
cubation with 10 nM Torin2 from 2 to 6 h after infection was also
capable of eliminating more than 90% of all parasites (Fig. 4A);
Torin2 treatment from 6 to 24 h postinfection was similarly ef-
fective (Fig. 4A). The very few developing EEFs under the 2- to 6-
or 6- to 24-h conditions showed slightly reduced development
compared with the control (Fig. 4B). Interestingly, when Torin2
treatment was initiated only after the start of schizogony (24–50 h),
fewer parasites were eliminated, with parasite numbers about
60% of the control (Fig. 4B). However, in this treatment group,
EEF development showed the strongest inhibition—to 30% of
control levels (Fig. 4B); on an individual level, these parasites
show aberrant development and fail to form merozoites (Fig.
S1D). Our data demonstrate that Torin2 is a potent inhibitor of
all phases of Plasmodium EEF development through late schi-
zogony. Torin2-treated parasite elimination, however, occurred
efﬁciently only when EEFs were exposed to Torin2 before the
onset of schizogony.
Torin2 Treatment Leaves the PVM Structurally Intact, but Lacking
PVM-Resident Proteins. A number of gene-knockout parasite
lines that successfully invade hepatocytes exist, but fail during
PVM establishment or remodeling and are rapidly eliminated
(11, 12, 17–20, 38). Given this phenotypic parallel to the effects
of Torin treatment, which also does not affect the invasion
Fig. 2. Torins potently inhibit Plasmodium blood stage infection. (A) Effect
of Torin1 and Torin2 in P. falciparum blood stage in vitro cultures. Syn-
chronized P. falciparum 3D7 ring stage parasites were treated with 200 nM
Torin1, 10 nM Torin2, or DMSO (vehicle control); reinvasion was analyzed
after SybrGreen labeling of parasite DNA 48 h later. Data represent mean ±
SD of three independent experiments. Starting parasitaemia are repre-
sented by dotted line. (B) Dose-dependent effect of Torin2 on P. falciparum
blood growth. Data represent mean ± SD of three independent experi-
ments. (C and D) Effect of a single 10-mg/kg oral dose of Torin2 administered
on day 4 after infection of C57BL/6 mice with 1 × 106 Pb-GFP–parasitized RBC
on survival (C) and parasitemia (D). Animals were monitored daily for
malaria-associated pathology (experimental cerebral malaria symptoms),
and parasitaemia was analyzed by ﬂow cytometry. (C) Cumulative survival
curve for three independent experiments; n = 10 mice for control and
Torin2-treated groups. (D) Parasitaemia; each point represents the mean ±
SD from three independent experiments.
Fig. 3. mTOR inhibition by other means does not phenocopy the anti-
plasmodial effect of torins. (A and B) Effect of PP242 on inhibition of liver
stage infection. Infected HepG2 cells were treated with 2.5 uM PP242 2 h
after spozoroite addition, and the infection was analyzed by ﬂow cytometry
48 h later, as in Fig. 1. Data represent mean ± SD three independent
experiments. (C) Effect of PP242 on blood stage infection. Synchronized P.
falciparum 3D7 rings were treated with 2.5 μM PP242 or DMSO (identical
control data set as in Fig. 2A), and reinvasion was analyzed after SybrGreen
labeling of parasite DNA 48 h later. Data represent mean ± SD of three in-
dependent experiments. (D–F) Effect of siRNA-mediated knockdown of
raptor or mTOR on liver stage infection. Validated siRNA pools were reverse-
transfected into HepG2 cells, which were infected with sporozoites 2 d later
and analyzed by ﬂow cytometry as described above or with immunoﬂuo-
rescence analysis (IFA) 24 h after sporozoite addition. (F) Representative
images with PbHSP7 (green), UIS4 (red), and DAPI (blue).
4 of 10 | www.pnas.org/cgi/doi/10.1073/pnas.1306097110 Hanson et al.
	   107	  
 
 
 
 
 
process itself, but leads to parasite elimination, we wondered if
Torin2 treatment might be altering the parasite PVM, or alter-
natively, if infected cells were selectively rendered nonviable by
a brief Torin2 treatment. To this end, we used a live imaging
setup to address two questions: (i) Are infected cells viable after
Torin2 treatment? and (ii) Is the PVM maintained intact after
Torin2 treatment? To that end, we infected HepG2 cells with
P. berghei-GFP sporozoites and used the vital dye tetrame-
thylrhodamine, ethyl ester (TMRE), which labels mitochon-
dria with an intact membrane potential, to assess host-cell
mitochondrial activity and unambiguously identify intracellular
EEFs. Additionally, we used the vital DNA dye Hoechst 33258,
which freely labels host-cell DNA or free sporozoites, which lack
a PVM, but is unable to label the DNA of developing EEFs until
maturation-induced PVM changes occur late in liver stage de-
velopment (39). Torin2 was added 2 h after infection, and the
cells were imaged 6 h later, after TMRE and Hoechst 33258 la-
beling. Based on our earlier data (Fig. 4B), the vast majority of
Torin2-treated EEFs are ultimately nonviable after such a treat-
ment. In both control and Torin2-treated cells, the 8-h EEFs
developed in host cells with normal nuclear morphology and
active mitochondria (Fig. S2A). Importantly, the EEF nuclei are
not labeled by Hoechst 33258 in either drug-treated or control
cells (Fig. S2A), although the nuclei of extracellular sporozoites
that have failed to invade clearly are an indication that Torin2-
treated EEFs reside in an intact PVM. To conﬁrm this in-
terpretation, we used transmission electron microscopy (TEM) to
investigate PVM integrity in EEFs that were exposed to Torin2
from 2 to 8 h after infection. As expected, the 8-h control EEFs
were uniformly PVM-positive (Fig. 5A). Torin2-treated parasites
were also clearly surrounded by a PVM in all cases (Fig. 5A)
and tended to have more parasite PM waviness and intracellu-
lar complexity (e.g., membranous whorls) than the control
parasites observed.
Given that the PVM appeared intact in Torin2-treated infec-
ted cells, we next checked whether Plasmodium proteins known
to localize to the PVM were altered after exposure to Torin2.
UIS4, which is already transcribed in mature salivary gland
sporozoites (40), is localized to the PVM throughout develop-
ment inside the hepatocyte (11). Using UIS4-speciﬁc antiserum,
we conﬁrmed that 2 h after infection UIS4 was already localized
to the PVM; the peak UIS4 signal is clearly outside of the par-
asite soma delineated by P. berghei heat shock protein 70
(HSP70) antibody staining (Fig. 5B). Torin2 treatment initiated 2
h after infection is thus acting upon developing parasites already
enclosed in UIS4-positive PVMs. Surprisingly, we found that 6 h
of Torin2 treatment completely abolished the PVM localization
of UIS4. In stark contrast to both the pretreated 2-h parasites
and the 8-h control parasites, UIS4 is found exclusively within
the parasite soma in Torin2-treated parasites (Fig. 5B).
Torins are potent antiplasmodials throughout liver stage de-
velopment, so we next investigated whether or not Torin2 treat-
ment could induce mislocalization of PVM-resident proteins in
more mature parasites. Infected HepG2 cells were treated with
10 nM Torin2 during a 12-h window starting 16 h after infection,
and localization of both UIS4 and EXP1, another known PVM-
resident protein [also called Hep17 (41)], was assessed in 28 h
EEFs. As expected, UIS4 and EXP1 were localized almost com-
pletely outside of the parasite soma in control 28-h EEFs (Fig.
5C). Again, Torin2 treatment led to a dramatic mislocalization of
UIS4, with signal largely found in the parasite soma in 28-h EEFs
(Fig. 5C), although some residual UIS4 could also be observed in
the host-cell cytoplasm. EXP1 localization was also completely
perturbed by Torin2 treatment, with a PVM (control) to soma
(Torin2-treated) shift paralleling that of UIS4 (Fig. 5C).
Additionally, Torin1 treatment also induces mislocalization of
UIS4 to the parasite soma (Fig. S2B). These data imply that
torins act against Plasmodium by altering the localization of
PVM-resident proteins.
Table 1. Torin2 is refractory to repeated attempts at resistance
selection in vitro
Selection
strategy
Recrudescence
of parasites
Days to recrudescence
(ﬁrst/second/third
round)*
Fold EC50
(nM)**
10× EC50, 192 h 0/8 NA NA
10x EC50, 144 h 0/4 NA NA
20x EC50, 48 h
pulsed three times
0/4 NA NA
20x EC50, 48 h 1/7 26/24/30 1.04
20x EC50, 36 h 1/3 26/23/30 0.93
20x EC50, 24 h 2/4 22/24/31 1.14
20x EC50, 12 h 0/2 NA NA
Asexual Dd2 parasites were subjected to varied step-wise intermittent
selection protocol with10x EC50 Torin2.
*Number of days for each independent selection to return to 1% parasite-
mia. The time to recrudescence for subsequent rounds of selection is
expressed separately for the ﬁrst/second/third round of selections and
expressed as the average of the number of days when multiple independent
selections were performed with identical protocols.
**Parental Dd2 strain EC50 is 0.7 nM (0.48,1.02). Values expressed as fold
change over Dd2 EC50.
Fig. 4. Plasmodium growth is inhibited by Torin2 through-
out liver stage development. (A and B) Effects of Torin2
throughout P. berghei liver stage development in vitro.
Infected HepG2 cells were treated with 10 nM Torin2 or
DMSO (vehicle control) as indicated in the schematic illus-
tration, and the infection analyzed by ﬂow cytometry 50 h
after sporozoite addition, as in Fig. 1. Data represent mean ±
SD of quadruplicates from one representative experiment
with all conditions processed in parallel.
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EEF Elimination and PVM-Resident Protein Mislocalization Are Not
General Aspects of Liver Stage Inhibition by Antimalarials, Indicating
a Distinct Mechanism of Action for Torins. Although a comprehen-
sive study of the activity of currently used antimalarials against
rodent liver stage parasites has been carried out (42), we lack
such information on a phenotypic level, leading us to wonder
whether parasite clearance is the inevitable outcome for EEFs
that are rendered nonviable during the ﬁrst hours of intra-
hepatocyte development. To address this, we ﬁrst conﬁrmed the
elimination of Torin2-treated parasites in HepG2 cells by mi-
croscopy; continuous exposure to Torin2 initiated after sporozo-
ite invasion results in a complete absence of developing EEFs
48 h later. We then compared Torin2 side by side with the re-
cently identiﬁed antiplasmodial decoquinate, which has the same
mechanism of action (MoA) as atovaquone (43, 44), the most
potent antimalarial in clinical use effective in the liver stage (42).
We chose to focus on decoquinate as its potency is more similar
to that of Torin2 than that of atovaquone. Treatment of infected
HepG2 cells 2 h after sporozoite invasion with either 10 nM
Torin2 or 26 nM decoquinate (10× EC50) resulted in complete
Plasmodium inhibition. Torin2 eliminated EEFs, as expected
(Fig. 6A, P < 0.0001), whereas decoquinate led to a modest re-
duction in the number of EEFs present 50 h after infection (Fig.
6A, P < 0.05). Furthermore, a 6-h treatment with decoquinate
from 2 to 8 h after infection was phenotypically equivalent to the
2- to 50-h treatment (Fig. S3). Despite the persistence of deco-
quinate-treated EEFs, they appear to be arrested very early in
development (Fig. 6A, P < 0.0001), a phenotype we have con-
ﬁrmed by microscopy in primary mouse hepatocytes (Fig. 6B).
EEF elimination is thus not a default outcome of parasite non-
viability early in development, but rather reﬂects a speciﬁc aspect
of the torin-treated EEF phenotype. This provides an intriguing
parallel to the phenotypes described for those mutant parasites
that successfully invade hepatocytes, but fail during PVM estab-
lishment or remodeling and are rapidly eliminated (17–20).
We next checked if the mislocalization of PVM-resident pro-
teins induced by the torins could be a previously unnoted feature
of pharmacological inhibition/killing of Plasmodium liver stages,
also provoked by known antimalarials active against the liver
stages. We tested this hypothesis by evaluating UIS4 and EXP1
localization in infected cells treated with representative members
of the classes, in terms of both chemical structure and MoA, of
currently known antimalarials (42). Primaquine, pyrimethamine,
and decoquinate were individually added to HepG2 cells 20 h after
infection at 10× EC50 concentrations. Ten hours later, coverslips
were ﬁxed and processed for immunoﬂuorescence. Compared with
the control and Torin2 conditions (Fig. 6C), decoquinate-treated
parasites retained robust anti-UIS4 labeling of the PVM but, no-
tably, EXP1 staining was nearly abolished (Fig. 6C), a feature we
also noted in mouse primary hepatocytes (Fig. 6B). In the pri-
maquine- and pyrimethamine-treated cells, both PVM-resident
proteins were properly localized (Fig. 6C). Additionally, PVM-
resident proteins remain properly localized in cells treated with the
known liver stage inhibitors genistein (45), lopinavir (46), and
cyclosporin A (47), as well as with the PI3K inhibitor LY294002
and rapamycin (Fig. S4). Furthermore, Torin2 treatment from 2 to
4 h postinfection is sufﬁcient to mislocalize UIS4, but is reversible,
in terms of both parasite growth and UIS4 localization at 48 h
postinfection (Fig. 6D). Additionally, cycloheximide treatment (10
μg/mL), which blocks translation and is a potent antiplasmodial
compound (48), during the same 2 h window is uniformly lethal
for the developing EEFs, which do not grow after this time period;
this lethality is not accompanied by a penetrant defect in UIS4
localization as assayed at either 4 or 50 h after infection (Fig. 6D).
Thus, PVM-protein mislocalization is deﬁnitively not a conse-
quence of parasite death.
As such, we conclude that both parasite elimination and al-
tered localization of PVM resident proteins are speciﬁc pheno-
types of torin-mediated Plasmodium liver stage inhibition, which
strongly indicates that torins have a distinct MoA from currently
used antimalarials.
Plasmodium Liver Stage Parasites Require Replenishment of PVM-
Resident Proteins for Viability. As the alteration of PVM-resident
protein localization was not a general consequence of antimalarial
activity against EEFs, we sought to determine the mechanism by
which Torin2 provokes the mislocalization of these proteins.
Trafﬁcking of blood stage P. falciparum proteins to speciﬁc
organelles, the vacuolar space, PVM, and beyond into the iRBC
itself has been a subject of intense study (49). Brefeldin A (BFA),
an inhibitor of eukaryotic ADP-ribosylation factor (ARF) GTPa-
ses and the retrograde Golgi-ER trafﬁcking that they mediate in
many species, including Plasmodium (50), blocks export of knob-
Fig. 5. Torin2 treatment leaves the PVM structurally intact but lacking
PVM-resident proteins. (A and B) Effect of Torin2 treatment on the PVM and
UIS4 localization in young liver stage trophozoites. Schematic illustrates
experimental setup. (A) Representative images of TEM of 8-h EEFs after
Torin2 or DMSO (control) treatment. (B) IFA at 2 h (control, single confocal
slice) and at 8 h in control [maximum intensity projection (MIP)] and Torin2-
treated cells [single confocal slice (HSP70, green; DAPI, blue; UIS4, red)].
Fluorescence intensity graphs of the trajectory indicated by the white lines in
the preaddition and Torin2-treated images show the relative spatial in-
tensity peaks of the three ﬂuorophores. (C) Effect of Torin2 treatment on
UIS4 and EXP1 during early liver stage schizogony. Schematic illustrates ex-
perimental setup. MIPs of the entire EEF are shown for A–C.
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associated histidine-rich protein (KAHRP), P. falciparum eryth-
rocytemembrane protein 1 (PfEMP1) (51), and EXP1 (52) among
other proteins in blood stage parasites. Nothing is known about
the trafﬁcking pathways used by the liver stage parasite, so we
tested whether UIS4 trafﬁcking to the PVM proceeds through
a BFA-sensitive pathway. We added BFA to HepG2 cells 2 h
after infection, when UIS4 is already present in the PVM. After
BFA (5 μM) treatment for 6 h postsporozoite invasion, UIS4 is
found inside the parasite soma as in Torin2-treated parasites
(Fig. 7A). Compared with Torin2 treatment, which causes UIS4
to accumulate in discrete intracellular puncta (Fig. 7A) during
the samewindow, BFA causesUIS4 to accumulate in what appears
to be a more continuous distribution within the parasite soma. As
UIS4 colocalizes with the microneme marker thrombospondin-
related anonymous protein (TRAP) in mature salivary gland
sporozoites (40) and as TRAP is maintained in puncta throughout
the majority of liver stage development (53), we tested whether
UIS4 relocalized into TRAP-positive structures upon Torin2 or
BFA treatment. The data clearly show that UIS4 and TRAP do
not substantially colocalize in control, BFA-, or Torin2-treated
cells (Fig. S5A).
Most strikingly, BFA treatment, which blocks only protein
secretion, phenocopied the complete loss of PVM-localized
UIS4 seen in the Torin2-treated parasites (Fig. 7A). We quan-
tiﬁed the distribution of UIS4 and found that, on average, 62%
of the UIS4 signal is present outside of the parasite soma in 8-h
control EEFs, whereas BFA or Torin2 treatment resulted in
>95% overlap of UIS4 and HSP70 in the parasite soma (Fig.
7B). We extended these results to P. berghei EEFs developing
inside murine primary hepatocytes ex vivo (Fig. S5B); UIS4 and
EXP1 trafﬁcking to the PVM is BFA- and Torin2-sensitive in
young liver stage schizonts (Fig. S5B), and both PVM-resident
proteins are also concomitantly depleted from the PVM.
Taken together, our data support a model (Fig. 7C) in which
Torin2 treatment prevents secretion of liver stage PVM-resident
proteins, leading to their accumulation inside the EEF soma.
This block in secretion causes the PVM to be left devoid of
PVM-resident proteins, particularly in trophozoites, which leads
to parasite elimination by the host hepatocyte.
Discussion
This study reports that torins, developed as ATP-competitive
mammalian mTOR kinase inhibitors, are extremely potent inhib-
Fig. 6. EEF elimination and PVM-resident protein-
trafﬁcking defects are torin-speciﬁc phenotypes, not
general aspects of liver stage inhibition by anti-
malarials. (A and B) Effects of decoquinate and
Torin2 on EEF numbers and development. (A) Sche-
matic of treatment and analysis. Infected HepG2
cells analyzed by ﬂow cytometry at 50 h after spo-
rozoite addition. Mean of n = 3 biological experi-
ments, each condition in triplicate. (B) Mouse
primary hepatocytes infected ex vivo with EXP1
(red), UIS4 (green), and HSP70 (blue) labeling. (C)
Effect of current antimalarial classes active against
the liver stage at the onset of schizogony. Schematic
illustrates experimental setup; representative con-
focal images shown with UIS4 (red), EXP1 (white),
PbHSP70 (green), and DAPI (blue) labeling. (D)
Effects of 2 h Torin2 or cycloheximide treatment on
UIS4 localization and EEF development. Schematic
illustrates experimental setup. Representative con-
focal images of control (DMSO), Torin2-, and cyclo-
heximide-treated EEFs labeled with anti-UIS4 (red),
anti-PbHSP70 (green), and DAPI (blue) 4 and 48 h
postinfection. Quantiﬁcation of the proportion of
UIS4+ pixels not overlapping PbHSP70 in 20 EEFs
from each condition at 4 and 48 h postinfection;
quantiﬁcation of EEF area 48 h postinfection.
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itors of both the liver and blood stages of Plasmodium parasites.
Although we ﬁrst tested Torin1 (together with rapamycin) to in-
vestigate the role of host hepatocyte mTOR signaling in liver stage
Plasmodium infection, our data as a whole provide extremely
strong support for a parasite-encoded target mediating the anti-
plasmodial activity of the torins.We present three lines of evidence
that suggest that host-cell mTOR is not the mediator of the anti-
plasmodial activity of the torins. First, unrelated small-molecule
mTOR inhibitors (rapamycin and PP242) or siRNA-mediated
reduction of mTOR signaling both fail to inhibit Plasmodium liver
stage infection. Strong evidence that host mTOR is uninvolved
comes from the nonequivalence of PP242 and torins. Both cause
complete inhibition of mTORC1 and mTORC2 activity (30, 32,
34). The chemical structures of the two compounds are not at all
similar although, as we show here, neither are their effects on liver
or blood stage Plasmodium infection. Second, torins inhibit both
liver and blood stage parasites, with Torin2 maintaining a near
identical EC50 for the two stages and for different Plasmodium
species. Although it is easy to envisage mechanisms by which re-
duction of host hepatocyte mTOR signaling could alter liver stage
Plasmodium development, this is not the case for the iRBC. The
matureRBC lacks the capacity for both protein and lipid synthesis,
as well as gene expression, and although mTOR has been found in
the RBC “hidden proteome,” no evidence of functional protein
exists (54). Third, torins are able to alter the localization of Plas-
modium proteins during liver stage infection, an effect very un-
likely to be mediated by a host protein. As a whole, our data point
unequivocally to a Plasmodium-encoded molecule or molecules,
conserved across the genus and expressed in all mammalian stages,
as the target of the antiplasmodial activity of Torin1 and Torin2.
Sequence homology queries of current Plasmodium genome
assemblies show that no Plasmodium orthologs of mTOR exist,
and indeed the PI3K-like protein kinase family, of which mTOR is
amember, is not found (55, 56). The P. berghei proteins showing the
highest sequence similarity to human mTOR are the single pre-
dicted phosphatidylinositol-3-kinase (PI3K) (PBANKA_111490)
and the two predicted phosphatidylinositol-4 kinases (PI4Ks)
(PBANKA_110940 and PBANKA_072200), which show conser-
vation primarily in the kinase catalytic domain. Although little is
known about the activity of the two predicted Plasmodium PI4Ks,
PbPI3K is an essential gene (57), and treatment with the known
PI3K inhibitors wortmannin and LY294002 reduced PI3P pro-
duction by PfPI3K in vitro and inhibited blood stage parasite growth
(58). LY294002 does not phenocopy Torin2 inhibition of P. berghei
liver stages, however, and the inhibition of P. falciparum replication
by wortmannin and LY294002 (58) is muchmoremodest than what
we observed with either Torin1 or Torin2.
Our data clearly show that Torin2 is a potent antimalarial with in
vivo activity against both liver and blood stages, capable of curing
liver stage infection with a single, well-tolerated oral dose. Still,
given its demonstrated potent inhibition of human mTOR, we
cannot, and do not, see Torin2 itself as a lead compound; further
medicinal chemistry elaboration will be necessary to realize a torin
analog as a suitable antimalarial lead. Nevertheless, torins repre-
sent a new antimalarial chemotype that certainly warrants further
medicinal chemistry investigation due to the following highly de-
sirable properties: (i) versatility: Torin2 targets both liver and
blood stages, and is active against immature gametocytes; (ii)
speed of action: torins render P. falciparum parasites nonviable in
a single blood stage cycle and short treatment windows are sufﬁ-
cient to kill liver stage parasites; (iii) distinct MoA from currently
utilized antimalarials: none of the compounds in current clinical
use which are active against Plasmodium liver stages provoke
PVM trafﬁcking defects; and (iv) Torin2 retains potency against
the multidrug resistant Dd2 strain of P. falciparum, and is not
amenable to in vitro resistance generation, in contrast to most
antimalarials in current clinical use and leading candidates (36,
37, 59–63). Additionally, the mediator(s) of the antiplasmodial
activity of the torins is clearly druggable in vivo during both
mammalian stages.
Although the value of torin analogs for human antimalarial
use will rely on future medicinal chemistry elaboration, the
utility of torins for probing PVM function and protein-traf-
ﬁcking pathways in the Plasmodium EEF is immediate. Plas-
modium parasites contain many unusual cellular compartments
and have evolved strategies to direct proteins not only to these
but also to destinations outside of the parasite soma—from the
PV to the host-cell membrane itself. The transport pathways
that the blood stage parasite uses to direct proteins to these
diverse locations has been a subject of intense study; whereas
speciﬁc trafﬁcking pathways and molecular determinants ulti-
mately mediate protein movement to discrete locations—i.e.,
the vacuolar space, the Maurer’s clefts in the iRBC cytoplasm,
the digestive vacuole, or the PVM—most secreted proteins seem
to initially follow a common, canonical BFA-sensitive ER-Golgi
route in the blood stage parasites (49). As such, it is perhaps not
surprising that UIS4 and EXP1 trafﬁcking to the liver stage PVM
requires the canonical BFA-sensitive ER-Golgi transport route, as
we have demonstrated. Still, it highlights the fact that the parasite
does use this, and undoubtedly other core pathways, throughout all
mammalian stages. It remains to be determined whether the EEF
uses the same parasite-encoded molecules for acquisition of host
hepatocyte resources that the blood stage parasite uses in remod-
Fig. 7. Plasmodium liver stage parasites require replenishment of PVM-
resident proteins for viability. (A and B) Comparative effects of Torin2 and
BFA on UIS4 trafﬁcking to the PVM in young liver stage trophozoites.
Schematic illustrates experimental setup. (A) Representative confocal images
of control (methanol, BFA vehicle), Torin2-, and BFA-treated EEFs labeled
with anti-UIS4 (red), anti-PbHSP70 (green), and DAPI (blue). (B) Quantiﬁca-
tion of the proportion of UIS4+ pixels not overlapping PbHSP70 in 20 EEFs
from each condition. DMSO and methanol, the vehicle controls for Torin2
and BFA, respectively, are grouped together as control. (C) Model of Torin2
liver stage MoA.
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elling the “inert” RBC or whether components of the host hepa-
tocyte vesicular trafﬁcking networks are co-opted by the parasite.
Comparing BFA- and Torin2-treated EEFs, we ﬁnd clear
commonalities and subtle differences in phenotype. When either
drug is added after sporozoite invasion and intial UIS4-positive
PVM establishment, both treatments result in complete loss of
UIS4 at the PVM 6 h later, as well as intracellular accumulation
of UIS4. BFA blocks ER to Golgi trafﬁcking by inhibiting the P.
falciparum orthologue of Arf1 (64). BFA-treated blood stage
parasites form a hybrid ER- Golgi compartment (65) that
accumulates proteins utilizing the canonical secretory pathway.
We interpret the similarity of BFA- and Torin2-treated EEF
phenotypes as highly suggestive that Torin2, like BFA, causes
a failure in anterograde protein trafﬁcking. The compartment in
which UIS4 is retained appears qualitatively different, however,
with Torin2 treatment leading to the appearance of small puncta of
UIS4 and BFA treatment leading to a more continuous distribu-
tion of UIS4 inside the parasite soma. Future characterization of
the intracellular location in which PVM-resident proteins accu-
mulate after Torin2 treatment may help shed light on which traf-
ﬁcking step is inhibited by Torin2.
Localization of a membrane protein to a speciﬁc compartment
can be achieved by either its retention at, or continuous transport
to, the compartment. Most intriguingly, our data illustrate that
UIS4 and EXP1 must be continuously transported to the PVM
throughout at least the ﬁrst 30 h of liver stage development.
Several fascinating questions arise from this: Are UIS4 and EXP1
“lost” to the host cell during EEF development? Are UIS4 and
EXP1 subject to retrograde trafﬁcking back into the PV or par-
asite soma? Are these dynamics generalizable to all liver stage
PVM-resident proteins, or do they reﬂect the speciﬁc functions of
EXP1 and UIS4? Whether or not torin treatment alters protein
trafﬁcking in Plasmodium asexual and sexual blood stages also
remains to be established.
Proteins that are known to populate the nascent PVM of the
invading P. falciparum merozoite are synthesized during the pre-
ceding schizont stage and stored in the apical organelles of the
merozoite before release in the invasion process (66). The trans-
locon components HSP101, PTEX150, and EXP2 are examples of
this; they are found in the dense granules of merozoites, but will be
associated with the PVM throughout the subsequent cycle post-
invasion (67). The sporozoite invasion process is assumed to be
analogous to that of the merozoite. During the transit of the
Plasmodium sporozoite from the bite site to the hepatocytes, UIS4
is stored inside the sporozoite where it colocalizes with TRAP (40),
apparently in the micronemes, and is discharged only once the
sporozoite is in the process of hepatocyte invasion. We clearly
demonstrate that the pool of UIS4 that initially populates the
young EEF PVM is gone after 6 h of either Torin2 or BFA treat-
ment. As BFA is not thought to affect retrograde trafﬁcking, it is
very unlikely that this indicates a block in UIS4 recycling from the
parasite soma to the PVM, suggesting that this pool of UIS4 has
been degraded either by the host cell or the parasite itself. How-
ever, this is not the case with the translocon components in the
iRBC, in which the initial pool of proteins released from the dense
granules appears to be stably retained at the PVM throughout
blood stage development, with further synthesis and trafﬁcking
not required (67).
Although it is clear that the blood stage parasite is actively
secreting proteins, such as the stage-speciﬁc ETRAMPS (24), to
the PVM throughout development, more investigation will be
required to determine if some blood PVM proteins show dy-
namics like those of UIS4, and indeed whether EXP1 itself is
similarly dynamically localized to the blood stage PVM. The
hypothesis that PVM protein turnover would be related to pro-
tein function is attractive, but as the liver stage PVM also must
contend with extensive interactions with hepatocyte compo-
nents (22, 68), it remains possible that the host cell itself
dictates the turnover of the liver stage PVM-resident proteins
that we have examined.
Regardless of whether host or parasite ultimately drives the
turnover of the liver stage PVM-resident proteins that we have
studied, their replenishment at the PVM via continued expres-
sion and secretion through the early schizont stage, at the least,
is crucial for parasite viability. Clearly, the trafﬁcking route to
the liver stage PVM and the molecular players that mediate it,
as well as the protective role of the PVM, constitute fascinating
avenues for future research into Plasmodium biology, as well as
antimalarial drug development.
Experimental Procedures
See detailed version in SI Experimental Procedures.
Plasmodium Liver Stage Assays. GFP-expressing P. berghei sporozoites were
added to HepG2 or Huh7 cells cultured in 24-well plates. Infected cells were
processed and analyzed by ﬂow cytometry as described in ref. 31.
A total of 10,000 P. berghei-GFP sporozoites were injected i.v. into C57BL6
mice; 2 h later, a 10-mg/kg dose of Torin2 was given orally as a sunﬂower oil
slurry. Control animals received an equal dose of oil. Livers were harvested
44 h after infection, mRNA was extracted, and liver parasite load was de-
termined by quantitative RT-PCR of P. berghei 18s rRNA.
Plasmodium Blood Stage Assays. P. falciparum strains were cultured in vitro,
and parasite proliferation was determined by ﬂow cytometry.
To test the antimalarial properties of Torin2 in vivo, 1 × 106 P. berghei-GFP
iRBCs were injected intraperitoneally into C57BL/6 mice, and parasitaemia
was monitored by ﬂow cytometry. Torin2 (10 mM) in DMSO was diluted in
PBS, and 10 mg/kg was given orally on day 4 postinfection when parasitaemia
was above 3%. Control animals received equal doses of DMSO in PBS.
For resistance selection, ∼109 parasites were subject to a stepwise in-
termittent selection protocol beginning with 10× EC50 for various exposure-
time windows. Optimal resistance-selection conditions were obtained that
selected against the majority of parasites, but allowed recrudescence of
resistant parasites within 60 d. Upon recrudescence, additional selection
rounds were conducted to optimally obtain clones uninhibited by Torin2.
Immunoﬂuorescence and Microscopy. Infected cells were ﬁxed in 4% para-
formaldehyde (wt/vol) for 10 min at room temperature, permeabilized,
blocked in 2% BSA (wt/vol), and incubated with 1° antibodies. After wash-
ing, appropriate 2° antibodies were added, and coverslips were mounted in
Fluoromount. All images were acquired on Zeiss confocal microscopes.
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